<SEC-DOCUMENT>0001213900-25-090129.txt : 20250922
<SEC-HEADER>0001213900-25-090129.hdr.sgml : 20250922
<ACCEPTANCE-DATETIME>20250922162604
ACCESSION NUMBER:		0001213900-25-090129
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20250917
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250922
DATE AS OF CHANGE:		20250922

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oruka Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		251330397

	BUSINESS ADDRESS:	
		STREET 1:		855 OAK GROVE AVE.
		STREET 2:		SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-606-7910

	MAIL ADDRESS:	
		STREET 1:		855 OAK GROVE AVE.
		STREET 2:		SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARCA biopharma, Inc.
		DATE OF NAME CHANGE:	20090128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0257865-8k_oruka.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:ORKA="http://orukatx.com/20250917">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_ORKA_orukatx.com_20250917 -->
<!-- Field: Set; Name: xdx; ID: xdx_049_20250917_20250917 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0000907654 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000004" name="dei:EntityCentralIndexKey">0000907654</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="orka-20250917.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-09-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-17</xbrli:startDate>
        <xbrli:endDate>2025-09-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES<br/>
SECURITIES AND EXCHANGE COMMISSION<br/>
WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90A_edei--DocumentType_c20250917__20250917_zLyhh5Zz9ZH7"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):
<span id="xdx_90E_edei--DocumentPeriodEndDate_c20250917__20250917_zWXydZ1eKtv1"><ix:nonNumeric contextRef="AsOf2025-09-17" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">September 17, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityRegistrantName_c20250917__20250917_zbvgR1X8A8r"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000011" name="dei:EntityRegistrantName">Oruka Therapeutics, Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of Registrant as Specified in its
Charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20250917__20250917_zpc6kZ3ZOZoj"><ix:nonNumeric contextRef="AsOf2025-09-17" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><b><span id="xdx_907_edei--EntityFileNumber_c20250917__20250917_zEM7GmjbEgP5"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000013" name="dei:EntityFileNumber">000-22873</ix:nonNumeric></span></b></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20250917__20250917_zfr3pDNygzhc"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000014" name="dei:EntityTaxIdentificationNumber">36-3855489</ix:nonNumeric></span></b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><b>(State or other jurisdiction<br/>
of incorporation)</b></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><b>(Commission File Number)</b></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><b>(IRS Employer<br/>
Identification No.)</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20250917__20250917_z4ZJZXw1jhD5"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000015" name="dei:EntityAddressAddressLine1">855 Oak Grove Avenue</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90E_edei--EntityAddressAddressLine2_c20250917__20250917_zBkPJlnTunEl"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 100</ix:nonNumeric></span></b></p></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 49%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><b><span id="xdx_90C_edei--EntityAddressCityOrTown_c20250917__20250917_zuS0UFmvSbc3"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000017" name="dei:EntityAddressCityOrTown">Menlo Park</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressStateOrProvince_c20250917__20250917_zWZGnenAwls3"><ix:nonNumeric contextRef="AsOf2025-09-17" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><b><span id="xdx_90D_edei--EntityAddressPostalZipCode_c20250917__20250917_zaF2Y4BhD3of"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000019" name="dei:EntityAddressPostalZipCode">94025</ix:nonNumeric></span></b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><b>(Address of principal executive offices)</b></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><b>(Zip Code)</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number, including
area code: (<span id="xdx_90A_edei--CityAreaCode_c20250917__20250917_z7zdCECif9sf"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000020" name="dei:CityAreaCode">650</ix:nonNumeric></span>) <span id="xdx_904_edei--LocalPhoneNumber_c20250917__20250917_zNqV6BHFMeil"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000021" name="dei:LocalPhoneNumber">606-7910</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former Name or Former Address, if Changed Since Last Report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_edei--WrittenCommunications_c20250917__20250917_z70AxQhvjVBk"><ix:nonNumeric contextRef="AsOf2025-09-17" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-indent: -24.5pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_edei--SolicitingMaterial_c20250917__20250917_zAooWG8GgQYf"><ix:nonNumeric contextRef="AsOf2025-09-17" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-indent: -24.5pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_edei--PreCommencementTenderOffer_c20250917__20250917_zS1q5Cpf0uU9"><ix:nonNumeric contextRef="AsOf2025-09-17" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-indent: -24.5pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_edei--PreCommencementIssuerTenderOffer_c20250917__20250917_zC8p1UexzyZk"><ix:nonNumeric contextRef="AsOf2025-09-17" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities registered pursuant to Section 12(b)
of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><b>Title of each class</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><b>Trading Symbol(s)</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><b>Name of each exchange on which registered</b></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span id="xdx_908_edei--Security12bTitle_c20250917__20250917_zjmVY73xxjW4"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000026" name="dei:Security12bTitle">Common Stock, $0.001 par value</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_edei--TradingSymbol_c20250917__20250917_zdPFjCURc5C7"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000027" name="dei:TradingSymbol">ORKA</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center">The <span id="xdx_906_edei--SecurityExchangeName_c20250917__20250917_zyJIZaDo2PJ"><ix:nonNumeric contextRef="AsOf2025-09-17" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Global Market</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_edei--EntityEmergingGrowthCompany_c20250917__20250917_zP6oCKCqSgE7"><ix:nonNumeric contextRef="AsOf2025-09-17" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01 Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 17, 2025, Oruka Therapeutics, Inc.,
a Delaware corporation (the &#8220;Company&#8221;), entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;)
for a private placement (the &#8220;Private Placement&#8221;) with certain institutional and accredited investors (each, a &#8220;Purchaser&#8221;
and collectively, the &#8220;Purchasers&#8221;). The closing of the Private Placement occurred on September 19, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Purchase Agreement, the Purchasers purchased (i) an aggregate of 10,933,405 shares (the &#8220;Common Shares&#8221;) of the Company&#8217;s common stock, par
value $0.001 per share (the &#8220;Common Stock&#8221;), at a price per share of $15.00, and (ii) pre-funded warrants (the &#8220;Pre-Funded
Warrants&#8221;) to purchase an aggregate of 1,066,666 shares of Common Stock (the &#8220;Pre-Funded Warrant Shares&#8221;) at a purchase
price of $14.999 per Pre-Funded Warrant, which represents the per share purchase price of the Common Shares less the $0.001 per share
exercise price for each Pre-Funded Warrant, for an aggregate purchase price of approximately $180 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Pre-Funded Warrants will be exercisable at
any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates,
would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.
A holder of Pre-Funded Warrants may increase or decrease this percentage to a percentage not in excess of 19.99% by providing at least
61 days&#8217; prior notice to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Purchase Agreement contains customary representations
and warranties of the Company, on the one hand, and the Purchasers, on the other hand, and customary conditions to closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also on September 17, 2025, the Company entered
into a Registration Rights Agreement (the &#8220;Registration Rights Agreement&#8221;) with the Purchasers, which provides that the Company
will register the resale of the Common Shares and the Pre-Funded Warrant Shares. The Company is required to prepare and file a registration
statement with the Securities and Exchange Commission no later than October 15, 2025, and to use its commercially reasonable efforts to
have the registration statement declared effective within 90 days thereafter, subject to certain exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has also agreed to, among other things,
indemnify the Purchasers, their officers, directors, agents, partners, members, managers, stockholders, affiliates, investment advisers
and employees under the registration statement from certain liabilities and pay all fees and expenses (excluding any legal fees of the
selling holder(s), and any underwriting discounts and selling commissions) incident to the Company&#8217;s obligations under the Registration
Rights Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities issued and sold to the Purchasers
under the Purchase Agreement will not be registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) in
reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act, or under any state securities laws. The
Company relied on this exemption from registration based in part on representations made by the Purchasers. The securities may not be
offered or sold in the United States absent registration or an applicable exemption from registration requirements. Neither this Current
Report on Form 8-K, nor the exhibits attached hereto, is an offer to sell or the solicitation of an offer to buy the securities described
herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has engaged Jefferies LLC, TD Securities
(USA) LLC, Guggenheim Securities, LLC and LifeSci Capital LLC as placement agents for the Private Placement. The Company has agreed to
pay customary placement fees and reimburse certain expenses of the placement agents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing summary of the Purchase Agreement,
the Registration Rights Agreement and the Pre-Funded Warrants does not purport to be complete and is qualified in its entirety by reference
to the Purchase Agreement, the form of Registration Rights Agreement and the form of Pre-Funded Warrant, copies of which are filed as
Exhibits 10.1, 10.2 and 4.1 to this Current Report on Form 8-K, respectively, and are incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the closing of the Private
Placement, the Company has 48,384,150 shares of Common Stock issued and outstanding and approximately 67.1 million shares of Common
Stock issued and outstanding on a pro forma basis, which gives effect to the full conversion of the Company&#8217;s Series B
Non-Voting Convertible Preferred Stock, par value $0.001 per share (&#8220;Series B Preferred Stock&#8221;), as of September 19,
2025, without regard to beneficial ownership limitations that may limit the ability of certain holders of Series B Preferred Stock
to convert such shares to Common Stock at such time, and assumes the exercise of all outstanding pre-funded warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 3.02 Unregistered Sales of Equity Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent required by Form 8-K, the disclosures
in Item 1.01 above are incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 7.01 Regulation FD Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 17, 2025, the Company made available
a press release announcing the Private Placement. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form
8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also on September 17, 2025, the Company made available a press release
announcing certain clinical data from its Phase 1 clinical trial of ORKA-001, as well as  upcoming scientific presentations at the European Academy of Dermatology
and Venereology Congress. A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in Item 7.01 of this Current Report on Form 8-K, including
the information in the press releases attached as Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K, is furnished pursuant
to Item 7.01 of Form 8-K and shall not be deemed &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of
1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Current Report
on Form 8-K, including the information in the press releases attached as Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form
8-K, shall not be deemed to be incorporated by reference in the filings of the Company under the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: left; width: 9%"><b>Exhibit No.</b></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; width: 90%"><b>Description</b></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; white-space: nowrap; vertical-align: top">4.1</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="ea025786501ex4-1_oruka.htm">Form of Pre-Funded Warrant.</a></td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; white-space: nowrap; vertical-align: top">10.1&#8224;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="ea025786501ex10-1_oruka.htm">Securities Purchase Agreement, dated September 17, 2025, by and between Oruka Therapeutics, Inc. and each purchaser identified on Annex A thereto.</a>&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; white-space: nowrap; vertical-align: top">10.2</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="ea025786501ex10-2_oruka.htm">Form of Registration Rights Agreement.</a></td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; white-space: nowrap; vertical-align: top">99.1</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="ea025786501ex99-1_oruka.htm">Press Release, dated September 17, 2025.</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; white-space: nowrap; vertical-align: top">99.2</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="ea025786501ex99-2_oruka.htm">Press Release, dated September 17, 2025.</a></td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; white-space: nowrap; vertical-align: top">104</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">The cover page from the Company&#8217;s Current Report on Form 8-K formatted in Inline XBRL.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0in"/>
    <td style="width: 0.25in">&#8224;</td>
    <td style="text-align: justify">Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the Securities and Exchange Commission; provided, however, that the registrant may request confidential treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so furnished.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3"><b>Oruka Therapeutics, Inc.</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3">(Registrant)</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1.5pt">Date:</td>
    <td style="padding-bottom: 1.5pt">September 22, 2025</td>
    <td style="padding-bottom: 1.5pt">By:</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid">/s/ Lawrence Klein</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 6%">&#160;</td>
    <td style="width: 54%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 5%">Name:&#160; </td>
    <td style="width: 31%">Lawrence Klein</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Title:</td>
    <td>President and Chief Executive Officer</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">3</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LbMb/u5Oh4o4RYaIt8VFKW7NSOvUR/ItrRtiCITknC9HiJ5Y0VKXyHCa5xkcsKpL5RByvCCjOaN3pOtNAn7meNXWsTKuXX9gSp5Bz4zCWPl762y0xSIBOe1Hk348BDlI5BhmWxF89ZTMRRdonFYlKFPAnqlmjU7xq/twUE8yVL3apCOy1WQSiELZyW+IZRTDjhr1IL5ZyLJUBL22ArFiutfetXg6NF8SFiVWPs529L+DD8hbSlY= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ea025786501ex4-1_oruka.htm
<DESCRIPTION>FORM OF PRE-FUNDED WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 4.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THIS WARRANT AND THE SHARES OF COMMON STOCK
ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE &ldquo;SECURITIES&rdquo;) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED
FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES
ACT, (II) SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144 UNDER THE SECURITIES ACT, (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL
REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT, OR (IV) THE SECURITIES
ARE TRANSFERRED WITHOUT CONSIDERATION TO AN AFFILIATE OF SUCH HOLDER OR A CUSTODIAL NOMINEE (WHICH FOR THE AVOIDANCE OF DOUBT SHALL REQUIRE
NEITHER CONSENT NOR THE DELIVERY OF AN OPINION).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON
STOCK </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: right; text-indent: 0.5in">Number of Shares:
[&#9679;] (subject to adjustment)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">Warrant No. [&#9679;]</TD>
    <TD STYLE="text-align: right; width: 50%; font-size: 10pt">Original Issue Date: September [&#9679;], 2025</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Oruka Therapeutics, Inc.,
</B>a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), hereby certifies that, for good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, [&#9679;] or its registered assigns (the &ldquo;<B>Holder</B>&rdquo;), is entitled, subject
to the terms set forth below, to purchase from the Company up to a total of [&#9679;] shares of common stock, $0.001 par value per share
(the &ldquo;<B>Common Stock</B>&rdquo;), of the Company (each such share, a &ldquo;<B>Warrant Share</B>&rdquo; and all such shares, the
&ldquo;<B>Warrant Shares</B>&rdquo;) at an exercise price per share equal to $0.001 (as adjusted from time to time as provided in <U>Section
9</U> herein, the &ldquo;<B>Exercise Price</B>&rdquo;), upon surrender of this Pre-Funded Warrant to Purchase Common Stock (including
any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the &ldquo;<B>Warrant</B>&rdquo;) at any time
and from time to time on or after the date hereof (the &ldquo;<B>Original Issue Date</B>&rdquo;), subject to the following terms and conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Warrant is one of a series
of similar warrants issued pursuant to that certain Securities Purchase Agreement, dated September 17, 2025, by and among the Company
and the Investors identified therein (the &ldquo;<B>Purchase Agreement</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.3pt; text-align: justify; text-indent: 31.7pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.3pt; text-align: justify; text-indent: 31.7pt"><B>1.   <U>Definitions</U></B>.
For purposes of this Warrant, the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Affiliate</B>&rdquo;
means any Person directly or indirectly controlled by, controlling or under common control with, a Holder, but only for so long as such
control shall continue. For purposes of this definition, &ldquo;control&rdquo; (including, with correlative meanings, &ldquo;controlled
by&rdquo;, &ldquo;controlling&rdquo; and &ldquo;under common control with&rdquo;) means, with respect to a Person, possession, direct
or indirect, of (i) the power to direct or cause direction of the management and policies of such Person (whether through ownership of
securities or partnership or other ownership interests, by contract or otherwise), or (ii) at least 50% of the voting securities (whether
directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Attribution Parties</B>&rdquo;
means, collectively, the following Persons and entities: (i) any direct or indirect Affiliates of the Holder, (ii) any Person acting or
who could be deemed to be acting as a Group together with the Holder or any Attribution Parties and (iii) any other Persons whose beneficial
ownership of the Company&rsquo;s Common Stock would or could be aggregated with the Holder&rsquo;s and/or any other Attribution Parties
for purposes of Section 13(d) or Section 16 of the Exchange Act. For clarity, the purpose of the foregoing is to subject collectively
the Holder and all other Attribution Parties to the Maximum Percentage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Closing Sale Price</B>&rdquo;
means, for any security as of any date, the last trade price for such security on the Principal Trading Market for such security, as reported
by Bloomberg Financial Markets, or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate
the last trade price, then the last trade price of such security prior to 4:00 P.M., New York City time, as reported by Bloomberg Financial
Markets, or if the foregoing do not apply, the last trade price of such security in the over-the-counter market on the electronic bulletin
board for such security as reported by Bloomberg Financial Markets. If the Closing Sale Price cannot be calculated for a security on a
particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as
mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such
security, then the Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of
Directors&rsquo; determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately
adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Commission</B>&rdquo;
means the U.S. Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Exchange Act</B>&rdquo;
means the U.S. Securities Exchange Act of 1934, as amended, and all of the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Group</B>&rdquo;
shall have the meaning ascribed to it in Section 13(d) of the Exchange Act, and all related rules, regulations and jurisprudence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Person</B>&rdquo;
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization,
any other entity and a government or any department or agency thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Principal Trading
Market</B>&rdquo; means the national securities exchange or other trading market on which the Common Stock is primarily listed on and
quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Securities Act</B>&rdquo;
means the U.S. Securities Act of 1933, as amended, and all of the rules and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Standard Settlement
Period</B>&rdquo; means the standard settlement period, expressed in a number of Trading Days, for the Principal Trading Market with respect
to the Common Stock that is in effect on the date of delivery of an applicable Exercise Notice, which as of the Original Issue Date was
&ldquo;T+1.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Value: 2; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Trading Day</B>&rdquo;
means any weekday on which the Principal Trading Market is normally open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Transfer Agent</B>&rdquo;
means Computershare Inc., the Company&rsquo;s transfer agent and registrar for the Common Stock, and any successor appointed in such capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>2.   <U>Issuance
of Securities; Registration of Warrants</U></B>. The Company shall register ownership of this Warrant, upon records to be maintained by
the Company for that purpose (the &ldquo;<B>Warrant Register</B>&rdquo;), in the name of the record Holder (which shall include the initial
Holder or, as the case may be, any assignee to which this Warrant is permissibly assigned hereunder) from time to time. The Company may
deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>3.   <U>Registration
of Transfers</U></B>. Subject to compliance with all applicable securities laws, the Company shall, or will cause its Transfer Agent to,
register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all
applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to purchase Common Stock in substantially the
form of this Warrant (any such new warrant, a &ldquo;<B>New Warrant</B>&rdquo;) evidencing the portion of this Warrant so transferred
shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall
be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such
transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company
shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company&rsquo;s own expense any New Warrant under this <U>Section
3</U>. Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder
for all purposes, and the Company shall not be affected by any notice to the contrary.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>4. <U>Exercise of Warrants</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)   </FONT>All
or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by this Warrant (including <U>Section
11</U>) at any time and from time to time on or after the Original Issue Date, and such rights shall not expire until exercised in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)   </FONT>The
Holder may exercise this Warrant by delivering to the Company (i) an exercise notice, in the form attached as <U>Schedule 1</U> hereto
(the &ldquo;<B>Exercise Notice</B>&rdquo;), completed and duly signed, and (ii) payment of the Exercise Price for the number of Warrant
Shares as to which this Warrant is being exercised (which may take the form of a &ldquo;cashless exercise&rdquo; if so indicated in the
Exercise Notice pursuant to <U>Section 10</U> below), and the date on which the last of such items is delivered to the Company (as determined
in accordance with the notice provisions hereof) is an <B>&ldquo;Exercise Date</B>.&rdquo; The Holder shall not be required to deliver
the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect
as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant
Shares, if any. The delivery by (or on behalf of) the Holder of the Exercise Notice and the applicable Exercise Price as provided above
shall constitute the Holder&rsquo;s certification to the Company that its representations contained in Sections 4.1 and 4.3 through 4.14
of the Purchase Agreement are true and correct as of the Exercise Date as if remade in their entirety (or, in the case of any transferee
Holder that is not a party to the Purchase Agreement, such transferee Holder&rsquo;s certification to the Company that such representations
are true and correct as to such transferee Holder as of the Exercise Date).</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>5. <U>Delivery of Warrant
Shares</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)   </FONT>Upon
exercise of this Warrant, the Company shall promptly (but in no event later than the number of Trading Days comprising the Standard Settlement
Period following the Exercise Date), upon the request of the Holder, credit such aggregate number of shares of Common Stock specified
by the Holder in the Exercise Notice and to which the Holder is entitled pursuant to such exercise (the &ldquo;<B>Exercise Shares</B>&rdquo;)
to the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company (&ldquo;<B>DTC</B>&rdquo;) through its
Deposit Withdrawal At Custodian system, assuming the Transfer Agent is then a participant in the DTC Fast Automated Securities Transfer
Program (the &ldquo;<B>FAST Program</B>&rdquo;) and either (A) there is an effective registration statement permitting the issuance of
the Warrant Shares to or the resale of such Warrant Shares by the Holder or (B) the Exercise Shares are eligible for resale by the Holder
without volume or manner-of-sale restrictions pursuant to Rule 144 promulgated under the Securities Act (assuming cashless exercise of
this Warrant). If the Transfer Agent is not a participant in the FAST Program or if (A) and (B) above are not true, the Transfer Agent
will either (i) record the Exercise Shares in the name of the Holder or its designee on the certificates reflecting the Exercise Shares
with an appropriate legend regarding restriction on transferability, which shall be issued and dispatched by overnight courier to the
address as specified in the Exercise Notice, and on the Company&rsquo;s share register or (ii) issue such Exercise Shares in the name
of the Holder or its designee in restricted book-entry form in the Company&rsquo;s share register. The Holder, or any Person so designated
by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise
Date, irrespective of the date such Warrant Shares are credited to the Holder&rsquo;s DTC account, the date of the book entry positions
or the date of delivery of the certificates evidencing such Exercise Shares, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)   </FONT>If
the Company fails to deliver to the Holder or its designee Exercise Shares in the manner required pursuant to <U>Section 5(a)</U> within
the Standard Settlement Period following the Exercise Date (other than a failure caused by incorrect or incomplete information provided
by Holder to the Company) and the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction
of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<B>Buy-In</B>&rdquo;)
but did not receive within the Standard Settlement Period, then the Company shall, within two (2) Trading Days after the Holder&rsquo;s
request and in the Holder&rsquo;s sole discretion, promptly honor its obligation to deliver to the Holder or its designee the Exercise
Shares pursuant to Section 5(a) and pay cash to the Holder in an amount equal to the excess (if any) of the Holder&rsquo;s total purchase
price (including brokerage commissions, if any) for the shares of Common Stock so purchased in the Buy-In, less the product of (A) the
number of shares of Common Stock purchased in the Buy-In, times (B) the Closing Sale Price of a share of Common Stock on the Exercise
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)   </FONT>To
the extent permitted by law and subject to <U>Section 5(b)</U>, the Company&rsquo;s obligations to issue and deliver Warrant Shares in
accordance with and subject to the terms hereof (including the limitations set forth in <U>Section 11</U> below) are absolute and unconditional,
irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof,
the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation
or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or
alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such
obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Subject to <U>Section 5(b)</U>, nothing herein
shall limit the Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common
Stock upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.   </B></FONT><B><U>Charges,
Taxes and Expenses</U></B>. Issuance and delivery of shares of Common Stock upon exercise of this Warrant shall be made without charge
to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties)
in respect of the issuance of such shares, all of which taxes and expenses shall be paid by the Company; <I>provided</I>, <I>however</I>,
that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any
Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all
other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>7.   </B></FONT><B><U>Replacement
of Warrant</U></B>. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange
and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt
of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each case, a customary and
reasonable contractual indemnity, if requested by the Company. If a New Warrant is requested as a result of a mutilation of this Warrant,
then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company&rsquo;s obligation to issue
the New Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>8.   </B></FONT><B><U>Reservation
of Warrant Shares</U></B>. The Company covenants that it will, at all times while this Warrant is outstanding, reserve and keep available
out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue
Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable
upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the
Holder (taking into account the adjustments and restrictions of <U>Section 9</U>). The Company covenants that all Warrant Shares so issuable
and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and
validly authorized, issued and fully paid and non-assessable. The Company will take all such action as may be reasonably necessary to
assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of
any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. The Company further
covenants that it will not, without the prior written consent of the Holder, take any actions to increase the par value of the Common
Stock at any time while this Warrant is outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.   </B></FONT><B><U>Certain
Adjustments</U></B>. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant (the &ldquo;<B>Number of Warrant
Shares</B>&rdquo;) are subject to adjustment from time to time as set forth in this <U>Section 9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)   </FONT><U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Common Stock
or otherwise makes a distribution on any class of capital stock issued and outstanding on the Original Issue Date and in accordance with
the terms of such stock on the Original Issue Date or as amended, that is payable in shares of Common Stock, (ii) subdivides its outstanding
shares of Common Stock into a larger number of shares of Common Stock, (iii) combines its outstanding shares of Common Stock into a smaller
number of shares of Common Stock or (iv) issues by reclassification of shares of capital stock any additional shares of Common Stock of
the Company, then in each such case the Number of Warrant Shares shall be multiplied by a fraction, the numerator of which shall be the
number of shares of Common Stock outstanding immediately after such event and the denominator of which shall be the number of shares of
Common Stock outstanding immediately before such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective
immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, <I>provided,
however</I>, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Number
of Warrant Shares shall be recomputed accordingly as of the close of business on such record date and thereafter the Number of Warrant
Shares shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause
(ii), (iii) or (iv) of this paragraph shall become effective immediately after the effective date of such subdivision, combination or
issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)   </FONT><U>Pro
Rata Distributions</U>. If, on or after the Original Issue Date, the Company shall declare or make any dividend or other pro rata distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property, options, evidence of indebtedness or any other assets
by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction, but, for
the avoidance of doubt, excluding any distribution of shares of Common Stock subject to <U>Section 9(a)</U>, any distribution of Purchase
Rights (as defined below) subject to <U>Section 9(c)</U> and any Fundamental Transaction (as defined below) subject to <U>Section 9(d))</U>
(a &ldquo;<B>Distribution</B>&rdquo;) then, in each such case, the Holder shall be entitled to participate in such Distribution to the
same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon
complete exercise of this Warrant (without regard to any limitations or restrictions on exercise of this Warrant, including without limitation,
the Maximum Percentage (as defined below)) immediately before the date on which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such
Distribution (<I>provided</I>, that to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in
the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in
such Distribution to such extent (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such
Distribution (and beneficial ownership) to such extent) and the portion of such Distribution shall be held in abeyance for the benefit
of the Holder until such time or times as its right thereto would not result in the Holder and the other Attribution Parties exceeding
the Maximum Percentage, at which time or times the Holder shall be granted such Distribution (and any Distributions declared or made on
such initial Distribution or on any subsequent Distribution held similarly in abeyance) to the same extent as if there had been no such
limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)   </FONT><U>Purchase
Rights</U>. If at any time on or after the Original Issue Date, the Company grants, issues or sells any Options, Convertible Securities
or rights to purchase stock, warrants, securities or other property, in each case pro rata to the record holders of any class of Common
Stock (the &ldquo;<B>Purchase Rights</B>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase
Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations or restrictions on exercise of this Warrant, including
without limitation, the Maximum Percentage) immediately before the date on which a record is taken for the grant, issuance or sale of
such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for
the grant, issuance or sale of such Purchase Rights (<I>provided</I>, that to the extent that the Holder&rsquo;s right to participate
in any such Purchase Right would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (and shall not be entitled to beneficial ownership of such
Common Stock as a result of such Purchase Right (and beneficial ownership) to such extent) and such Purchase Right to such extent shall
be held in abeyance for the benefit of the Holder until such time or times as its right thereto would not result in the Holder and the
other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted such right (and any Purchase
Right granted, issued or sold on such initial Purchase Right or on any subsequent Purchase Right to be held similarly in abeyance) to
the same extent as if there had been no such limitation. As used in this <U>Section 9(c)</U>, (i) &ldquo;Options&rdquo; means any rights,
warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities and (ii) &ldquo;Convertible Securities&rdquo;
mean any stock or securities (other than Options) directly or indirectly convertible into or exercisable or exchangeable for shares of
Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)   </FONT><U>Fundamental
Transactions</U>. If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation of the Company
with or into another Person, in which the Company is not the surviving entity or in which the stockholders of the Company immediately
prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the voting power of the surviving entity immediately
after such merger or consolidation, (ii) the Company effects any sale to another Person of all or substantially all of its assets in one
or a series of related transactions, (iii) pursuant to any tender offer or exchange offer (whether by the Company or another Person),
holders of capital stock tender shares representing more than 50% of the voting power of the capital stock of the Company and the Company
or such other Person, as applicable, accepts such tender for payment, (iv) the Company consummates a stock purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another
Person whereby such other Person acquires more than 50% of the voting power of the capital stock of the Company (except for any such transaction
in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting
power of such Person immediately after the transaction) or (v) the Company effects any reclassification of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other
than as a result of a subdivision or combination of shares of Common Stock covered by <U>Section 9(a)</U> above) (in any such case, a
&ldquo;<B>Fundamental Transaction</B>&rdquo;), then following such Fundamental Transaction the Holder shall have the right to receive,
upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon
the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number
of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations on exercise contained herein (the
&ldquo;<B>Alternate Consideration</B>&rdquo;). The Company shall not effect any Fundamental Transaction in which the Company is not the
surviving entity or the Alternate Consideration includes securities of another Person unless (i) the Alternate Consideration is solely
cash and the Company provides for the simultaneous &ldquo;cashless exercise&rdquo; of this Warrant pursuant to <U>Section 10</U> below
or (ii) prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including
any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance
with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of
this paragraph (d) shall similarly apply to subsequent transactions analogous to a Fundamental Transaction type.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)   </FONT><U>Number
of Warrant Shares</U>. Simultaneously with any adjustment to the Number of Warrant Shares pursuant to <U>Section 9</U>, the Exercise Price
shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the
increased or decreased Number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such
adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the par value of the Common Stock then
in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)   </FONT><U>Calculations</U>.
All calculations under this <U>Section 9</U> shall be made to the nearest one-tenth of one cent or the nearest share, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)   </FONT><U>Notice
of Adjustments</U>. Upon the occurrence of each adjustment pursuant to this <U>Section 9</U>, the Company at its expense will, at the
written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare
a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant
Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments
and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of
each such certificate to the Holder and to the Company&rsquo;s transfer agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)   </FONT><U>Notice
of Corporate Events</U>. If, while this Warrant is outstanding, the Company (i) declares a dividend or any other distribution of cash,
securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe
for or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves, enters into any agreement contemplating
or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding
up of the affairs of the Company, then the Company shall deliver to the Holder a notice of such transaction at least ten (10) days prior
to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect
to such transaction; <I>provided, however</I>, that the failure to deliver such notice or any defect therein shall not affect the validity
of the corporate action required to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes
or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by
<U>Section 9(d)</U>, other than a Fundamental Transaction under clause (iii) of <U>Section 9(d),</U> the Company shall deliver to the
Holder a notice of such Fundamental Transaction at least thirty (30) days prior to the date such Fundamental Transaction is consummated.
Holder agrees to maintain any information disclosed pursuant to this <U>Section 9(h)</U> in confidence until such information is publicly
available, and shall comply with applicable law with respect to trading in the Company&rsquo;s securities following receipt of any such
information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>10. <U>Payment of
Exercise Price</U>.</B> Notwithstanding anything contained herein to the contrary, the Holder may, in its sole discretion, satisfy
its obligation to pay the Exercise Price through a &ldquo;cashless exercise&rdquo;, in which event the Company shall issue to the
Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section 3(a)(9) of the Securities Act, as
determined as follows:</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0pt 0pt 0.5in">X = Y [(A-B)/A]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in">where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;X&rdquo;
</FONT>equals the number of Warrant Shares to be issued to the Holder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;Y&rdquo;
</FONT>equals the total number of Warrant Shares with respect to which this Warrant is then being exercised;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;A&rdquo;
</FONT>equals the Closing Sale Price of the shares of Common Stock (as reported by Bloomberg Financial Markets) as of the
Trading Day on the date immediately preceding the Exercise Date; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;B&rdquo;
</FONT>equals the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify">For purposes of Rule 144 promulgated under the
Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in a &ldquo;cashless exercise&rdquo; transaction
shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced,
on the date this Warrant was originally issued (<I>provided </I>that the Commission continues to take the position that such treatment
is proper at the time of such exercise). In the event that a registration statement registering the issuance of Warrant Shares is, for
any reason, not effective at the time of exercise of this Warrant, then this Warrant may only be exercised through a cashless exercise,
as set forth in this <U>Section 10</U>. If the Warrant Shares are issued in such a cashless exercise, the Company acknowledges and agrees
that, in accordance with Section 3(a)(9) of the Securities Act, the Exercise Shares issued in such exercise shall take on the registered
characteristics of the Warrants being exercised and may be tacked on to the holding period of the Warrants being exercised. Except as
set forth in <U>Section 5(b)</U> (Buy-In remedy) and <U>Section 12 </U>(No Fractional Shares), in no event will the exercise of this Warrant
be settled in cash.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt"><B></B></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>11. <U>Limitations on
Exercise</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">(a)   Notwithstanding
anything to the contrary contained herein, the Company shall not effect the exercise of any portion of this Warrant, and the Holder of
this Warrant shall not have the right to exercise any portion of the Warrant, and any such exercise shall be null and void ab initio and
treated as if the exercise had not been made, to the extent that immediately prior to or following such exercise, the Holder, together
with the Attribution Parties, beneficially owns or would beneficially own as determined in accordance with Section 13(d) of the Exchange
Act and the rules promulgated thereunder, in excess of 9.99% (the &ldquo;<B>Maximum Percentage</B>&rdquo;) of the Common Stock that would
be issued and outstanding following such exercise. For purposes of calculating beneficial ownership for determining whether the Maximum
Percentage is or will be exceeded, the aggregate number of shares of Common Stock held and/or beneficially owned by the Holder together
with the Attribution Parties, shall include the number of shares of Common Stock held and/or beneficially owned by the Holder together
with the Attribution Parties plus the number of shares of Common Stock issuable upon exercise of the relevant Warrant with respect to
which the determination is being made but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise
of the remaining, unexercised Warrant held and/or beneficially owned by the Holder or the Attribution Parties and (ii) exercise or conversion
of the unexercised or unconverted portion of any other securities of the Company held and/or beneficially owned by such Holder or any
Attribution Party (including, without limitation, any convertible notes, convertible stock or warrants) that are subject to a limitation
on conversion or exercise analogous to the limitation contained herein. For purposes of this <U>Paragraph 11(a)</U>, beneficial ownership
of the Holder or the Attribution Parties shall, except as set forth in the immediately preceding sentence, be calculated and determined
in accordance with Section 13(d) of the Exchange Act and the rules promulgated thereunder. For purposes of this Warrant, in determining
the number of outstanding shares of Common Stock, a Holder of this Warrant may rely on the number of outstanding shares of Common Stock
as reflected in (1) the Company&rsquo;s most recent Form 10-K, Form 10-Q, Current Report on Form 8-K or other public filing with the Commission,
as the case may be, (2) a more recent public announcement by the Company or (3) any other notice by the Company or the Company&rsquo;s
transfer agent setting forth the number of shares of Common Stock outstanding (such issued and outstanding shares, the &ldquo;<B>Reported
Outstanding Share Number</B>&rdquo;). For any reason at any time, upon the written or oral request of the Holder, the Company shall within
one (1) business day confirm orally and in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding.
The Holder shall disclose to the Company the number of shares of Common Stock that it, together with the Attribution Parties holds and/or
beneficially owns and has the right to acquire through the exercise of derivative securities and any limitations on exercise or conversion
analogous to the limitation contained herein contemporaneously or immediately prior to submitting an Exercise Notice for the relevant
Warrant. If the Company receives an Exercise Notice from the Holder at a time when the actual number of outstanding shares of Common Stock
is less than the Reported Outstanding Share Number, the Company shall (i) notify the Holder in writing of the number of shares of Common
Stock then outstanding and, to the extent that such Exercise Notice would otherwise cause the Holder&rsquo;s, together with the Attribution
Parties&rsquo;, beneficial ownership, as determined pursuant to this <U>Section 11(a)</U>, to exceed the Maximum Percentage, the Holder
must notify the Company of a reduced number of Warrant Shares to be purchased pursuant to such Exercise Notice (the number of shares by
which such purchase is reduced, the &ldquo;<B>Reduction Shares</B>&rdquo;) and (ii) as soon as reasonably practicable, the Company shall
return to the Holder any exercise price paid by the Holder for the Reduction Shares. In any case, the number of outstanding shares of
Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant,
by the Holder and the Attribution Parties since the date as of which the Reported Outstanding Share Number was reported. In the event
that the issuance of Common Stock to the Holder upon exercise of this Warrant results in the Holder, together with the Attribution Parties,
being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock
(as determined under Section 13(d) of the Exchange Act), the number of shares so issued by which the Holder&rsquo;s, together with the
Attribution Parties&rsquo;, aggregate beneficial ownership exceeds the Maximum Percentage (the &ldquo;<B>Excess Shares</B>&rdquo;) shall
be deemed null and void and shall be cancelled ab initio, and the Holder and/or the Attribution Parties shall not have the power to vote
or to transfer the Excess Shares. As soon as reasonably practicable after the issuance of the Excess Shares has been deemed null and void,
the Company shall return to the Holder the exercise price paid by the Holder for the Excess Shares. By written notice to the Company,
a Holder of this Warrant may from time to time increase or decrease the Maximum Percentage to any other percentage not in excess of 19.99%
specified in such notice; <I>provided </I>that any increase in the Maximum Percentage will not be effective until the sixty-first (61st)
day after such notice is delivered to the Company and shall not negatively affect any partial exercise effected prior to such change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">(b)   This
<U>Section 11</U> shall not restrict the number of shares of Common Stock which a Holder or the Attribution Parties may receive or beneficially
own in order to determine the amount of securities or other consideration that such Holder or the Attribution Parties may receive in the
event of a Fundamental Transaction as contemplated in <U>Section 9(c)</U> of this Warrant. For purposes of clarity, the shares of Common
Stock issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be beneficially owned
by the Holder or the Attribution Parties for any purpose including for purposes of Section 13(d) of the Exchange Act and the rules promulgated
thereunder or Section 16 of the Exchange Act and the rules promulgated thereunder, including Rule 16a-1(a)(1). No prior inability to exercise
this Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to
any subsequent determination of exercisability. The provisions of this paragraph shall be construed and implemented in a manner otherwise
than in strict conformity with the terms of this <U>Section 11</U> to the extent necessary to correct this paragraph or any portion of
this paragraph which may be defective or inconsistent with the intended beneficial ownership limitation contained in this <U>Section 11</U>
or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitation contained in this
paragraph may not be waived and shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>12.   </B></FONT><B><U>No
Fractional Shares</U></B>. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any
fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole
number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any such fractional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>13.   </B></FONT><B><U>Notices</U></B>.
Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing
and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered
confirmed e-mail at the e-mail address specified in the books and records of the Transfer Agent prior to 5:30 P.M., New York City time,
on a Trading Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via confirmed
e-mail at the e-mail address specified in the books and records of the Transfer Agent on a day that is not a Trading Day or later than
5:30 P.M., New York City time, on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally recognized
overnight courier service specifying next business day delivery, or (iv) upon actual receipt by the Person to whom such notice is required
to be given, if by hand delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>14.   </B></FONT><B><U>Warrant
Agent</U></B>. The Company shall initially serve as warrant agent under this Warrant. Upon thirty (30) days&rsquo; notice to the Holder,
the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation
resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company
or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant
agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant
agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&rsquo;s last address as shown on the Warrant Register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>15.   </B></FONT><B><U>Miscellaneous</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)   </FONT><U>No
Rights as a Stockholder</U>. Except as otherwise set forth in this Warrant, the Holder, solely in such Person&rsquo;s capacity as a holder
of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose,
nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&rsquo;s capacity as the Holder
of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action
(whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise),
receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant
Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant
shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or
as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)   </FONT><U>Further
Assurances</U>. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without
limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger,
dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of
the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such
actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting
the generality of the foregoing, the Company will (a) not increase the par value of any Warrant Shares above the amount payable therefor
upon such exercise immediately prior to such increase in par value, (b) take all such action as may be necessary or appropriate in order
that the Company may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Warrant, and (c)
use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction
thereof as may be necessary to enable the Company to perform its obligations under this Warrant. Before taking any action which would
result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall
obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies
having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)   </FONT><U>Successors
and Assigns</U>. Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not
be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction.
This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject
to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any
legal or equitable right, remedy or cause of action under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)   </FONT><U>Amendment
and Waiver</U>. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns. Except
as otherwise provided herein, the provisions of the Warrants may be amended and the Company may take any action herein prohibited, or
omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)   </FONT><U>Acceptance</U>.
Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)   </FONT><U>Governing
Law; Jurisdiction</U>. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED
BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW
THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING
IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION
CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY
WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF
ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING
SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE
OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT
SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY
MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)   </FONT><U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any
of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)   </FONT><U>Severability</U>.
If any part or provision of this Warrant is held unenforceable or in conflict with the applicable laws or regulations of any jurisdiction,
the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original
business purpose of such part or provision in a valid and enforceable manner, and the remainder of this Warrant shall remain binding upon
the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.</P>

<P STYLE="text-indent: 20pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD COLSPAN="3" STYLE="text-align: left"><FONT STYLE="text-transform: uppercase"><B>Oruka Therapeutics, Inc.</B></FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 60%">&nbsp;</TD>
<TD STYLE="text-align: left; width: 4%">&nbsp;</TD><TD STYLE="text-align: left; width: 5%">&nbsp;</TD><TD STYLE="text-align: left; width: 31%">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
<TD STYLE="padding-bottom: 1.5pt; text-align: left">By:</TD><TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">Name:</TD><TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">Title:</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>SCHEDULE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>FORM OF EXERCISE NOTICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">To be executed by the Holder to purchase shares
of Common Stock under the Warrant</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">(1) The undersigned is the Holder of Warrant No. __ (the &ldquo;Warrant&rdquo;)
issued by Oruka Therapeutics, Inc., a Delaware corporation (the &ldquo;Company&rdquo;). Capitalized terms used herein and not otherwise
defined herein have the respective meanings set forth in the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">(2) The undersigned hereby exercises its right to purchase _____ Warrant
Shares pursuant to the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">(3) The Holder intends that payment of the Exercise Price shall be
made as (check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Cash Exercise </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt"><FONT STYLE="font-size: 10pt">&ldquo;Cashless Exercise&rdquo; under <U>Section&nbsp;10</U> of the Warrant </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">(4) If the Holder has elected a Cash Exercise, the Holder shall pay
the sum of $ _____ in immediately available funds to the Company in accordance with the terms of the Warrant.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">(5) Pursuant to this Exercise Notice, the Company shall deliver to
the Holder Warrant Shares determined in accordance with the terms of the Warrant. The Warrant Shares shall be delivered (check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="white-space: nowrap; padding: 0pt; width: 0.25in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0pt; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="white-space: nowrap; padding: 0pt; vertical-align: top; width: 2in"><FONT STYLE="font-size: 10pt">to the following DWAC Account Number:&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; padding: 0pt; vertical-align: top"> <FONT STYLE="font-size: 10pt">_______________________________</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; padding: 0pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0pt; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding: 0pt; vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; padding: 0pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding: 0pt; vertical-align: top"><FONT STYLE="font-size: 10pt">in book-entry form via a direct registration system</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; padding: 0pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0pt; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding: 0pt; vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; padding: 0pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="white-space: nowrap; padding: 0pt; vertical-align: top">by physical delivery of a certificate to:</TD>
    <TD STYLE="white-space: nowrap; padding: 0pt; vertical-align: top">  ________________________________________________________</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; padding: 0pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0pt; vertical-align: top">________________________________________________________</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; padding: 0pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0pt; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding: 0pt; vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; padding: 0pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding: 0pt; vertical-align: top"><FONT STYLE="font-size: 10pt">in restricted book-entry form in the Company&rsquo;s share register</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">(6) By its delivery of this Exercise Notice, the undersigned represents
and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder (i) the Holder is an &ldquo;accredited investor&rdquo;
as defined in Regulation D promulgated under the Securities Act of 1933, as amended, or a &ldquo;qualified institutional buyer&rdquo;
as defined in Rule 144A under the Securities Act of 1933, as amended, and (ii) will not beneficially own in excess of the number of shares
of Common Stock (as determined in accordance with Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended) permitted to
be owned under <U>Section&nbsp;11(a)</U> of the Warrant to which this notice relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding: 0.25pt"><FONT STYLE="font-size: 10pt">Dated:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.25pt; width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding: 0.25pt"><FONT STYLE="font-size: 10pt">Name&nbsp;of&nbsp;Holder:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.25pt 1.5pt; white-space: nowrap">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.25pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.25pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">(Signature must conform in all respects to name
of Holder as specified on the face of the Warrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ea025786501ex10-1_oruka.htm
<DESCRIPTION>SECURITIES PURCHASE AGREEMENT, DATED SEPTEMBER 17, 2025, BY AND BETWEEN ORUKA THERAPEUTICS, INC. AND EACH PURCHASER IDENTIFIED ON ANNEX A THERETO
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This <B>SECURITIES PURCHASE
AGREEMENT</B> (this &ldquo;<B>Agreement</B>&rdquo;) is dated as of September 17, 2025, by and among Oruka Therapeutics, Inc., a Delaware
corporation (the &ldquo;<B>Company</B>&rdquo;), and each of the entities listed on <U>Exhibit A</U> attached to this Agreement (each,
an &ldquo;<B>Investor</B>&rdquo; and together, the &ldquo;<B>Investors</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Company
and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by
Section 4(a)(2) of the U.S. Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Company
desires to sell to the Investors, and each Investor desires to purchase from the Company, severally and not jointly, upon the terms and
subject to the conditions stated in this Agreement, (A) shares (the &ldquo;<B>Initial Shares</B>&rdquo;) of the Company&rsquo;s common
stock, par value $0.001 per share (the &ldquo;<B>Common Stock</B>&rdquo;) and/or (B) the pre-funded warrants to purchase shares of Common
Stock (the &ldquo;<B>Pre-Funded Warrants</B>&rdquo;) substantially in the form attached hereto as <U>Exhibit B</U>; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, contemporaneously
with the sale of the Initial Shares and/or the Pre-Funded Warrants, the parties hereto will execute and deliver a Registration Rights
Agreement, substantially in the form attached hereto as <U>Exhibit C</U>, pursuant to which the Company will agree to provide certain
registration rights in respect of the Shares (as defined below) and the Pre-Funded Warrant Shares (as defined below) under the Securities
Act and applicable state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW THEREFORE</B>, in consideration
of the mutual agreements, representations, warranties and covenants herein contained, the Company and each Investor, severally and not
jointly, agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. <FONT STYLE="font-size: 10pt"><U>Definitions.</U>
As used in this Agreement, the following terms shall have the following respective meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>2025 SEC Reports</B>&rdquo;
means (a) the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and (b) any Quarterly Reports on
Form 10-Q or any Current Reports on Form 8-K filed or furnished (as applicable) by the Company after January 1, 2025 and prior to the
Business Day immediately preceding the date hereof, together in each case with any documents incorporated by reference therein or exhibits
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Affiliate</B>&rdquo;
means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled
by or is under common control with such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Aggregate Purchase
Amount</B>&rdquo; has the meaning set forth in <U>Section 2.2</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Agreement</B>&rdquo;
has the meaning set forth in the recitals hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Amended and Restated
Bylaws</B>&rdquo; means the bylaws of the Company, as currently in effect and as in effect on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Amended and Restated
Certificate of Incorporation</B>&rdquo; means the Certificate of Incorporation of the Company, as currently in effect and as in effect
on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Benefit Plan</B>&rdquo;
or &ldquo;<B>Benefit Plans</B>&rdquo; means employee benefit plans as defined in Section 3(3) of ERISA and all other employee benefit
practices or arrangements, including, without limitation, any such practices or arrangements providing severance pay, sick leave, vacation
pay, salary continuation for disability, retirement benefits, deferred compensation, bonus pay, incentive pay, stock options or other
stock-based compensation, hospitalization insurance, medical insurance, life insurance, scholarships or tuition reimbursements, maintained
by the Company or to which the Company or any of its Subsidiaries is obligated to contribute for employees or former employees of the
Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Board of Directors</B>&rdquo;
means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Business Day</B>&rdquo;
means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking
institutions in the State of New York are authorized or required by law or other governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Closing</B>&rdquo;
has the meaning set forth in <U>Section 2.2</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Closing Date</B>&rdquo;
has the meaning set forth in <U>Section 2.2</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Code</B>&rdquo;
means the U.S. Internal Revenue Code of 1986, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Common Stock</B>&rdquo;
has the meaning set forth in the recitals hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Company</B>&rdquo;
has the meaning set forth in the recitals hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Confidential Data</B>&rdquo;
has the meaning set forth in <U>Section 3.33</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Disclosure Document</B>&rdquo;
has the meaning set forth in <U>Section 5.3</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Disclosure Time</B>&rdquo;
has the meaning set forth in <U>Section 5.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Drug Regulatory
Agency</B>&rdquo; means the U.S. Food and Drug Administration (&ldquo;<B>FDA</B>&rdquo;) or other foreign, state, local or comparable
governmental authority responsible for regulation of the research, development, testing, manufacturing, processing, storage, labeling,
sale, marketing, advertising, distribution and importation or exportation of drug or biological products and drug or biological product
candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Environmental Laws</B>&rdquo;
has the meaning set forth in <U>Section 3.15</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>ERISA</B>&rdquo;
means the U.S. Employee Retirement Income Security Act of 1974, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Exchange Act</B>&rdquo;
means the U.S. Securities Exchange Act of 1934, as amended, and all of the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Financial Statements</B>&rdquo;
has the meaning set forth in <U>Section 3.8(b)</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>FINRA</B>&rdquo;
means the Financial Industry Regulatory Authority, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Fundamental Representations</B>&rdquo;
means the representations and warranties made by the Company in <U>Sections 3.1 (Organization and Power)</U>, <U>3.2 (Capitalization)</U>,
<U>3.4 (Authorization)</U>, <U>3.5 (Valid Issuance)</U>, <U>3.6 (No Conflict)</U>, <U>3.7 (Consents)</U>, <U>3.8 (SEC Filings; Financial
Statements)</U>, <U>3.18 (Nasdaq Stock Market)</U>, <U>3.19 (Sarbanes-Oxley Act)</U>, <U>3.23 (Price Stabilization of Common Stock)</U>,
<U>3.24 (Investment Company Act)</U>, <U>3.25 (General Solicitation; No Integration or Aggregation)</U>, <U>3.26 (Brokers and Finders)</U>,
<U>3.27 (Reliance by the Investors)</U>, and <U>3.31 (No Additional Agreements)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>GAAP</B>&rdquo;
has the meaning set forth in <U>Section 3.8(b)</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>GDPR</B>&rdquo;
has the meaning set forth in <U>Section 3.34</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Governmental Authorizations</B>&rdquo;
has the meaning set forth in <U>Section 3.11</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Health Care Laws</B>&rdquo;
has the meaning set forth in <U>Section 3.21</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>HIPAA</B>&rdquo;
has the meaning set forth in <U>Section 3.33</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Indemnified Persons</B>&rdquo;
has the meaning set forth in <U>Section 5.10(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Initial Shares</B>&rdquo;
has the meaning set forth in the recitals hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Intellectual Property</B>&rdquo;
has the meaning set forth in <U>Section 3.12</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Investor</B>&rdquo;
and &ldquo;<B>Investors</B>&rdquo; have the meanings set forth in the recitals hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Investor Majority</B>&rdquo;
means, (i) prior to the Closing, the Investors committed to purchase at least a majority of the Securities (provided that such majority
shall include each Investor that committed an Aggregate Purchase Amount of no less than $25 million (including the Aggregate Purchase
Amount of such Investor&rsquo;s affiliates and related funds)), and (ii) following the Closing, the Investors who hold at least a majority
of the Securities (including any Pre-Funded Warrant Shares) still held by the Investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>IT Systems</B>&rdquo;
has the meaning set forth in <U>Section 3.33</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Material Adverse
Effect</B>&rdquo; means any change, event, circumstance, development, condition, occurrence or effect that, individually or in the aggregate,
(a) was, is, or would reasonably be expected to be, materially adverse to the business, financial condition, properties, assets, liabilities,
stockholders&rsquo; equity or results of operations of the Company and its Subsidiaries, taken as a whole, or (b) materially delays or
materially impairs the ability of the Company to timely comply, or prevents the Company from complying, with its obligations under this
Agreement, the other Transaction Agreements, or with respect to the Closing, or would reasonably be expected to do so; provided, however,
that none of the following will be deemed in themselves, either alone or in combination, to constitute, and that none of the following
will be taken into account in determining whether there has been or will be, a Material Adverse Effect under subclause (a) of this definition:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) any
change generally affecting the economy, financial markets or political, economic or regulatory conditions in the United States or any
other geographic region in which the Company conducts business, provided that the Company is not disproportionately affected thereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii) general
financial, credit or capital market conditions, including interest rates or exchange rates, or any changes therein, provided that the
Company is not disproportionately affected thereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii) any
change that generally affects industries in which the Company and its Subsidiaries conduct business, provided that the Company is not
disproportionately affected thereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv) earthquakes,
hurricanes, tsunamis, tornadoes, floods, mudslides, fires or other natural disasters, weather conditions, global pandemics, including
the COVID-19 pandemic and related strains, epidemic or similar health emergency, and other force majeure events in the United States or
any other location, provided that the Company is not disproportionately affected thereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v) national
or international political or social conditions (or changes in such conditions), whether or not pursuant to the declaration of a national
emergency or war, or the occurrence of any military or terrorist attack, provided that the Company is not disproportionately affected
thereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vi) material
changes in laws after the date of this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vii) in
and of itself, any material failure by the Company to meet any published or internally prepared estimates of drug development timelines
(it being understood that the facts and circumstances giving rise to such failure may be deemed to constitute, and may be taken into account
in determining whether there has been, a Material Adverse Effect to the extent that such facts and circumstances are not otherwise described
in clauses (i)-(v) of this definition).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Nasdaq</B>&rdquo;
means the Nasdaq Stock Market LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>National Exchange</B>&rdquo;
means (i) on and prior to the Closing Date, the Nasdaq Global Market, and (ii) following the Closing Date, any of the following markets
or exchanges on which the Common Stock is listed or quoted for trading on the date in question, together with any successor thereto: the
NYSE American, The New York Stock Exchange, the Nasdaq Global Market, the Nasdaq Global Select Market and the Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Person</B>&rdquo;
means an individual, partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association,
joint venture or any other entity or organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Personal Data</B>&rdquo;
has the meaning set forth in <U>Section 3.33</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Placement Agent</B>&rdquo;
means each of Jefferies LLC, TD Securities (USA) LLC, Guggenheim Securities, LLC and LifeSci Capital LLC (collectively, the &ldquo;<U>Placement
Agents</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Pre-Funded Warrant
Price</B>&rdquo; means $14.999.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Pre-Funded Warrant
Shares</B>&rdquo; has the meaning set forth in <U>Section 3.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Pre-Funded Warrants</B>&rdquo;
has the meaning set forth in the recitals hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Privacy Laws</B>&rdquo;
has the meaning set forth in <U>Section 3.34</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Privacy Statements</B>&rdquo;
has the meaning set forth in <U>Section 3.34</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Process</B>&rdquo;
or &ldquo;<B>Processing</B>&rdquo; has the meaning set forth in <U>Section 3.34</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Registration Rights
Agreement</B>&rdquo; has the meaning set forth in <U>Section 6.1(j)</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Regulatory Agencies</B>&rdquo;
has the meaning set forth in <U>Section 3.20 </U>hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Rule 144</B>&rdquo;
means Rule 144 promulgated by the SEC pursuant to the Securities Act, as such rule may be amended from time to time, or any similar rule
or regulation hereafter adopted by the SEC having substantially the same effect as such rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>SEC</B>&rdquo; means
the U.S. Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Securities</B>&rdquo;
has the meaning set forth in <U>Section 2.1</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Securities Act</B>&rdquo;
has the meaning set forth in the recitals hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Share Price</B>&rdquo;
means $15.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Shares</B>&rdquo;
means the Initial Shares and the Pre-Funded Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Short Sales</B>&rdquo;
include, without limitation, (i) all &ldquo;short sales&rdquo; as defined in Rule 200 promulgated under Regulation SHO under the Exchange
Act, whether or not against the box, and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls,
short sales, swaps, &ldquo;put equivalent positions&rdquo; (as defined in Rule 16a-1(h) under the Exchange Act) and similar arrangements
(including on a total return basis), and (ii) sales and other transactions through non-U.S. broker dealers or non-U.S. regulated brokers
(but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock), in each case, solely to the
extent it has the same economic effect as a &ldquo;short sale&rdquo; (as defined in Rule 200 promulgated under Regulation SHO under the
Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Subsidiaries</B>&rdquo;
has the meaning set forth in <U>Section 3.1</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tax</B>&rdquo; or
&ldquo;<B>Taxes</B>&rdquo; means any and all federal, state, local, foreign and other taxes, levies, fees, imposts, duties and charges
of whatever kind (including any interest, penalties or additions to the tax imposed in connection therewith or with respect thereto),
whether or not imposed on the Company, including, without limitation, taxes imposed on, or measured by, income, franchise, profits or
gross receipts, and also ad valorem, value added, sales, use, service, real or personal property, capital stock, license, payroll, withholding,
employment, social security, workers&rsquo; compensation, unemployment compensation, utility, severance, production, excise, stamp, occupation,
premium, windfall profits, transfer and gains taxes and customs duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tax Returns</B>&rdquo;
means returns, reports, information statements and other documentation (including any additional or supporting material) filed or maintained,
or required to be filed or maintained, in connection with the calculation, determination, assessment or collection of any Tax and shall
include any amended returns required as a result of examination adjustments made by the Internal Revenue Service or other Tax authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Transaction Agreements</B>&rdquo;
means this Agreement, the Pre-Funded Warrants, the Registration Rights Agreement and any other documents or agreements explicitly contemplated
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Transfer Agent</B>&rdquo;
means, with respect to the Common Stock, Computershare Inc., or such other financial institution that provides transfer agent services
as the Company may engage from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Transfer Taxes</B>&rdquo;
means all real property transfer, sales, use, value added, stamp, documentary, recording, registration, conveyance, stock transfer, intangible
property transfer, personal property transfer, gross receipts, registration, duty, securities transactions or similar fees or Taxes (together
with any interest, penalty, or addition thereto) incurred in connection with the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. <FONT STYLE="font-size: 10pt"><U>Purchase
and Sale of Securities.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1 <U>Purchase and Sale</U>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Investors, severally
and not jointly, agree to purchase, up to an aggregate of $180,000,000 of Securities (as defined below), with a purchase price per Initial
Share equal to the Share Price and a purchase price per Pre-Funded Warrant equal to the Pre-Funded Warrant Price. Subject to and upon
the terms and conditions set forth in this Agreement, at the Closing, the Company shall issue and sell to each Investor, and each Investor,
severally and not jointly, shall purchase from the Company, (A) that number of Initial Shares set forth opposite such Investor&rsquo;s
name on <U>Exhibit A</U> under the heading &ldquo;Shares&rdquo; and/or (B) a Pre-Funded Warrant exercisable for a number of shares of
Common Stock set forth opposite such Investor&rsquo;s name on <U>Exhibit A</U> under the heading &ldquo;Shares Underlying Pre-Funded
Warrants.&rdquo; The Initial Shares and the Pre-Funded Warrants to be issued in the Closing are collectively referred to herein as the
&ldquo;<B>Securities</B>.&rdquo; Notwithstanding the foregoing, for any Investor that has provided notice to the Company that this sentence
shall apply to it, the Company shall not issue or sell, and the Investor shall not purchase or acquire, any Initial Shares and/or Pre-Funded
Warrants under this Agreement which, when aggregated with all shares of Common Stock then beneficially owned by the Investor, its affiliates
and any Person acting as a group together with such Investor or any of such Investor&rsquo;s affiliates (as calculated pursuant to Section
13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder), would result in the beneficial ownership by the Investor of more than
4.99%, 9.99% or 14.99% (as applicable) of the outstanding shares of Common Stock immediately after giving effect to the Closing and the
consummation of the transactions contemplated hereby, and the number of Initial Shares and/or Pre-Funded Warrants and the Aggregate Purchase
Amount for such Investor shall be reduced accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2 <U>Closing</U>. Subject
to the satisfaction or waiver of the conditions set forth in <U>Section 6</U> of this Agreement, the closing of the purchase and sale
of the Securities (the &ldquo;<B>Closing</B>&rdquo; and the date on which the Closing occurs, the &ldquo;<B>Closing Date</B>&rdquo;)
shall occur remotely via the exchange of documents and signatures on the second Business Day after the date hereof, or at such other
time as agreed to by the Company and the Investor Majority, but in no event later than the fifth Business Day after the date hereof.
At the Closing, the Securities shall be issued and registered in the name of such Investor, or in such nominee name(s) as designated
by such Investor, representing the number of Securities to be purchased by such Investor at such Closing as set forth in <U>Exhibit A</U>,
in each case against payment to the Company of the purchase price therefor (the &ldquo;<B>Aggregate Purchase Amount</B>&rdquo;) in full,
by wire transfer to the Company of immediately available funds, at or prior to the Closing, in accordance with wire instructions provided
by the Company to the Investors at least one Business Day prior to the Closing. On the Closing Date, the Company will (A) cause the Transfer
Agent to issue the Initial Shares in book-entry form, free and clear of all restrictive and other legends (except as expressly provided
in <U>Section 4.10</U> hereof) and the Company shall provide evidence of such issuance from the Company&rsquo;s Transfer Agent as soon
as reasonably practical following the Closing Date to each Investor and (B) deliver to such Investor (or such Investor&rsquo;s designated
custodian per its delivery instructions), or in such nominee name(s) as designated by such Investor, a Pre-Funded Warrant exercisable
for a number of shares of Common Stock as set forth in <U>Exhibit A</U> with respect to such Investor. If the Closing has not occurred
within two Business Days after the expected Closing Date, unless otherwise agreed by the Company and such Investor, the Company shall
promptly (but no later than one Business Day thereafter) return the previously wired Aggregate Purchase Amount to each respective Investor
by wire transfer of United States dollars in immediately available funds to the account specified by each Investor, and any book entries
for the Securities shall be deemed cancelled; provided that, unless this Agreement has been terminated pursuant to Section 7, such return
of funds shall not terminate this Agreement or relieve such Investor of its obligation to purchase, or the Company of its obligation
to issue and sell, the Securities at the Closing. Notwithstanding the foregoing and anything in this Agreement to the contrary and as
may be agreed to among the Company and one or more Investors, if an Investor is (a) an investment company registered under the Investment
Company Act of 1940, as amended, (b) advised by an investment adviser subject to regulation under the Investment Advisers Act of 1940,
as amended, or (c) otherwise subject to internal policies and/or procedures relating to the timing of funding and issuance of securities,
such Investor shall not be required to wire its Aggregate Purchase Amount until it confirms receipt of evidence of the issuance of such
Investor&rsquo;s Initial Shares from the Transfer Agent in form and substance reasonably acceptable to the Investor and, if applicable,
copies of such Investor&rsquo;s Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. <FONT STYLE="font-size: 10pt"><U>Representations
and Warranties of the Company</U>. Except as disclosed or reflected in the 2025 SEC Reports (but other than as to Fundamental Representations,
which are not qualified, and excluding any risk factor disclosures contained under the heading &ldquo;Risk Factors,&rdquo; any disclosure
of risks included in any &ldquo;forward-looking statements&rdquo; disclaimer or any other statements that are similarly predictive or
forward-looking in nature, in each case, other than any specific factual information contained therein), the Company hereby represents
and warrants to each of the Investors and the Placement Agents that the statements contained in this <U>Section 3</U> are true and correct
as of the date hereof and as of the Closing Date (except for the representations and warranties that speak as of a specific date, which
shall be made as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1 <U>Organization
and Power</U><FONT STYLE="font-size: 10pt">. The Company is a corporation duly organized, validly existing and in good standing under
the laws of the State of Delaware, has the requisite power and authority to own, lease and operate its properties and to carry on its
business as now conducted and described in the 2025 SEC Reports and is qualified to do business in each jurisdiction in which the character
of its properties or the nature of its business requires such qualification, except where such failure to be in good standing or to have
such power and authority or to so qualify would not reasonably be expected to have a Material Adverse Effect. As of the date hereof, the
Company has the following subsidiaries: Oruka Therapeutics Operating Company, LLC, a Delaware limited liability company and Oruka Therapeutics
Australia Pty Ltd, an Australian company (collectively, the &ldquo;<B>Subsidiaries</B>&rdquo;). Each of the Subsidiaries is duly incorporated
and validly existing and in good standing under the laws of the jurisdiction of its incorporation and has the requisite power and authority
to carry on their business as now conducted and to own or lease its properties. Each of the Subsidiaries is duly qualified to do business
as a foreign corporation and is in good standing in each jurisdiction in which such qualification is required unless the failure to so
qualify has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.2 <U>Capitalization</U><FONT STYLE="font-size: 10pt">.
The authorized capital stock of the Company consists of 545,000,000 shares of Common Stock and 5,000,000 shares of preferred stock, par
value $0.001 per share. The Company&rsquo;s disclosure of its issued and outstanding capital stock in the 2025 SEC Reports containing
such disclosure was accurate in all material respects as of the date indicated in such 2025 SEC Reports. All of the issued and outstanding
shares of Common Stock have been duly authorized and validly issued and are fully paid and non-assessable. None of the outstanding shares
of capital stock of the Company were issued in violation of any preemptive or other similar rights of any securityholder of the Company
which have not been waived, and such shares were issued in compliance in all material respects with applicable state and federal securities
law and any rights of third parties. Except as set forth in the Transaction Agreements or as disclosed in the 2025 SEC Reports, there
are no outstanding rights (including, without limitation, pre-emptive or other similar rights), warrants or options to acquire, or instruments
convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or any of its Subsidiaries,
or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of the
Company or any such Subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options (except equity
awards that have been granted under the Company&rsquo;s equity award plans described in the 2025 SEC Reports); the capital stock of the
Company conforms in all material respects to the description thereof contained in the 2025 SEC Reports; and all the outstanding shares
of capital stock or other equity interests of each Subsidiary owned, directly or indirectly, by the Company have been duly and validly
authorized and issued, are fully paid and non-assessable (except, in the case of any foreign subsidiary, for directors&rsquo; qualifying
shares).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.3 <U>Registration
Rights</U><FONT STYLE="font-size: 10pt">. Except as set forth in the Transaction Agreements (including in <U>Section 3.7</U>), the Company
is presently not under any obligation, and has not granted any rights, to register under the Securities Act any of the Company&rsquo;s
presently outstanding securities or any of its securities that may hereafter be issued that have not expired or been satisfied or waived.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.4 <U>Authorization</U><FONT STYLE="font-size: 10pt">.
The Company has all requisite corporate power and authority to enter into the Transaction Agreements and to carry out and perform its
obligations under the terms of the Transaction Agreements, including the issuance and sale of the Securities and the issuance of the shares
of Common Stock issuable upon exercise of the Pre-Funded Warrants (the &ldquo;<B>Pre-Funded Warrant Shares</B>&rdquo;). All corporate
action on the part of the Company, its officers, directors and stockholders necessary for the authorization of the Securities and the
Pre-Funded Warrant Shares, the authorization, execution, delivery and performance of the Transaction Agreements and the consummation of
the transactions contemplated herein, including the issuance and sale of the Securities and the Pre-Funded Warrant Shares, has been taken.
This Agreement has been duly executed and delivered by the Company and assuming the due authorization, execution and delivery by each
Investor and that this Agreement constitutes the legal, valid and binding agreement of each Investor, this Agreement and each of the Pre-Funded
Warrants constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms,
except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws relating to or affecting
creditors generally or by general equity principles (regardless of whether such enforceability is considered in a proceeding in equity
or at law). Upon its execution by the Company and the other parties thereto and assuming that it constitutes legal, valid and binding
agreements of the other parties thereto, the Registration Rights Agreement will constitute a legal, valid and binding obligation of the
Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency,
reorganization, moratorium and similar laws relating to or affecting creditors generally or by general equity principles (regardless of
whether such enforceability is considered in a proceeding in equity or at law).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.5 <U>Valid
Issuance</U><FONT STYLE="font-size: 10pt">. The Initial Shares being purchased by the Investors hereunder have been duly and validly authorized
and, upon issuance pursuant to the terms of this Agreement against full payment therefor in accordance with the terms of this Agreement,
will be duly and validly issued, fully paid and non-assessable and will be issued free and clear of any liens or other restrictions (other
than those as provided in the Transaction Agreements or restrictions on transfer under applicable state and federal securities laws),
and the holder of the Initial Shares shall be entitled to all rights accorded to a holder of Common Stock. The Pre-Funded Warrant Shares
have been duly and validly authorized and reserved for issuance and, upon issuance pursuant to the terms of the Pre-Funded Warrants, against
full payment therefor in accordance with the terms of the Pre-Funded Warrants, will be duly and validly issued, fully paid and non-assessable
and will be issued free and clear of any liens or other restrictions (other than those as provided in the Transaction Agreements or restrictions
on transfer under applicable state and federal securities laws) and the holder of the Pre-Funded Warrant Shares shall be entitled to all
rights accorded to a holder of Common Stock. The issuance and delivery of the Initial Shares and the Pre-Funded Warrants do not, and the
exercise in full of the Pre-Funded Warrants (without regard to any limitations or restrictions on exercise of such warrants) and the issuance
and delivery of the Pre-Funded Warrant Shares thereupon will not (a) obligate the Company to offer to issue, or issue, shares of Common
Stock or other securities to any Person (other than the Investors) pursuant to any preemptive rights, rights of first refusal, rights
of participation or similar rights, or (b) result in any adjustment (automatic, at the election of any Person or otherwise) of the exercise,
conversion, exchange or reset price under, or any other anti-dilution adjustment pursuant to, any outstanding securities of the Company
or (c) be subject to any preemptive right, right of first offer, or any similar right of any Person. Subject to the accuracy of the representations
and warranties made by the Investors in <U>Section 4</U> hereof, the offer and sale of the Securities to the Investors is and will be
in compliance with applicable exemptions from (i) the registration and prospectus delivery requirements of the Securities Act and (ii)
the registration and qualification requirements of applicable securities laws of the states of the United States. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.6 <U>No
Conflict</U><FONT STYLE="font-size: 10pt">. The execution, delivery and performance of the Transaction Agreements by the Company, the
issuance and sale of the Securities and the consummation of the other transactions contemplated by the Transaction Agreements will not
(i) violate any provision of the Amended and Restated Certificate of Incorporation or Amended and Restated Bylaws, (ii) conflict with
or result in a violation of or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination,
cancellation or acceleration of any obligation, a change of control right or to a loss of a benefit under any agreement or instrument,
credit facility, franchise, license, judgment, order, statute, law, ordinance, rule or regulations, applicable to the Company or any Subsidiary
or their respective properties or assets,&nbsp;<FONT STYLE="background-color: white">or (iii)&nbsp;result in a violation of any law, rule,
regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or any
Subsidiary is subject (including federal and state securities laws and regulations) and the rules and regulations of any self-regulatory
organization to which the Company or its securities are subject, or by which any property or asset of the Company or any Subsidiary is
bound or affected,&nbsp;</FONT>except, in the case of clauses (ii) and (iii), as would not, individually or in the aggregate, be reasonably
expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.7 <U>Consents</U><FONT STYLE="font-size: 10pt">.
Assuming the accuracy of the representations and warranties of the Investors in <U>Section 4</U>, no consent, approval, authorization,
filing with or order of or registration with, any court or governmental agency or body or self-regulatory organization to which the Company
or its securities is subject is required in connection with the authorization, execution or delivery or performance by the Company of
the Transaction Agreements, the issuance and sale of the Securities and the performance by the Company of its other obligations under
the Transaction Agreements, except such as (a) have been or will be obtained or made under the Securities Act, the Exchange Act or the
Company&rsquo;s existing registration rights agreement, (b) the filing of any requisite notices and/or application(s) to the National
Exchange for the issuance and sale of the Shares or the Pre-Funded Warrants and the listing of the Shares for trading or quotation, as
the case may be, thereon in the time and manner required thereby, (c) customary post-closing filings with the SEC or pursuant to state
securities laws in connection with the offer and sale of the Initial Shares or the Pre-Funded Warrants by the Company in the manner contemplated
herein, which will be filed on a timely basis, (d) the filing of the registration statement required to be filed by the Company pursuant
to the Registration Rights Agreement, or (e) such that the failure of which to obtain would not have a Material Adverse Effect. All notices,
consents, authorizations, orders, filings and registrations which the Company is required to deliver or obtain prior to the Closing pursuant
to the preceding sentence have been obtained or made or will be delivered or obtained or effected, and shall remain in full force and
effect, on or prior to the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.8 <U>SEC
Filings; Financial Statements</U><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) The
Company has timely filed or furnished, as applicable, all forms, statements, certifications, reports and documents required to be filed
or furnished by it with the SEC under the Exchange Act or the Securities Act for the one year preceding the date of this Agreement. As
of the time it was filed with, or furnished to, the SEC (or, if amended or superseded by a filing prior to the date of this Agreement,
then on the date of such filing), each of the 2025 SEC Reports complied in all material respects with the applicable requirements of the
Securities Act or the Exchange Act (as the case may be), and the rules and regulations promulgated thereunder, and, as of the time they
were filed or furnished, none of the 2025 SEC Reports contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they
were made, not misleading. There are no outstanding or unresolved comments from the SEC staff with respect to the 2025 SEC Reports. None
of the 2025 SEC Reports is the subject of an ongoing SEC review. The interactive data in eXtensible Business Reporting Language included
in the 2025 SEC Reports fairly presents the information called for in all material respects and has been prepared in accordance with the
SEC&rsquo;s rules and guidelines applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) The
consolidated financial statements of the Company included in the 2025 SEC Reports (collectively, the &ldquo;<B>Financial Statements</B>&rdquo;)
comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto
as in effect at the time of filing (or to the extent corrected by a subsequent restatement) and fairly present in all material respects
the consolidated financial position of the Company and its Subsidiaries as of the dates indicated, and the results of its operations and
cash flows for the periods therein specified, all in accordance with United States generally accepted accounting principles (&ldquo;<B>GAAP</B>&rdquo;)
(except as otherwise noted therein, and in the case of unaudited financial statements, as permitted by Form 10-Q of the SEC, and except
that the unaudited financial statements may not contain footnotes and are subject to normal and recurring year-end adjustments) applied
on a consistent basis unless otherwise noted therein throughout the periods therein specified. Except as set forth in the Financial Statements
filed prior to the date hereof, the Company has not incurred any liabilities, contingent or otherwise, except (i) those incurred in the
ordinary course of business, consistent with past practices since the date of such financial statements or (ii) liabilities not required
under GAAP to be reflected in the Financial Statements, in either case, none of which, individually or in the aggregate, have had or would
reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.9 <U>Absence
of Changes</U><FONT STYLE="font-size: 10pt">. Except as otherwise stated or disclosed in the 2025 SEC Reports, since January 1, 2025:
(a) the Company has conducted its business only in the ordinary course of business and there have been no material transactions entered
into by the Company or any Subsidiary (except for the execution and performance of this Agreement and the discussions, negotiations and
transactions related thereto); (b) no material change to any material contract or arrangement by which the Company or any Subsidiary is
bound or to which any of their respective assets or properties is subject has been entered into that has not been disclosed in the 2025
SEC Reports; and (c) there has not been any other event or condition of any character that has had or would reasonably be expected to
have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.10 <U>Absence
of Litigation</U><FONT STYLE="font-size: 10pt">. There is no action, suit, proceeding, arbitration, claim, investigation, charge, complaint
or inquiry pending or, to the Company&rsquo;s knowledge, threatened against the Company or any Subsidiary which, individually or in the
aggregate, has had or would reasonably be expected to have a Material Adverse Effect, nor are there any orders, writs, injunctions, judgments
or decrees outstanding of any court or government agency or instrumentality and binding upon the Company or any Subsidiary that have had
or would reasonably be expected to have a Material Adverse Effect. <FONT STYLE="background-color: white">Neither the Company nor any Subsidiary,
nor to the knowledge of the Company, any director or officer of the Company or any Subsidiary, is, or within the last ten years has been,
the subject of any action involving a claim of violation of or liability under federal or state securities laws relating to the Company
or such Subsidiary or a claim of breach of fiduciary duty relating to the Company or such Subsidiary.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.11 <U>Compliance
with Law; Permits</U><FONT STYLE="font-size: 10pt">. None of the Company or any Subsidiary is in violation of, or has received any notices
of violations with respect to, any laws, statutes, ordinances, rules or regulations of any governmental body, court or government agency
or instrumentality, except for violations which, individually or in the aggregate, have not had and would not reasonably be expected to
have a Material Adverse Effect. The Company and its Subsidiaries have all required licenses, permits, certificates and other authorizations
(collectively, &ldquo;<B>Governmental Authorizations</B>&rdquo;) from such federal, state or local government or governmental agency,
department or body that are currently necessary for the operation of the business of the Company and its Subsidiaries as currently conducted,
except where the failure to possess currently such Governmental Authorizations has not had and is not reasonably expected to have a Material
Adverse Effect. None of the Company or any Subsidiary has received any written (or, to the Company&rsquo;s knowledge, oral) notice regarding
any revocation or material modification of any such Governmental Authorization, which, individually or in the aggregate, if the subject
of an unfavorable decision, ruling or finding, has or would reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.12 <U>Intellectual
Property</U><FONT STYLE="font-size: 10pt">. The Company and its Subsidiaries own, or have rights to use, all material inventions, patent
applications, patents, trademarks, trade names, service names, service marks, copyrights, trade secrets, know how (including unpatented
and/or unpatentable proprietary of confidential information, systems or procedures) and other intellectual property as described in the
2025 SEC Reports necessary for, or used in the conduct of their respective businesses (including as described in the 2025 SEC Reports)
(collectively, &ldquo;<B>Intellectual Property</B>&rdquo;), except where any failure to own, possess or acquire such Intellectual Property
has not had, and would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Intellectual
Property of the Company and its Subsidiaries has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable,
in whole or in part. To the Company&rsquo;s knowledge: (i) there are no third parties who have rights to any Intellectual Property, including
no liens, security interests, or other encumbrances; and (ii) there is no infringement by third parties of any Intellectual Property.
No action, suit, or other proceeding is pending, or, to the Company&rsquo;s knowledge, is threatened: (A) challenging the Company&rsquo;s
or its Subsidiaries&rsquo; rights in or to any Intellectual Property; (B) challenging the validity, enforceability or scope of any Intellectual
Property; or (C) alleging that the Company or any of its Subsidiaries infringes, misappropriates, or otherwise violates any patent, trademark,
trade name, service name, copyright, trade secret or other proprietary rights of others, except, in each case, which, individually or
in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect. The Company and its Subsidiaries
have complied in all material respects with the terms of each agreement pursuant to which Intellectual Property has been licensed to the
Company or any of its Subsidiaries in all material respects, and to the Company&rsquo;s knowledge all such agreements are in full force
and effect. To the Company&rsquo;s knowledge, there are no material defects in any of the patents or patent applications included in the
Intellectual Property. The Company and its Subsidiaries have taken all reasonable steps to protect, maintain and safeguard their Intellectual
Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.13 <U>Employee
Benefits</U><FONT STYLE="font-size: 10pt">. Except as would not be reasonably likely to result in a Material Adverse Effect, each Benefit
Plan has been established and administered in accordance with its terms and in compliance with the applicable provisions of ERISA, the
Code, the Patient Protection and Affordable Care Act of 2010, as amended, and other applicable laws, rules and regulations. The Company
and its Subsidiaries are in compliance with all applicable federal, state and local laws, rules and regulations regarding employment,
except for any failures to comply that are not reasonably likely, individually or in the aggregate, to have a Material Adverse Effect.
There is no labor dispute, strike or work stoppage against the Company or its Subsidiaries pending or, to the knowledge of the Company,
threatened which may interfere with the business activities of the Company, except where such dispute, strike or work stoppage is not
reasonably likely, individually or in the aggregate, to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.14 <U>Taxes</U><FONT STYLE="font-size: 10pt">.
The Company and its Subsidiaries have filed all federal, state and foreign income Tax Returns and other Tax Returns required to have been
filed under applicable law (or extensions have been duly obtained) and have paid all Taxes required to have been paid by them, except
for those which are being contested in good faith and except where failure to file such Tax Returns or pay such Taxes would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect. No assessment in connection with United States federal
tax returns has been made against the Company. The charges, accruals and reserves on the books of the Company in respect of any income
and corporation tax liability for any years not finally determined are adequate to meet any assessments or reassessments for additional
income tax for any years not finally determined, except to the extent of any inadequacy that would not result in a Material Adverse Effect.
No audits, examinations, or other proceedings with respect to any material amounts of Taxes of the Company and its Subsidiaries are presently
in progress or have been asserted or proposed in writing without subsequently being paid, settled or withdrawn. There are no liens on
any of the assets of the Company. The Company, at all times since inception, has been and continues to be each classified as a corporation
for U.S. federal income tax purposes. Neither the Company nor any of its Subsidiaries has been a United States real property holding corporation
within the meaning of Code Section 897(c)(2) during the period specified in Code Section 897(c)(1)(A)(ii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.15 <U>Environmental
Laws</U><FONT STYLE="font-size: 10pt">. The Company and its Subsidiaries (i)&nbsp;are in compliance with any and all applicable foreign,
federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic
substances or wastes, pollutants or contaminants (&ldquo;<B>Environmental Laws</B>&rdquo;), (ii)&nbsp;have received all permits and other
Governmental Authorizations required under applicable Environmental Laws to conduct its business and (iii)&nbsp;are in compliance with
all terms and conditions of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to
receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or
approvals would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. None of the Company or
any Subsidiary has received since January 1, 2025, any written notice or other communication (in writing or otherwise), whether from a
governmental authority or other Person, that alleges that the Company or any Subsidiary is not in compliance with any Environmental Law
and, to the knowledge of the Company, there are no circumstances that may prevent or interfere with the Company&rsquo;s or any Subsidiary&rsquo;s
compliance with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Material
Adverse Effect. To the knowledge of the Company: (i) no current or (during the time a prior property was leased or controlled by the Company)
prior property leased or controlled by the Company or any Subsidiary has received since January 1, 2025, any written notice or other communication
relating to property owned or leased at any time by the Company, whether from a governmental authority, or other Person, that alleges
that such current or prior owner or the Company or any Subsidiary is not in compliance with or violated any Environmental Law relating
to such property and (ii) the Company has no material liability under any Environmental Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.16 <U>Title</U><FONT STYLE="font-size: 10pt">.
Each of the Company and its Subsidiaries has good and marketable title to all personal property owned by it that is material to the business
of the Company, free and clear of all liens, encumbrances and defects except such as do not materially affect the value of such property
and do not materially and adversely interfere with the use made and proposed to be made of such property by the Company or its Subsidiaries,
as the case may be. Any real property and buildings held under lease by the Company or its Subsidiaries is held under valid, subsisting
and enforceable leases with such exceptions as are not material and do not materially and adversely interfere with the use made and proposed
to be made of such property and buildings by the Company or its Subsidiaries, as the case may be. The Company does not own any real property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.17 <U>Insurance</U><FONT STYLE="font-size: 10pt">.
The Company carries or is entitled to the benefits of insurance in such amounts and covering such risks that is customary for comparably
situated companies and is adequate for the conduct of its business and the value of its properties (owned or leased) and assets, and each
of such insurance policies is in full force and effect and the Company is in compliance in all material respects with the terms thereof.
Other than customary end of policy notifications from insurance carriers, since January 1, 2025, the Company has not received any notice
or other communication regarding any actual or possible: (i) cancellation or invalidation of any insurance policy or (ii) refusal or denial
of any coverage, reservation of rights or rejection of any material claim under any insurance policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.18 <U>Nasdaq
Stock Market</U><FONT STYLE="font-size: 10pt">. The issued and outstanding shares of Common Stock are registered pursuant to Section 12(b)
of the Exchange Act and are listed for trading on the Nasdaq Global Market under the symbol &ldquo;ORKA&rdquo;. The Company is in compliance
in all material respects with all applicable listing requirements of Nasdaq applicable to the Company. There is no suit, action, proceeding
or investigation pending or, to the knowledge of the Company, threatened against the Company by Nasdaq or the SEC, respectively, to prohibit
or terminate the listing of the Common Stock on the Nasdaq Global Market or to deregister the Common Stock under the Exchange Act. The
Company has taken no action that is designed to terminate the registration of the Common Stock under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.19 <U>Sarbanes-Oxley
Act</U><FONT STYLE="font-size: 10pt">. The Company is, and since January 1, 2025 has been, in compliance in all material respects with
all applicable requirements of the Sarbanes-Oxley Act of 2002 and applicable rules and regulations promulgated by the SEC thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.20 <U>Clinical
Data and Regulatory Compliance</U><FONT STYLE="font-size: 10pt">. Except as would not reasonably be expected to result in a Material Adverse
Effect: (i) the preclinical tests and clinical trials, and other studies used to support regulatory approval (collectively, &ldquo;<B>studies</B>&rdquo;)
being conducted by or on behalf of, or sponsored by, the Company or its Subsidiaries that are described in, or the results of which are
referred to in, 2025 SEC Reports were and, if still pending, are being conducted in all material respects in accordance with the protocols,
procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; (ii) each
description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from
such studies, and the Company and its Subsidiaries have no knowledge of any other studies the results of which are required to be disclosed
in accordance with the Exchange Act and are inconsistent with, or otherwise call into question, the results described or referred to in
the 2025 SEC Reports; (iii) the Company and its Subsidiaries have made all such filings and obtained all such approvals as may be required
by the FDA or from any other U.S. federal, state or local government or foreign government or Drug Regulatory Agency, or Institutional
Review Board, each having jurisdiction over biopharmaceutical products (collectively, the &ldquo;<B>Regulatory Agencies</B>&rdquo;) for
the conduct of its business as described in the 2025 SEC Reports; (iv) neither the Company nor any of its Subsidiaries has received any
notice of, or correspondence from, any Regulatory Agency requiring the termination or suspension of or imposing any clinical hold on any
clinical trials that are described or referred to in the 2025 SEC Reports; and (v) the Company and its Subsidiaries have each operated
and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.21 <U>Compliance
with Health Care Laws</U><FONT STYLE="font-size: 10pt">. The Company and its Subsidiaries are in compliance in all material respects with
all Health Care Laws to the extent applicable to the current business of the Company and its Subsidiaries or any of their respective activities.
For purposes of this Agreement, &ldquo;<B>Health Care Laws</B>&rdquo; means: (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section
301 et seq.) and the Public Health Service Act (42 U.S.C. Section 201 et seq.), and the regulations promulgated thereunder; (ii) all applicable
federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C.
Section 1320a-7b(b)); (iii) HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section
17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation
Act of 2010; (v) the European Union (&ldquo;<B>EU</B>&rdquo;) Clinical Trials Regulation (Regulation (EU) No. 536/2014); (vi) the EU Regulation
regarding community procedures for authorization and supervision of medicinal products for human and veterinary use and establishing a
European Medicines Agency (Regulation (EC) No. 726/2004); (vii) licensure, quality, safety and accreditation requirements under applicable
federal, state, local or foreign laws or regulatory bodies; (viii) all other local, state, federal, national, supranational and foreign
laws, relating to the regulation of the Company or its Subsidiaries, and (ix) the regulations promulgated pursuant to such statutes and
any state or non-U.S. counterpart thereof. Neither the Company nor any of its Subsidiaries has received written or, to the Company&rsquo;s
knowledge, oral notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any
court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in material
violation of any Health Care Laws nor, to the Company&rsquo;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action threatened. The Company and its Subsidiaries have filed, maintained or submitted all material
reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health
Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were
complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission). Neither
the Company nor any of its Subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement
orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company, any of its
Subsidiaries nor any of their respective employees, officers, directors, or, to the knowledge of the Company, agents has been excluded,
suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the
Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to
result in debarment, suspension, or exclusion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.22 <U>Accounting
Controls and Disclosure Controls and Procedures</U><FONT STYLE="font-size: 10pt">. The Company maintains a system of internal control
over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that is designed to comply with the requirements
of the Exchange Act applicable to the Company and provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with GAAP, including policies and procedures sufficient to provide
reasonable assurance (i) that the Company maintains records that in reasonable detail accurately and fairly reflect the Company&rsquo;s
transactions and dispositions of assets, (ii) that transactions are recorded as necessary to permit preparation of financial statements
in accordance with GAAP, (iii) that receipts and expenditures are made only in accordance with authorizations of management and the Board
of Directors and (iv) regarding prevention or timely detection of the unauthorized acquisition, use or disposition of the Company&rsquo;s
assets that could have a material effect on the Company&rsquo;s financial statements. Since the end of the Company&rsquo;s most recent
audited fiscal year, there has been (a) no material weaknesses in the design or operation of the Company&rsquo;s internal control over
financial reporting(whether or not remediated) and (b) no change in the Company&rsquo;s internal control over financial reporting that
has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting.
The Company&rsquo;s &ldquo;disclosure controls and procedures&rdquo; (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act)
are designed to provide reasonable assurance that all information (both financial and non-financial) required to be disclosed by the Company
in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods
specified in the rules and forms of the SEC, and that all such information is accumulated and communicated to the Company&rsquo;s management
as appropriate to allow timely decisions regarding required disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.23 <U>Price
Stabilization of Common Stock</U><FONT STYLE="font-size: 10pt">. The Company has not taken, nor will it take, directly or indirectly,
any action designed to stabilize or manipulate the price of the Common Stock to facilitate the sale or resale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.24 <U>Investment
Company Act</U><FONT STYLE="font-size: 10pt">. The Company is not, and immediately after receipt of payment for the Securities will not
be, an &ldquo;investment company&rdquo; within the meaning of the U.S. Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.25 <U>General
Solicitation; No Integration or Aggregation</U><FONT STYLE="font-size: 10pt">. Neither the Company nor any other person or entity authorized
by the Company to act on its behalf has engaged in a general solicitation or general advertising (within the meaning of Regulation D of
the Securities Act) of investors with respect to offers or sales of the Securities pursuant to this Agreement. The Company has not, directly
or indirectly, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the
Securities Act) which, to its knowledge, is or will be (i) integrated with the offer and sale of the Securities pursuant to this Agreement
for purposes of the Securities Act <FONT STYLE="background-color: white">or (ii)&nbsp;aggregated with prior offerings by the Company for
the purposes of the rules and regulations of the Nasdaq Global Market</FONT>. Assuming the accuracy of the representations and warranties
of the Investors set forth in Section 4, neither the Company nor any of its Affiliates, its subsidiaries nor any Person acting on their
behalf has, directly or indirectly, made any offers or sales of any Company security or solicited any offers to buy any Company security,
under circumstances that would adversely affect reliance by the Company on Section 4(a)(2) of the Securities Act for the exemption from
registration for the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.26 <U>Brokers
and Finders</U><FONT STYLE="font-size: 10pt">. Other than the Placement Agents, neither the Company nor any other Person authorized by
the Company to act on its behalf has retained, utilized or been represented by any broker or finder in connection with the transactions
contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.27 <U>Reliance
by the Investors</U><FONT STYLE="font-size: 10pt">. The Company has a reasonable basis for making each of the representations set forth
in this Section 3. The Company acknowledges that each of the Investors will rely upon the truth and accuracy of, and the Company&rsquo;s
compliance with, the representations, warranties, agreements, acknowledgements and understandings of the Company set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.28 <U>[<I>Reserved</I>].</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.29 <U>Office
of Foreign Assets Control.</U> Neither the Company nor any subsidiary nor, to the Company&rsquo;s knowledge, any director, officer, agent,
employee or Affiliate of the Company or any subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign
Assets Control of the U.S. Treasury Department.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.30 </FONT>
<U>OISP.</U> Neither the Company nor any Subsidiary is or intends to become a &ldquo;covered foreign person&rdquo; within the meaning
of the Outbound Investment Security Program. &ldquo;Outbound Investment Security Program&rdquo; means the regulations implemented by the
U.S. Department of the Treasury under Executive Order 14105 &ldquo;Addressing United States Investments in Certain National Security Technologies
and Products in Countries of Concern,&rdquo; as codified at 31 C.F.R. Part 850.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.31 <U>No
Additional Agreements</U><FONT STYLE="font-size: 10pt">. There are no agreements or understandings between the Company, on one hand, and
any Investor, on the other hand, with respect to the transactions contemplated by the Transaction Agreements other than as specified in
the Transaction Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.32 <U>Anti-Bribery
and Anti-Money Laundering Laws; Sanctions</U><FONT STYLE="font-size: 10pt">. Each of the Company, its Subsidiaries and, to the knowledge
of the Company, any of their respective officers, directors, supervisors, managers, agents, or employees are and have at all times been
in compliance with and its participation in the offering will not violate: (A) anti-bribery laws, including but not limited to, any applicable
law, rule, or regulation of any locality, including but not limited to any law, rule, or regulation promulgated to implement the OECD
Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, signed December 17, 1997, including
the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other law, rule or regulation of similar
purposes and scope, (B) anti-money laundering laws, including, but not limited to, applicable federal, state, international, foreign or
other laws, regulations or government guidance regarding anti-money laundering, including, without limitation, Title 18 US. Code sections
1956 and 1957, the Patriot Act, the Bank Secrecy Act, and international anti-money laundering principles or procedures by an intergovernmental
group or organization, such as the Financial Action Task Force on Money Laundering, of which the United States is a member and with which
designation the United States representative to the group or organization continues to concur, all as amended, and any executive order,
directive, or regulation pursuant to the authority of any of the foregoing, or any orders or licenses issued thereunder, or (C) except
as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect, any laws with respect to
import and export control and economic sanctions, including the U.S. Export Administration Regulations, the U.S. International Traffic
in Arms Regulations, and economic sanctions regulations and executive orders administered by the U.S. Department of the Treasury Office
of Foreign Asset Control. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.33 <U>Cybersecurity</U><FONT STYLE="font-size: 10pt">.
The Company and its Subsidiaries&rsquo; information technology assets and equipment, computers, systems, networks, hardware, software,
websites, applications, and databases (collectively, &ldquo;<B>IT Systems</B>&rdquo;) are adequate for, and operate and perform in all
material respects as required in connection with the operation of the business of the Company and its Subsidiaries as currently conducted,
and are free and clear of all material Trojan horses, time bombs, malware and other malicious code. The Company and its Subsidiaries have
implemented and maintained commercially reasonable physical, technical and administrative controls designed to maintain and protect the
confidentiality, integrity, availability, privacy and security of all sensitive, confidential or regulated data (&ldquo;<B>Confidential
Data</B>&rdquo;) used or maintained in connection with their businesses and Personal Data (defined below), and the integrity, availability
continuous operation, redundancy and security of all IT Systems. &ldquo;<B>Personal Data</B>&rdquo; means the following data used in connection
with the Company&rsquo;s and its Subsidiaries&rsquo; businesses and in their possession or control: (i) a natural person&rsquo;s name,
street address, telephone number, e-mail address, photograph, social security number or other tax identification number, driver&rsquo;s
license number, passport number, credit card number or bank information; (ii) information that identifies or may reasonably be used to
identify an individual; (iii) any information that would qualify as &ldquo;protected health information&rdquo; under the Health Insurance
Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively,
&ldquo;<B>HIPAA</B>&rdquo;); and (iv) any information that would qualify as &ldquo;personal data,&rdquo; &ldquo;personal information&rdquo;
(or similar term) under the Privacy Laws. To the Company&rsquo;s knowledge, there have been no breaches, outages or unauthorized uses
of or accesses to the Company&rsquo;s IT Systems, Confidential Data, or Personal Data that would require notification under Privacy Laws
(as defined below). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.34 <U>Compliance
with Data Privacy Laws</U><FONT STYLE="font-size: 10pt">. The Company and its Subsidiaries are, and at all prior times were, in material
compliance with all applicable state, federal and foreign data privacy and security laws and regulations regarding the collection, use,
storage, retention, disclosure, transfer, disposal, or any other processing (collectively &ldquo;<B>Process</B>&rdquo; or &ldquo;<B>Processing</B>&rdquo;)
of Personal Data, including without limitation HIPAA, the EU General Data Protection Regulation (&ldquo;<B>GDPR</B>&rdquo;) (Regulation
(EU) No. 2016/679), all other local, state, federal, national, supranational and foreign laws relating to the regulation of the Company
or its Subsidiaries, and the regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof (collectively,
the &ldquo;<B>Privacy Laws</B>&rdquo;). To ensure material compliance with the Privacy Laws, the Company and its Subsidiaries have in
place, comply with, and take all appropriate steps necessary to ensure compliance in all material respects with their policies and procedures
relating to data privacy and security, and the Processing of Personal Data and Confidential Data (the &ldquo;<B>Privacy Statements</B>&rdquo;).
The Company and its Subsidiaries have, except as would not reasonably be expected, individually or in the aggregate, to result in a Material
Adverse Effect, at all times since inception provided accurate notice of its Privacy Statements then in effect to its customers, employees,
third party vendors and representatives. None of such disclosures made or contained in any Privacy Statements have been materially inaccurate,
misleading, incomplete, or in material violation of any Privacy Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.35 <U>Transactions
with Affiliates and Employees</U><FONT STYLE="font-size: 10pt">. No relationship, direct or indirect, exists between or among the Company
or any Subsidiary, on the one hand, and any director, officer, stockholder, customer or supplier of the Company, on the other hand, that
is required to be described in the 2025 SEC Reports that is not so described or will not be so described in accordance with the Exchange
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4. <FONT STYLE="font-size: 10pt"><U>Representations
and Warranties of Each Investor</U>. Each Investor, severally for itself and not jointly with any other Investor, represents and warrants
to the Company and the Placement Agents that the statements contained in this <U>Section 4</U> are true and correct as of the date hereof
and the Closing Date (except for the representations and warranties that speak as of a specific date, which shall be made as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.1 <U>Organization</U><FONT STYLE="font-size: 10pt">.
Such Investor is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization and has
the requisite power and authority to own, lease and operate its properties and to carry on its business as now conducted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2 <U>Authorization</U><FONT STYLE="font-size: 10pt">.
Such Investor has all requisite corporate or similar power and authority to enter into this Agreement and the other Transaction Agreements
to which it will be a party and to carry out and perform its obligations hereunder and thereunder. All corporate, member or partnership
action on the part of such Investor or its stockholders, members or partners necessary for the authorization, execution, delivery and
performance of this Agreement and the other Transaction Agreements to which it will be a party and the consummation of the other transactions
contemplated herein has been taken. The signature of the Investor on this Agreement is genuine and the signatory to this Agreement, if
the Investor is an individual, has the legal competence and capacity to execute the same or, if the Investor is not an individual, the
signatory has been duly authorized to execute the same on behalf of the Investor. Assuming this Agreement constitutes the legal and binding
agreement of the Company, this Agreement constitutes a legal, valid and binding obligation of such Investor, enforceable against such
Investor in accordance with its respective terms, except as such enforceability may be limited or otherwise affected by bankruptcy, insolvency,
fraudulent conveyance, reorganization, moratorium and/or similar laws relating to or affecting the rights of creditors generally or by
general equity principles (regardless of whether such enforceability is considered in a proceeding in equity or at law).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.3 <U>No
Conflicts</U><FONT STYLE="font-size: 10pt">. The execution, delivery and performance of the Transaction Agreements by such Investor, the
purchase of the Securities in accordance with their terms and the consummation by such Investor of the other transactions contemplated
hereby will not conflict with or result in any violation of, breach or default by such Investor (with or without notice or lapse of time,
or both) under, conflict with, or give rise to a right of termination, cancellation or acceleration of any obligation, a change of control
right or to a loss of a material benefit under (i) any provision of the organizational documents of such Investor, including, without
limitation, its incorporation or formation papers, bylaws, indenture of trust or partnership or operating agreement, as may be applicable
or (ii) any agreement or instrument, undertaking, credit facility, franchise, license, judgment, order, ruling, statute, law, ordinance,
rule or regulations, applicable to such Investor or its respective properties or assets, except, in the case of clause (ii), as would
not, individually or in the aggregate, be reasonably expected to materially delay or materially hinder the ability of such Investor to
perform its obligations under the Transaction Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.4 <U>Residency</U><FONT STYLE="font-size: 10pt">.
Such Investor&rsquo;s residence (if an individual) or offices in which its investment decision with respect to the Securities was made
(if an entity) are located at the address immediately below such Investor&rsquo;s name on <U>Exhibit A</U>, except as otherwise communicated
by such Investor to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.5 <U>Brokers
and Finders</U><FONT STYLE="font-size: 10pt">. Such Investor has not retained, utilized or been represented by any broker or finder in
connection with the transactions contemplated by this Agreement whose fees the Company would be required to pay.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.6 <U>Investment
Representations and Warranties</U><FONT STYLE="font-size: 10pt">. Each Investor hereby represents and warrants that, it (i) as of the
date hereof is, if an entity, a &ldquo;qualified institutional buyer&rdquo; (as defined in Rule 144A under the Securities Act) or an &ldquo;accredited
investor&rdquo; as that term is defined in Rule 501(a) under Regulation D promulgated pursuant to the Securities Act; or (ii) if an individual,
is an &ldquo;accredited investor&rdquo; as that term is defined in Rule 501(a) of Regulation D of the Securities Act and has such knowledge
and experience in financial and business matters as to be able to protect its own interests in connection with an investment in the Securities.
Each Investor further represents and warrants that (x) it is capable of evaluating the merits and risk of such investment, and (y) that
it has not been organized for the purpose of acquiring the Securities and is an &ldquo;institutional account&rdquo; as defined by FINRA
Rule 4512(c). Such Investor understands and agrees that the offering and sale of the Securities has not been registered under the Securities
Act or any applicable state securities laws and is being made in reliance upon federal and state exemptions for transactions not involving
a public offering which depend upon, among other things, the bona fide nature of the investment intent and the accuracy of such Investor&rsquo;s
representations as expressed herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.7 <U>Intent</U><FONT STYLE="font-size: 10pt">.
Each Investor is purchasing the Securities solely for investment purposes, for such Investor&rsquo;s own account and not for the account
of others, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act, and the Investor
has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of the Securities
Act without prejudice, however, to the Investor&rsquo;s right at all times to sell or otherwise dispose of all or any part of such Securities
in compliance with applicable federal and state securities laws. Notwithstanding the foregoing, if such Investor is purchasing the Securities
as a fiduciary or agent for one or more investor accounts, such Investor has full investment discretion with respect to each such account,
and the full power and authority to make the acknowledgements, representations and agreements herein on behalf of each owner of each such
account. Each Investor has no present arrangement to sell the Securities to or through any person or entity. Each Investor understands
that the Securities must be held indefinitely unless such Securities are resold pursuant to a registration statement under the Securities
Act or an exemption from registration is available. Nothing contained herein shall be deemed a representation or warranty by such Investor
to hold the Securities for any period of time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.8 <U>Investment
Experience; Ability to Protect Its Own Interests and Bear Economic Risks</U><FONT STYLE="font-size: 10pt">. Each Investor acknowledges
that it can bear the economic risk and complete loss of its investment in the Securities and has knowledge and experience in finance,
securities, taxation, investments and other business matters as to be capable of evaluating the merits and risks of investments of the
kind described in this Agreement and contemplated hereby, and the Investor has had an opportunity to seek, and has sought, such accounting,
legal, business and tax advice as such Investor has considered necessary to make an informed investment decision. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Each Investor acknowledges that
such Investor (i) is a sophisticated investor, experienced in investing in private placements of equity securities and capable of evaluating
investment risks independently, both in general and with regard to all transactions and investment strategies involving a security or
securities and (ii) has exercised independent judgment in evaluating its participation in the purchase of the Securities. Each Investor
acknowledges that such Investor is aware that there are substantial risks incident to the purchase and ownership of the Securities, including
those set forth in the Company&rsquo;s filings with the SEC. Alone, or together with any professional advisor(s), such Investor has adequately
analyzed and fully considered the risks of an investment in the Securities and determined that the Securities are a suitable investment
for the Investor. Each Investor is, at this time and in the foreseeable future, able to afford the loss of such Investor&rsquo;s entire
investment in the Securities and such Investor acknowledges specifically that a possibility of total loss exists.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.9 <U>Independent
Investment Decision</U><FONT STYLE="font-size: 10pt">. Such Investor understands that nothing in the Transaction Agreements or any other
materials presented by or on behalf of the Company to such Investor in connection with the purchase of the Securities constitutes legal,
tax or investment advice. Such Investor has consulted such legal, tax and investment advisors as it, in their sole discretion, has deemed
necessary or appropriate in connection with its purchase of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.10 <U>Securities
Not Registered; Legends</U><FONT STYLE="font-size: 10pt">. Such Investor acknowledges and agrees that the Securities are being offered
in a transaction not involving any public offering within the meaning of the Securities Act, and such Investor understands that the Securities
have not been registered under the Securities Act, by reason of their issuance by the Company in a transaction exempt from the registration
requirements of the Securities Act, and that the Securities must continue to be held and may not be offered, resold, transferred, pledged
or otherwise disposed of by such Investor unless a subsequent disposition thereof is registered under the Securities Act or is exempt
from such registration and in each case in accordance with any applicable securities laws of any state of the United States. Such Investor
understands that the exemptions from registration afforded by Rule 144 (the provisions of which are known to it) promulgated under the
Securities Act depend on the satisfaction of various conditions including, but not limited to, the time and manner of sale, the holding
period and on requirements relating to the Company which are outside of such Investor&rsquo;s control and which the Company may not be
able to satisfy, and that, if applicable, Rule 144 may afford the basis for sales only in limited amounts. Such Investor acknowledges
and agrees that it has been advised to consult legal counsel prior to making any offer, resale, transfer, pledge or disposition of any
of the Securities. Such Investor acknowledges that no federal or state agency has passed upon or endorsed the merits of the offering of
the Securities or made any findings or determination as to the fairness of this investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Investor understands
that any certificates or book entry notations evidencing the Securities may bear one or more legends in substantially the following form
and substance:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;THE SECURITIES REPRESENTED HEREBY
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), OR THE SECURITIES LAWS OF ANY
STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH
SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II) SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144, (III)
THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION
UNDER THE SECURITIES ACT, OR (IV) THE SECURITIES ARE TRANSFERRED WITHOUT CONSIDERATION TO AN AFFILIATE OF SUCH HOLDER OR A CUSTODIAL NOMINEE
(WHICH FOR THE AVOIDANCE OF DOUBT SHALL REQUIRE NEITHER CONSENT NOR THE DELIVERY OF AN OPINION). NOTWITHSTANDING THE FOREGOING, THE SECURITIES
MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Securities
may contain a legend regarding affiliate status of the Investor, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.11 <U>Placement
Agents</U><FONT STYLE="font-size: 10pt">. Each Investor hereby acknowledges and agrees that (a) each Placement Agent is acting solely
as placement agent in connection with the execution, delivery and performance of the Transaction Agreements and the issuance of the Securities
to the Investor and neither any Placement Agent nor any of its affiliates have acted as an underwriter or in any other capacity and is
not and shall not be construed as a fiduciary or financial advisor for such Investor, the Company or any other person or entity in connection
with the execution, delivery and performance of the Transaction Agreements and the issuance and purchase of the Securities, (b) no Placement
Agent has made and does not make any representation or warranty, whether express or implied, of any kind or character, or has not provided
any advice or recommendation in connection with the execution, delivery and performance of the Transaction Agreements or with respect
to the Securities, nor is such information or advice necessary or desired, (c) no Placement Agent will have any responsibility with respect
to (i) any representations, warranties or agreements made by any person or entity under or in connection with the execution, delivery
and performance of the Transaction Agreements, or the execution, legality, validity or enforceability (with respect to any person) thereof,
or (ii) the business, affairs, financial condition, operations, properties or prospects of, or any other matter concerning the Company,
and (d) no Placement Agent will have any liability or obligation (including without limitation, for or with respect to any losses, claims,
damages, obligations, penalties, judgments, awards, liabilities, costs, expenses or disbursements incurred by such Investor, the Company
or any other person or entity), whether in contract, tort or otherwise, to such Investor, or to any person claiming through it, in respect
of the execution, delivery and performance of the Transaction Agreements, except in each case for such party&rsquo;s own gross negligence,
willful misconduct or bad faith. No disclosure or offering document has been prepared by any Placement Agent or any of its affiliates
in connection with the offer and sale of the Securities. Neither the Placement Agents nor any of their respective affiliates have made
or make any representation as to the quality or value of the Securities and the Placement Agents and any their respective affiliates may
have acquired non-public information with respect to the Company which the Investor agrees need not be provided to it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.12 <U>No
General Solicitation</U><FONT STYLE="font-size: 10pt">. Each Investor acknowledges and agrees that the Investor is purchasing the Securities
directly from the Company. Such Investor became aware of this offering of the Securities solely by means of direct contact from the Placement
Agents or directly from the Company as a result of a pre-existing, substantive relationship with the Company or the Placement Agents,
and/or their respective advisors (including, without limitation, attorneys, accountants, bankers, consultants and financial advisors),
agents, control persons, representatives, affiliates, directors, officers, managers, members, and/or employees, and/or the representatives
of such persons. The Securities were offered to such Investor solely by direct contact between such Investor and the Company, the Placement
Agents and/or their respective representatives. Such Investor did not become aware of this offering of the Securities, nor were the Securities
offered to such Investor, by any other means, and none of the Company, the Placement Agents and/or their respective representatives acted
as investment advisor, broker or dealer to such Investor. Such Investor is not purchasing the Securities as a result of any general or
public solicitation or general advertising, or publicly disseminated advertisement, article, notice or other communication regarding the
Securities published in any newspaper, magazine or similar media or broadcast over television, radio or the internet or presented at any
seminar or any other general solicitation or general advertisement, including any of the methods described in Section 502(c) of Regulation
D under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.13 <U>Access
to Information</U><FONT STYLE="font-size: 10pt">. In making its decision to purchase the Securities, each Investor has relied solely upon
independent investigation made by such Investor, upon the 2025 SEC Reports and upon the representations, warranties and covenants set
forth herein. Such Investor acknowledges and agrees that such Investor has received such information as such Investor deems necessary
in order to make an investment decision with respect to the Securities, including, with respect to the Company. Without limiting the generality
of the foregoing, each Investor acknowledges that copies of the 2025 SEC Reports are available on EDGAR at www.sec.gov. Each Investor
acknowledges and agrees that such Investor and such Investor&rsquo;s professional advisor(s), if any, have had the opportunity to ask
such questions, receive such answers and obtain such information from the Company regarding the Company, its business and the terms and
conditions of the offering of the Securities as such Investor and such Investor&rsquo;s professional advisor(s), if any, have deemed necessary
to make an investment decision with respect to the Securities and that such Investor has independently made its own analysis and decision
to invest in the Company. Neither such inquiries nor any other due diligence investigation conducted by such Investor shall modify, limit
or otherwise affect such Investor&rsquo;s right to rely on the Company&rsquo;s representations and warranties contained in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.14 <U>Certain
Trading Activities</U><FONT STYLE="font-size: 10pt">. Other than consummating the transaction contemplated hereby, the Investor has not,
nor has any Person acting on behalf of or pursuant to any understanding with such Investor, directly or indirectly executed any purchases
or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Investor was first
contacted by the Company or any other Person regarding the transaction contemplated hereby and ending immediately prior to the date hereof.
Notwithstanding the foregoing, (i) in the case of an Investor that is a multi-managed investment vehicle whereby separate portfolio managers
manage separate portions of such Investor&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions
made by the portfolio managers managing other portions of such Investor&rsquo;s assets, the representation set forth above shall only
apply with respect to the portion of the assets managed by the portfolio manager that made the investment decision to purchase the Securities
covered by this Agreement and (ii) in the case of an Investor whose investment adviser utilized an information barrier with respect to
the information regarding the transactions contemplated hereunder after first being contacted by the Company or such other Person representing
the Company, the representation set forth above shall only apply after the point in time when the portfolio manager who manages such Investor&rsquo;s
assets was informed of the information regarding the transactions contemplated hereunder and, with respect to the Investor&rsquo;s investment
adviser, the representation set forth above shall only apply with respect to any purchases or sales, including Short Sales, of the securities
of the Company on behalf of other funds or investment vehicles for which the Investor&rsquo;s investment adviser is also an investment
adviser or subadviser after the point in time when the portfolio manager who manages the assets of such other funds or investment vehicles
for which the Investor&rsquo;s investment adviser is also an investment adviser or sub-adviser was informed of the information regarding
the transactions contemplated hereunder. Other than to other Persons party to this Agreement and to its advisors and agents who had a
need to know such information, such Investor has maintained the confidentiality of all disclosures made to it in connection with this
transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability
of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5. <FONT STYLE="font-size: 10pt"><U>Covenants</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.1 <U>Further
Assurances</U><FONT STYLE="font-size: 10pt">. Prior to the Closing, each party agrees to cooperate with each other and their respective
officers, employees, attorneys, accountants and other agents, and, generally, do such other reasonable acts and things in good faith as
may be necessary to effectuate the intents and purposes of this Agreement, subject to the terms and conditions hereof and compliance with
applicable law, including taking reasonable action to facilitate the filing of any document or the taking of reasonable action to assist
the other parties hereto in complying with the terms hereof. Each Investor acknowledges that the Company and the Placement Agents will
rely on the acknowledgments, understandings, agreements, representations and warranties contained in this Agreement. Prior to the Closing,
the Investor agrees to promptly notify the Company if any of the acknowledgments, understandings, agreements, representations and warranties
set forth in <U>Section 4</U> of this Agreement are no longer accurate and the Company agrees to promptly notify each Investor if any
of the acknowledgments, understandings, agreements, representations and warranties set forth in <U>Section 3</U> of this Agreement are
no longer accurate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.2 <U>Listing</U><FONT STYLE="font-size: 10pt">.
The Company shall use commercially reasonable efforts to maintain the listing and trading of its Common Stock on the Nasdaq Global Market
and, in accordance therewith, will use reasonable best efforts to comply in all material respects with the Company&rsquo;s reporting,
filing and other obligations under the rules and regulations of Nasdaq. The Company agrees to use commercially reasonable efforts to maintain
the eligibility of the Common Stock for electronic transfer through an established clearing corporation, including, without limitation,
by timely payment of fees to such clearing corporation in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.3 <U>Disclosure
of Transactions</U><FONT STYLE="font-size: 10pt">. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) The
Company shall, by 9:00 a.m., New York City time, on the first (1st) Business Day immediately following the date hereof (provided that,
if this Agreement is executed between midnight and 9:00 a.m., New York City time on a Business Day, no later than 9:01 a.m., New York
City time, on the date hereof), issue a press release and/or file with the SEC a Current Report on Form 8-K (including all exhibits thereto,
the &ldquo;<B>Disclosure Document</B>&rdquo; and the actual filing of such press release and/or Current Report on Form 8-K, the &ldquo;<B>Disclosure
Time</B>&rdquo;) disclosing (i) all material terms of the transactions contemplated hereby and by the other Transaction Agreements, and
(ii) all material non-public information concerning the Company disclosed to the Investors. Following the Disclosure Time, no Investor
shall be in possession of any material non-public information received from the Company, its subsidiaries or any of their respective officers,
directors, employees or agents (including the Placement Agents). <FONT STYLE="font-size: 10pt">In addition, unless it has already done
so by filing the Disclosure Document, on or before the fourth (4th) Business Day following the date of this Agreement, the Company shall
file with the SEC a Current Report on Form 8-K disclosing all material terms of the transactions contemplated by this Agreement.</FONT>
The Company understands and confirms that the Investors will rely on the foregoing representation in effecting securities transactions.
Notwithstanding anything in this Agreement to the contrary, the Company shall not disclose the name of any Investor or any of its affiliates
or advisers, or include the name of any Investor or any of its affiliates or advisers in any press release, public announcement or filing
with the SEC (other than any registration statement contemplated by the Registration Rights Agreement, which shall be subject to review
of the Investors in accordance with the terms of the Registration Rights Agreement) or any regulatory agency, without the prior written
consent of such Investor, except (i) as required by the federal securities law in connection with (A) any registration statement contemplated
by the Registration Rights Agreement and (B) the filing of final Transaction Agreements with the SEC or pursuant to other routine proceedings
of regulatory authorities, or (ii) to the extent such disclosure is required by law, at the request of the staff of the SEC or regulatory
agency or under the regulations of the Nasdaq Global Market, provided that the Company shall use commercially reasonable efforts to provide
the Investors with prior written notice of and a reasonable opportunity to review such disclosure permitted under foregoing clauses (i)
and (ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.4 <U>Integration</U><FONT STYLE="font-size: 10pt">.
The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of the Company shall, sell, offer
for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that
will be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities Act of
the sale of the Securities to the Investors, or that will be integrated with the offer or sale of the Securities for purposes of the rules
and regulations of any National Exchange such that it would require stockholder approval prior to the closing of such other transaction
unless stockholder approval is obtained before the closing of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.5 <U>Removal
of Legends</U><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) In
connection with any sale, assignment, transfer or other disposition of the Initial Shares or any other Shares by an Investor pursuant
to Rule 144 or pursuant to any other exemption under the Securities Act such that the purchaser acquires freely tradable shares and upon
compliance by the Investor with the requirements of this Agreement, if requested by the Investor by notice to the Company, the Company
shall request the Transfer Agent to remove any restrictive legends related to the book entry account holding such shares and make a new,
unlegended entry for such book entry shares sold or disposed of without restrictive legends as soon as reasonably practicable following
any such request therefor from such Investor, provided that the Company has timely received from the Investor a completed Investor representation
letter in substantially the form attached hereto as <U>Exhibit D </U> and such other customary representations as may be reasonably required,
in accordance with applicable law, in connection therewith. The Company shall be responsible for the fees of its Transfer Agent and its
legal counsel associated with such legend removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) Subject
to receipt from the Investor by the Company and the Transfer Agent of customary representations and other documentation reasonably acceptable
to the Company and the Transfer Agent in connection therewith, upon the earliest of such time as the Initial Shares or any other Shares
(i) have been registered under the Securities Act pursuant to an effective registration statement, (ii) have been sold pursuant to Rule
144, or (iii) are eligible for resale under Rule 144(b)(1) without the requirement for the Company to be in compliance with the current
public information requirements under Rule 144(c)(1) (or any successor provision), the Company shall, in accordance with the provisions
of this <U>Section 5.5(b)</U> and as soon as reasonably practicable following any request therefor from an Investor accompanied by such
customary and reasonably acceptable documentation referred to above, (A) deliver to the Transfer Agent irrevocable instructions that the
Transfer Agent shall make a new, unlegended entry for such book entry shares, and (B) cause its counsel to promptly deliver to the Transfer
Agent one or more opinions to the effect that the removal of such legends in such circumstances may be effected under the Securities Act
if required by the Transfer Agent to effect the removal of the legend in accordance with the provisions of this Agreement. The Company
shall be responsible for the fees of its Transfer Agent and its legal counsel associated with such legend removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.6 <U>Withholding
Taxes</U><FONT STYLE="font-size: 10pt">. Each Investor agrees to furnish the Company with any information, representations and forms as
shall reasonably be requested by the Company from time to time to assist the Company in complying with any applicable tax law (including
any withholding obligations).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.7 <U>Fees
and Taxes</U><FONT STYLE="font-size: 10pt">. The Company shall be solely responsible for the payment of any placement agent&rsquo;s fees,
financial advisory fees, or broker&rsquo;s commissions (other than for Persons engaged by an Investor) relating to or arising out of the
transactions contemplated hereby, including, without limitation, any fees or commissions payable to the Placement Agents. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.8 <U>No
Conflicting Agreements</U><FONT STYLE="font-size: 10pt">. The Company will not take any action, enter into any agreement or make any commitment
that would conflict or interfere in any material respect with the Company&rsquo;s obligations to the Investors under the Transaction Agreements.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.9 <U>Reporting
Status</U><FONT STYLE="font-size: 10pt">. The Company shall timely file all reports required to be filed with the SEC pursuant to the
Exchange Act, and the Company shall not terminate its status as an issuer required to file reports under the Exchange Act even if the
Exchange Act or the rules and regulations thereunder would otherwise permit such termination. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.10 <U>Indemnification.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) The
Company agrees to indemnify and hold harmless each Investor and its Affiliates, and their respective directors, officers, trustees, members,
stockholders, partners, managers, employees, investment advisers and agents <FONT STYLE="font-size: 10pt">(and any other Persons with
a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) each Person who
controls such Investor (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors,
officers, stockholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person
holding such titles notwithstanding a lack of such title or any other title) of such controlling persons </FONT>(collectively, the &ldquo;<B>Indemnified
Persons</B>&rdquo;), from and against any and all losses, claims, damages, liabilities and expenses (including without limitation reasonable
and documented attorney fees and disbursements and other documented out-of-pocket expenses reasonably incurred in connection with investigating,
preparing or defending any action, claim or proceeding, pending or threatened and the costs of enforcement thereof) to which such Indemnified
Person may become subject (i) as a result of any breach of representation, warranty, covenant or agreement made by or to be performed
on the part of the Company under the Transaction Agreements or (ii) as a result of or arising out of any action, claim or proceeding,
pending or threatened, against an Indemnified Person in any capacity by any stockholder of the Company (whether directly or in a derivative
capacity) who is not an Affiliate of the Indemnified Person with respect to the transactions contemplated by the Transaction Agreements,
and in each case will reimburse any such Indemnified Person for all such amounts as they are incurred by such Indemnified Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) Any
person entitled to indemnification hereunder shall (i) give prompt written notice to the indemnifying party of any claim with respect
to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably
satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder shall have the right to employ separate
counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person
unless (a) the indemnifying party has agreed in writing to pay such fees or expenses, (b) the indemnifying party shall have failed to
assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c) in the reasonable judgment of any such
person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying party with respect
to such claims (in which case, if the person notifies the indemnifying party in writing that such person elects to employ separate counsel
at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf
of such person); and provided, further, that the failure of any indemnified party to give written notice as provided herein shall not
relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely
affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall not,
in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys
at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified party, which consent
shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement unless such
judgment or settlement (i) imposes no liability or obligation on, (ii) includes as an unconditional term thereof the giving of a complete,
explicit and unconditional release from the party bringing such indemnified claims of all liability of the indemnified party in respect
of such claim or litigation in favor of, and (iii) does not include any admission of fault, culpability, wrongdoing, or wrongdoing or
malfeasance by or on behalf of, the indemnified party. No indemnified party will, except with the consent of the indemnifying party, which
consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.11 <U>Reservation
of Common Stock</U><FONT STYLE="font-size: 10pt">. As of the date hereof, the Company has reserved and the Company shall continue to reserve
and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling
the Company to issue the Pre-Funded Warrant Shares that are issuable upon the exercise of the Pre-Funded Warrants, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6. <FONT STYLE="font-size: 10pt"><U>Conditions
of Closing</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.1 <U>Conditions
to the Obligation of the Investors</U><FONT STYLE="font-size: 10pt">. The several obligations of each Investor to consummate the transactions
to be consummated at the Closing, and to purchase and pay for the Securities being purchased by it at the Closing pursuant to this Agreement,
are subject to the satisfaction or waiver in writing of the following conditions precedent:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) <U>Representations
and Warranties</U>. The representations and warranties of the Company contained herein shall be true and correct in all respects as of
the date hereof except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation
or warranty shall be true and correct in all respects as of such earlier date, and the representations and warranties of the Company contained
herein shall be true and correct in all material respects as of the Closing Date, as though made on and as of such date, except for those
representations and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects and
except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or
warranty shall be true and correct in all material respects as of such earlier date, except for those representations and warranties qualified
by materiality or Material Adverse Effect, which shall be true and correct in all respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) <U>Performance</U>.
The Company shall have performed in all material respects the obligations and conditions herein required to be performed or observed by
the Company on or prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) <U>No
Injunction</U>. The purchase of and payment for the Securities by each Investor shall not be prohibited or enjoined by any law or governmental
or court order or regulation and no such prohibition shall have been threatened in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d) <U>Consents</U>.
The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary for the consummation of
the purchase and sale of the Securities, all of which shall be in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e) <U>Transfer
Agent</U>. The Company shall have furnished all required materials to the Transfer Agent to reflect the issuance of the Initial Shares
at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(f) <U>Adverse
Changes</U>. Since the date hereof, no event or series of events shall have occurred that has had or would reasonably be expected to have
a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(g) <U>Opinion
of Company Counsel</U>. The Company shall have delivered to the Investors and the Placement Agents the opinion of Davis Polk &amp; Wardwell
LLP, dated as of the Closing Date, in customary form and substance to be reasonably agreed upon with the Placement Agents and the Investors
and addressing such legal matters as the Placement Agents, the Investors and the Company reasonably agree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(h) <U>Compliance
Certificate</U>. An authorized officer of the Company shall have delivered to the Investors at the Closing Date a certificate certifying
that the conditions specified in <U>Sections 6.1(a) (Representations and Warranties)</U>, <U>6.1(b) (Performance)</U>, <U>6.1(c) (No Injunction)</U>,
<U>6.1(d) (Consents)</U>, <U>6.1(e) (Transfer Agent)</U>, <U>6.1(f) (Adverse Changes)</U>, and <U>6.1(k) (Listing Requirements)</U> of
this Agreement have been fulfilled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i) <U>Secretary&rsquo;s
Certificate</U>. The Secretary of the Company shall have delivered to the Investors at the Closing Date a certificate in form and substance
reasonably acceptable to the Investors certifying (i) the Amended and Restated Certificate of Incorporation; (ii) the Amended and Restated
Bylaws; and (iii) resolutions of the Company&rsquo;s Board of Directors (or an authorized committee thereof) approving this Agreement,
the other Transaction Agreements, the transactions contemplated by this Agreement and the issuance of the Securities and the Pre-Funded
Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(j) <U>Registration
Rights Agreement</U>. The Company shall have executed and delivered the Registration Rights Agreement substantially in the form attached
hereto as <U>Exhibit C</U> (the &ldquo;<B>Registration Rights Agreement</B>&rdquo;) to the Investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(k) <U>No
Stop Orders; Listing</U>. No stop order or suspension of trading shall have been imposed by Nasdaq, the SEC or any other governmental
or regulatory body with respect to public trading in the Common Stock. The Common Stock shall be listed on the National Exchange and shall
not have been suspended, as of the Closing Date, by the SEC or the National Exchange from trading thereon nor shall suspension by the
SEC or the National Exchange have been threatened, as of the Closing Date, in writing by the SEC or the National Exchange. The Company
shall have filed with Nasdaq a Notification Form: Listing of Additional Shares for the listing of the Shares and Nasdaq shall have raised
no objection to such notice and the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(l) <U>Wire
Instructions</U>. The Company shall have provided wire instructions to the Investors at least one Business Day prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.2 <U>Conditions
to the Obligation of the Company</U><FONT STYLE="font-size: 10pt">. The obligation of the Company to consummate the transactions to be
consummated at the Closing, and to issue and sell to each Investor the Securities to be purchased by it at the Closing pursuant to this
Agreement, is subject to the satisfaction or waiver in writing of the following conditions precedent:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) <U>Representations
and Warranties</U>. The representations and warranties of each Investor in Section 4 hereto shall be true and correct on and as of the
Closing Date, with the same force and effect as though made on and as of the Closing Date and consummation of the Closing shall constitute
a reaffirmation by the Investor of each of the representations, warranties, covenants and agreements of the Investor contained in this
Agreement as of the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) <U>Performance</U>.
Each Investor shall have performed or complied with in all material respects all obligations and conditions herein required to be performed
or observed by such Investor on or prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) <U>Injunction</U>.
The purchase of and payment for the Securities by each Investor shall not be prohibited or enjoined by any law or governmental or court
order or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d) <U>Registration
Rights Agreement</U>. Each Investor shall have executed and delivered the Registration Rights Agreement to the Company in the form attached
as <U>Exhibit&nbsp;C</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e) <FONT STYLE="background-color: white"><U>Payment</U>.
Except </FONT>as may be agreed to among the Company and one or more Investors in accordance with <U>Section 2.2</U><FONT STYLE="background-color: white">,
the Company shall have received payment, by wire transfer of immediately available funds, in the full amount of the purchase price for
the number of </FONT>Securities <FONT STYLE="background-color: white">being purchased by each Investor at the Closing as set forth in
<U>Exhibit A</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7. <FONT STYLE="font-size: 10pt"><U>Termination</U>.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.1 <U>Termination</U><FONT STYLE="font-size: 10pt">.
The obligations of the Company, on the one hand, and each Investor, on the other hand, to effect the Closing shall terminate as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i) Upon
the mutual written consent of the Company and the Investor Majority prior to the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii) By
the Company if any of the conditions set forth in Section 6.2 shall have become incapable of fulfillment, and shall not have been waived
by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii) By
an Investor, solely as to itself, if any of the conditions set forth in Section 6.1 shall have become incapable of fulfillment, and shall
not have been waived by such Investor; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv) By
either the Company or an Investor if the Closing has not occurred on or prior to the fifth Business Day following the date of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">provided, however, that, except
in the case of clauses (ii) and (iii) above, the party seeking to terminate its obligation to effect the Closing shall not then be in
breach of any of its representations, warranties, covenants or agreements contained in the Transaction Agreements if such breach has resulted
in the circumstances giving rise to such party&rsquo;s seeking to terminate its obligation to effect the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.2 <U>Notice</U><FONT STYLE="font-size: 10pt">.
In the event of termination pursuant to Section 7.1, written notice thereof shall be given to each other Investor. Nothing in this Section
7 shall be deemed to release any party from any liability for any breach by such party of the other terms and provisions of the Transaction
Agreements or to impair the right of any party to compel specific performance by any other party of its other obligations under the Transaction
Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8. <FONT STYLE="font-size: 10pt"><U>Miscellaneous
Provisions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.1 <U>Public
Statements or Releases</U><FONT STYLE="font-size: 10pt">. Except as set forth in Section 5.3 or as required in order to satisfy its obligations
required by applicable law or regulation, neither the Company nor any Investor shall make any public announcement with respect to the
existence or terms of this Agreement or the transactions provided for herein without the prior consent of the other party (which consent
shall not be unreasonably withheld) other than filings pursuant to Section 13 and/or Section 16 of the Exchange Act, which, for avoidance
of doubt, shall not require the Company&rsquo;s consent; provided that, the Company shall not publicly disclose the name of any Investor
or any affiliate or investment adviser of any Investor without such Investor&rsquo;s consent. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.2 <U>Interpretation</U><FONT STYLE="font-size: 10pt">.
The words &ldquo;hereof,&rdquo; &ldquo;herein&rdquo; and &ldquo;hereunder&rdquo; and words of similar import when used in this Agreement
will refer to this Agreement as a whole and not to any particular provision of this Agreement, and section and subsection references are
to this Agreement unless otherwise specified. The headings in this Agreement are included for convenience of reference only and will not
limit or otherwise affect the meaning or interpretation of this Agreement. Whenever the words &ldquo;include,&rdquo; &ldquo;includes&rdquo;
or &ldquo;including&rdquo; are used in this Agreement, they will be deemed to be followed by the words &ldquo;without limitation.&rdquo;
The phrases &ldquo;the date of this Agreement,&rdquo; &ldquo;the date hereof&rdquo; and terms of similar import, unless the context otherwise
requires, will be deemed to refer to the date set forth in the first paragraph of this Agreement. The meanings given to terms defined
herein will be equally applicable to both the singular and plural forms of such terms. All matters to be agreed to by any party hereto
must be agreed to in writing by such party unless otherwise indicated herein. References to agreements, policies, standards, guidelines
or instruments, or to statutes or regulations, are to such agreements, policies, standards, guidelines or instruments, or statutes or
regulations, as amended or supplemented from time to time (or to successors thereto). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.3 <U>Notices</U><FONT STYLE="font-size: 10pt">.
Any notices or other communications required or permitted to be given hereunder shall be in writing and shall be deemed to be given (a)
when delivered if personally delivered to the party for whom it is intended, (b) when delivered, if sent by electronic mail during normal
business hours of the recipient, and if not sent during normal business hours, then on the recipient&rsquo;s next Business Day, provided
no rejection or undeliverable notice is received, (c) three (3) days after having been sent by certified or registered mail, return-receipt
requested and postage prepaid, or (d) one (1) Business Day after deposit with a nationally recognized overnight courier, freight prepaid,
specifying next business day delivery, with written verification of receipt:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) If
to the Company, addressed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Oruka Therapeutics, Inc.<BR>
855 Oak Grove Ave., Suite 100<BR>
Menlo Park, CA 94025<BR>
Attention: Paul Quinlan, General Counsel<BR>
Email:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">with a copy (which shall not constitute
notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Davis Polk &amp; Wardwell LLP<BR>
900 Middlefield Road<BR>
Redwood City, CA 94063<BR>
Attention: Alan Denenberg, Beth LeBow<BR>
Email:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) If
to any Investor, at its address set forth on <U>Exhibit A</U> or to such e-mail address, or address as subsequently modified by written
notice given in accordance with this <U>Section 8.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Any Person may change the address
to which notices and communications to it are to be addressed by notification as provided for herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.4 <U>[Reserved]</U><FONT STYLE="font-size: 10pt">.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.5 <U>Severability</U><FONT STYLE="font-size: 10pt">.
If any part or provision of this Agreement is held unenforceable or in conflict with the applicable laws or regulations of any jurisdiction,
the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original
business purpose of such part or provision in a valid and enforceable manner, and the remainder of this Agreement shall remain binding
upon the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.6 <U>Governing
Law; Submission to Jurisdiction; Venue; Waiver of Trial by Jury</U><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) This
Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware without regard to choice of laws or
conflicts of laws provisions thereof that would require the application of the laws of any other jurisdiction, except to the extent that
mandatory principles of Delaware law may apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) The
Company and each of the Investors hereby irrevocably and unconditionally:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i) submits
for itself and its property in any legal action or proceeding relating solely to this Agreement or the transactions contemplated hereby,
to the general jurisdiction of the any state court or United States Federal court sitting in the City of Wilmington in the State of Delaware;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii) consents
that any such action or proceeding may be brought in such courts, and waives any objection that it may now or hereafter have to the venue
of any such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court and agrees not
to plead or claim the same to the extent permitted by applicable law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii) agrees that service
of process in any such action or proceeding may be effected by mailing a copy thereof by registered or certified mail (or any substantially
similar form of mail), postage prepaid, to the party, as the case may be, at its address set forth in <U>Section 8.3</U> or at such other
address of which the other party shall have been notified pursuant thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv) agrees
that nothing herein shall affect the right to effect service of process in any other manner permitted by law or shall limit the right
to sue in any other jurisdiction for recognition and enforcement of any judgment or if jurisdiction in the courts referenced in the foregoing
clause (i) are not available despite the intentions of the parties hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v) agrees
that final judgment in any such suit, action or proceeding brought in such a court may be enforced in the courts of any jurisdiction to
which such party is subject by a suit upon such judgment, provided that service of process is effected upon such party in the manner specified
herein or as otherwise permitted by law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi) agrees
that to the extent that such party has or hereafter may acquire any immunity from jurisdiction of any court or from any legal process
with respect to itself or its property, such party hereby irrevocably waives such immunity in respect of its obligations under this Agreement,
to the extent permitted by law; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii) irrevocably
and unconditionally waives trial by jury in any legal action or proceeding in relation to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.7 <U>Waiver</U><FONT STYLE="font-size: 10pt">.
No waiver of any term, provision or condition of this Agreement, whether by conduct or otherwise, in any one or more instances, shall
be deemed to be, or be construed as, a further or continuing waiver of any such term, provision or condition or as a waiver of any other
term, provision or condition of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.8 <U>Expenses</U><FONT STYLE="font-size: 10pt">.
Except as expressly set forth in the Transaction Agreements to the contrary, each party shall pay its own out-of-pocket fees and expenses,
including the fees and expenses of attorneys, accountants and consultants employed by such party, incurred in connection with the proposed
investment in the Securities and the consummation of the transactions contemplated thereby; provided, however, that the Company shall
pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered
by the Company), Transfer Taxes, stamp taxes and other taxes (other than income taxes) and duties levied in connection with the delivery
of any Securities to the Investors. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.9 <U>Assignment</U><FONT STYLE="font-size: 10pt">.
None of the parties may assign its rights or obligations under this Agreement or designate another person (i) to perform all or part of
its obligations under this Agreement or (ii) to have all or part of its rights and benefits under this Agreement, in each case without
the prior written consent of (x) the Company, in the case of an Investor, and (y) the Investors, in the case of the Company, provided
that an Investor may, without the prior consent of the Company, assign its rights to purchase the Securities hereunder to any of its affiliates
or to any other investment funds or accounts managed or advised by the investment manager who acts on behalf of such Investor (provided
each such assignee agrees to be bound by the terms of this Agreement and makes the same representations and warranties set forth in <U>Section
4</U> hereof). In the event of any assignment in accordance with the terms of this Agreement, the assignee shall specifically assume and
be bound by the provisions of this Agreement by executing a writing agreeing to be bound by and subject to the provisions of this Agreement
and shall deliver an executed counterpart signature page to this Agreement and, notwithstanding such assumption or agreement to be bound
hereby by an assignee, no such assignment shall relieve any party assigning any interest hereunder from its obligations or liability pursuant
to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.10 <U>Confidential
Information</U><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) Each
Investor covenants that until such time as the transactions contemplated by this Agreement and any material non-public information provided
to such Investor are publicly disclosed by the Company or the earlier termination of this Agreement, such Investor will maintain the confidentiality
of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction), other than
to such Investor&rsquo;s outside attorney, accountant, auditor or investment advisor only to the extent necessary to permit evaluation
of the investment, and the performance of the necessary or required tax, accounting, financial, legal, or administrative tasks and services
and other than as may be required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) Prior
to the Closing, the Company may request from the Investors such reasonable and customary additional information as the Company may deem
necessary to evaluate the eligibility of the Investor to acquire the Securities, and the Investor shall promptly provide such information
as may reasonably be requested to the extent readily available; provided, that the Company agrees to keep any such information provided
by the Investor confidential, except (i) as required by the federal securities laws, rules or regulations and (ii) to the extent such
disclosure is required by other laws, rules or regulations, at the request of the staff of the SEC or regulatory agency or under the regulations
of Nasdaq. The Investor acknowledges that the Company may file a copy of this Agreement and the Registration Rights Agreement with the
SEC as exhibits to a periodic report or a registration statement of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.11 <U>Reliance
by and Exculpation of Placement Agents</U><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) Each
Investor agrees for the express benefit of the Placement Agents and their respective affiliates and representatives that (i) the Placement
Agents and their respective affiliates and representatives have not made, and will not make any representations or warranties with respect
to the Company or the offer and sale of the Securities, and such Investor will not rely on any statements made by any Placement Agent,
orally or in writing, to the contrary, (ii) such Investor will be responsible for conducting its own due diligence investigation with
respect to the Company and the offer and sale of the Securities, (iii) such Investor will be purchasing Securities based on the results
of its own due diligence investigation of the Company and the Placement Agents and each of their respective directors, officers, employees,
representatives, and controlling persons have made no independent investigation with respect to the Company, the Securities, or the accuracy,
completeness, or adequacy of any information supplied to the Investor by the Company, (iv) such Investor has negotiated the offer and
sale of the Securities directly with the Company, and the Placement Agents will not be responsible for the ultimate success of any such
investment and (v) the decision to invest in the Company will involve a significant degree of risk, including a risk of total loss of
such investment. This Section 8.11 shall survive any termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) The
Company agrees and acknowledges that the Placement Agents may rely on its representations, warranties, agreements and covenants contained
in this Agreement and each Investor agrees that the Placement Agents may rely on such Investor&rsquo;s representations and warranties
contained in this Agreement as if such representations and warranties, as applicable, were made directly to the Placement Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) Neither
the Placement Agents nor any of their respective affiliates or representatives (1) shall be liable for any improper payment made in accordance
with the information provided by the Company; (2) makes any representation or warranty, or has any responsibilities as to the validity,
accuracy, value or genuineness of any information, certificates or documentation delivered by or on behalf of the Company pursuant to
the Transaction Agreements or in connection with any of the transactions contemplated therein; or (3) shall be liable (x) for any action
taken, suffered or omitted by any of them in good faith and reasonably believed to be authorized or within the discretion or rights or
powers conferred upon it by the Transaction Agreements or (y) for anything which any of them may do or refrain from doing in connection
with the Transaction Agreements, except in each case for such party&rsquo;s own gross negligence or willful misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d) The
Company agrees that the Placement Agents and their respective affiliates and representatives shall be entitled to (1) rely on, and shall
be protected in acting upon, any certificate, instrument, notice, letter or any other document or security delivered to any of them by
or on behalf of the Company, and (2) be indemnified by the Company for acting as the Placement Agents hereunder pursuant to the indemnification
provisions set forth in the applicable letter agreement between the Company and the Placement Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.12 <U>Third
Parties</U><FONT STYLE="font-size: 10pt">. Nothing in this Agreement, express or implied, is intended to confer on any Person other than
the parties to this Agreement any rights, remedies, claims, benefits, obligations or liabilities under or by reason of this Agreement,
and no Person that is not a party to this Agreement (including, without limitation, any partner, member, shareholder, director, officer,
employee or other beneficial owner of any party to this Agreement, in its own capacity as such or in bringing a derivative action on behalf
of a party to this Agreement) shall have any standing as a third party beneficiary with respect to this Agreement or the transactions
contemplated hereby, except as expressly set forth in this Agreement. Notwithstanding the foregoing, each Placement Agent is an intended
third-party beneficiary of the representations and warranties of the Company set forth in <U>Section 3</U>, the representations and warranties
of each Investor set forth in <U>Section 4</U>, <U>Section 6.1(g)</U> and <U>Section 8.11</U> of this Agreement and the Indemnified Persons
are intended third-party beneficiaries of Section 5.10.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.13 <U>Independent
Nature of Investors&rsquo; Obligations and Right<FONT STYLE="font-size: 10pt">.</FONT></U><FONT STYLE="font-size: 10pt"> The obligations
of each Investor under this Agreement are several and not joint with the obligations of any other Investor, and no Investor shall be responsible
in any way for the performance obligations of any other Investor under this Agreement. Nothing contained herein, and no action taken by
any Investor pursuant hereto, shall be deemed to constitute the Investors as, and the Company acknowledges that the Investors do not so
constitute, a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are
in any way acting in concert or as a group, and the Company will not assert any such claim with respect to such obligations or the transactions
contemplated by this Agreement. The Company acknowledges and each Investor confirms that it has independently participated in the negotiation
of the transaction contemplated hereby with the advice of its own counsel and advisors. Each Investor also acknowledges that <U>Davis
Polk &amp; Wardwell LLP</U> has not rendered legal advice to such Investor. Each Investor shall be entitled to independently protect and
enforce its rights, including, without limitation, the rights arising out of this Agreement, and it shall not be necessary for any other
Investor to be joined as an additional party in any proceeding for such purpose. The Company has elected to provide all Investors with
the same terms and Transaction Agreements for the convenience of the Company and not because it was required or requested to do so by
any Investor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.14 <U>Headings</U><FONT STYLE="font-size: 10pt">.
The titles, subtitles and headings in this Agreement are for convenience of reference and shall not form part of, or affect the interpretation
of, this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.15 <U>Counterparts</U><FONT STYLE="font-size: 10pt">.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or
pdf signature including any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall be considered
due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not
a facsimile or pdf (or other electronic reproduction of a) signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.16 <U>Entire
Agreement; Amendments</U><FONT STYLE="font-size: 10pt">. This Agreement and the other Transaction Agreements (including all schedules
and exhibits hereto and thereto) constitute the entire agreement between the parties hereto respecting the subject matter hereof and supersede
all prior agreements, negotiations, understandings, representations and statements respecting the subject matter hereof, whether written
or oral. No amendment, modification, alteration, or change in any of the terms of this Agreement shall be valid or binding upon the parties
hereto unless made in writing and duly executed by the Company and the Investor Majority, provided that prior to the Closing the consent
of all Investors shall be required. Notwithstanding the foregoing, (i) this Agreement may not be amended with respect to any Investor
without the written consent of such Investor unless such amendment applies to all Investors in the same fashion and (ii) any amendment
to Section 5.5 or Section 5.10 shall require the consent of each Investor. The Company, on the one hand, and each Investor, on the other
hand, may by an instrument signed in writing by such parties waive the performance, compliance or satisfaction by such Investor or the
Company, respectively, with any term or provision hereof or any condition hereto to be performed, complied with or satisfied by such Investor
or the Company, respectively. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.17 <U>Survival</U><FONT STYLE="font-size: 10pt">.
The covenants, representations and warranties made by each party hereto contained in this Agreement shall survive the Closing and the
delivery of the Securities in accordance with their respective terms. Each Investor shall be responsible only for its own representations,
warranties, agreements and covenants hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.18 <U>Mutual
Drafting<FONT STYLE="font-size: 10pt">.</FONT></U><FONT STYLE="font-size: 10pt"> This Agreement is the joint product of each Investor
and the Company and each provision hereof has been subject to the mutual consultation, negotiation and agreement of such parties and shall
not be construed for or against any party hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.19 <U>Arm&rsquo;s
Length Negotiations</U><FONT STYLE="font-size: 10pt">. For the avoidance of doubt, the parties acknowledge and confirm that the terms
and conditions of the Securities were determined as a result of arm&rsquo;s-length negotiations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.20 <U>Further
Assurances</U><FONT STYLE="font-size: 10pt">. Each party shall do and perform, or cause to be done and performed, all such further acts
and things, and shall execute and deliver all such other agreements, certificates, instruments and documents as the other party may reasonably
request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the parties hereto have executed this Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt"><B>COMPANY:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Oruka Therapeutics, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Lawrence Klein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 32%"> <FONT STYLE="font-size: 10pt">Lawrence Klein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CEO</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">[Investor
Signature Pages Follow]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">EXHIBIT A<BR>
<BR>
INVESTORS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in">EXHIBIT B</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">FORM OF PRE-FUNDED WARRANT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[FILED SEPARATELY]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in">EXHIBIT C</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">FORM OF REGISTRATION RIGHTS
AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[FILED SEPARATELY]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">EXHIBIT D</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Investor
Representation Letter</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">D-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>ea025786501ex10-2_oruka.htm
<DESCRIPTION>FORM OF REGISTRATION RIGHTS AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION RIGHTS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS REGISTRATION RIGHTS
AGREEMENT</B> (this &ldquo;<B>Agreement</B>&rdquo;), dated as of September 17, 2025, is entered into by and among Oruka Therapeutics Inc.,
a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), and the several investors signatory hereto (individually as an &ldquo;<B>Investor</B>&rdquo;
and collectively together with their respective permitted assigns, the &ldquo;<B>Investors</B>&rdquo;).&nbsp;Capitalized terms used herein
and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement by and among the parties
hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the &ldquo;<B>Purchase
Agreement</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WHEREAS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.   Upon
the terms and subject to the conditions of the Purchase Agreement, the Company has agreed to issue to the Investors, and the Investors
have agreed to purchase, severally and not jointly, an aggregate of&nbsp;up to $180,000,000 of (x) shares (the &ldquo;<B>Initial Shares</B>&rdquo;)
of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;<B>Common Stock</B>&rdquo;) and/or (y) pre-funded warrants (the
&ldquo;<B>Pre-Funded Warrants</B>&rdquo;) to purchase shares of Common Stock, in each case, pursuant to the Purchase Agreement. The Initial
Shares, and the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants are collectively referred to herein as the &ldquo;<B>Shares</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.   To
induce the Investors to enter into the Purchase Agreement, the Company has agreed to provide certain registration rights under the U.S.
Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute (collectively, the &ldquo;<B>Securities
Act</B>&rdquo;), and applicable state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE,</B> in
consideration of the promises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Company and the Investors hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>DEFINITIONS.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">For purposes of this Agreement,
the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)   &ldquo;<B>Filing
Deadline</B>&rdquo; means, with respect to the Initial Registration Statement required hereunder, no later than October 15, 2025 and,
with respect to any New Registration Statements or other Registration Statement filed hereunder, the 30th calendar day following the later
of the (i) date on which the Company is permitted by SEC Guidance to file such New Registration Statement related to the Registrable Securities
and (ii) date on which the Company becomes aware of the necessity of filing such New Registration Statement related to the Registrable
Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)   &ldquo;<B>Person</B>&rdquo;
means any individual or entity including but not limited to any corporation, limited liability company, association, partnership, organization,
business, individual, governmental or political subdivision thereof or a governmental agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)   &ldquo;<B>Register</B>,&rdquo;
&ldquo;<B>Registered</B>,&rdquo; and &ldquo;<B>Registration</B>&rdquo; refer to a registration effected by preparing and filing one or
more registration statements of the Company in compliance with the Securities Act and providing for offering securities on a continuous
basis, and the declaration or ordering of effectiveness of such registration statement(s) by the U.S. Securities and Exchange Commission
(the &ldquo;<B>SEC</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)   &ldquo;<B>Registrable
Securities</B>&rdquo; means the Shares and any Common Stock issued or issuable with respect to the Shares as a result of any stock split
or subdivision, stock dividend, recapitalization, exchange or similar event. Registrable Securities shall cease to be Registrable Securities
(and the Company shall not be required to maintain the effectiveness of any, or file another, Registration Statement hereunder with respect
thereto) upon the earliest to occur of (i) the date on which the Investors shall have resold all the Registrable Securities covered by
the Registration Statement, (ii) the date on which such Registrable Securities have been previously sold in accordance with Rule 144,
(iii) the date on which such securities become eligible for resale without volume or manner-of-sale restrictions pursuant to Rule 144
and without the requirement for the Company to be in compliance with the current public information requirement under Rule 144, and (iv)
five (5) years after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)   &ldquo;<B>Registration
Expenses</B>&rdquo; means all registration and filing fee expenses incurred by the Company in effecting any registration pursuant to this
Agreement, including (i) all registration, qualification, and filing fees, printing expenses, and any other fees and expenses associated
with filings required to be made with the SEC, FINRA or any other regulatory authority, (ii) all fees and expenses in connection with
compliance with or clearing the Registrable Securities for sale under any securities or &ldquo;Blue Sky&rdquo; laws, (iii) all printing,
duplicating, word processing, messenger, telephone, facsimile and delivery expenses, and (iv) all fees and disbursements of counsel for
the Company and of all independent certified public accountants of the Company (including the expenses of any special audit and cold comfort
letters required by or incident to such performance); provided that in no event shall the Company be responsible for any underwriting,
broker or similar fees or commissions of any Investor or, except to the extent provided for in the Purchase Agreement, any legal fees
or other costs of the Investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)   &ldquo;<B>Registration
Statement</B>&rdquo; means any registration statement of the Company filed with, or to be filed with, the SEC under the Securities Act,
that Registers Registrable Securities, including the related prospectus, amendments and supplements to such registration statement, including
pre- and post-effective amendments, and all exhibits and all material incorporated by reference in such registration statement as may
be necessary to comply with applicable securities laws. &ldquo;Registration Statement&rdquo; shall also include a New Registration Statement,
as amended when each became effective, including all documents filed as part thereof or incorporated by reference therein, and including
any information contained in a prospectus subsequently filed with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)   &ldquo;<B>SEC
Guidance</B>&rdquo; means (i) any publicly-available written or oral guidance of the SEC staff, or any comments, requirements or requests
of the SEC staff (whether or not publicly-available); provided, that any such oral guidance, comments, requirements or requests are reduced
to writing by the SEC (and shared with the Investors if not publicly-available) and (ii) the Securities Act and the rules and regulations
promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)   &ldquo;<B>Selling
Expenses</B>&rdquo; means all underwriting discounts and selling commissions applicable to the sale of Registrable Securities and all
similar fees and commissions relating to the Investors&rsquo; disposition of the Registrable Securities.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>REGISTRATION.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)   <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Mandatory
Registration</U></FONT>. The Company shall, as promptly as reasonably practicable and in any event no later than the Filing Deadline,
prepare and file with the SEC an initial Registration Statement (the &ldquo;<B>Initial Registration Statement</B>&rdquo;) covering the
resale of all Registrable Securities. Before filing the Registration Statement, the Company shall furnish to the Investors a copy of the
Registration Statement. The Investors and their respective counsel shall have at least three (3) Business Days prior to the anticipated
filing date of a Registration Statement to review and comment upon such Registration Statement and any amendment or supplement to such
Registration Statement and any related prospectus (including any documents incorporated by reference therein), prior to its filing with
the SEC. Such Registration Statement also shall cover, to the extent allowable under the Securities Act and the rules promulgated thereunder
(including Rule 416), such indeterminate number of additional shares of Common Stock resulting from stock splits, stock dividends or similar
transactions with respect to the Registrable Securities. The Company shall (a) consider in good faith any comments as the Investor or
its counsel reasonably proposed by the Investor to such document prior to being so filed with the SEC, and (b) not file any Registration
Statement or related prospectus or any amendment or supplement thereto containing information regarding the Investor to which the Investor
reasonably believes contains untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary
to make the statements therein, in light of the circumstances under which they were made, not misleading, unless such information is required
(in the opinion of the Company) to comply with any applicable law or regulation or SEC Guidance. The Investors shall furnish all information
reasonably requested by the Company and as shall be reasonably required in connection with any registration referred to in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Value: 2; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)   <U>Effectiveness</U>.
The Company shall use its commercially reasonable efforts to have the Initial Registration Statement and any amendment declared effective
by the SEC at the earliest possible date but no later than the earlier of the ninetieth (90th) calendar day following the initial filing
date of the Initial Registration Statement if the SEC notifies the Company that it will &ldquo;review&rdquo; the Initial Registration
Statement and (b) the fifth (5th) Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by
the SEC that the Initial Registration Statement will not be &ldquo;reviewed&rdquo; or will not be subject to further review (the &ldquo;<B>Effectiveness
Deadline</B>&rdquo;). The Company shall notify the Investor by e-mail as promptly as practicable, and in any event, within twenty-four
(24) hours, after the Registration Statement is declared effective or is supplemented and shall provide the Investor with copies of any
related prospectus to be used in connection with the sale or other disposition of the securities covered thereby. The Company shall use
commercially reasonable efforts to keep the Initial Registration Statement continuously effective pursuant to Rule 415 promulgated under
the Securities Act and available for the resale by the Investors of all of the Registrable Securities covered thereby at all times until
the earliest to occur of the following events: (i) the date on which the Investors shall have resold all the Registrable Securities covered
thereby; (ii) the date on which the Registrable Securities may be resold by the Investors without registration and without regard to any
volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company to be in compliance with the current
public information requirement under Rule 144 under the Securities Act or any other rule of similar effect and (iii) five (5) years after
the date of this Agreement (the &ldquo;<B>Registration Period</B>&rdquo;). The Initial Registration Statement (including any amendments
or supplements thereto and prospectuses contained therein) shall not contain any untrue statement of a material fact or omit to state
a material fact required to be stated therein, or necessary to make the statements therein, in light of the circumstances in which they
were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)   <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Sufficient
Number of Shares Registered</U></FONT>. In the event the number of shares available under the Initial Registration Statement at any time
is insufficient to cover the Registrable Securities, the Company shall, to the extent necessary and permissible, amend the Initial Registration
Statement or file a new registration statement (together with any prospectuses or prospectus supplements thereunder, a &ldquo;<B>New Registration
Statement</B>&rdquo;), so as to cover all of such Registrable Securities as soon as reasonably practicable but in any event by the applicable
Filing Deadline. The Company shall use its commercially reasonable efforts to have such amendment and/or New Registration Statement become
effective as soon as reasonably practicable following the filing thereof but no later than the earlier of the seventy-fifth (75th) calendar
day following the initial filing date of the New Registration Statement if the SEC notifies the Company that it will &ldquo;review&rdquo;
the New Registration Statement and (b) the fifth (5th) Business Day after the date the Company is notified (orally or in writing, whichever
is earlier) by the SEC that the New Registration Statement will not be &ldquo;reviewed&rdquo; or will not be subject to further review
(the earlier of such dates, the &ldquo;<B>New Registration Effectiveness Deadline</B>&rdquo;). The provisions of Sections 2(a) and 2(b)
shall apply to the New Registration Statement, except as modified hereby.  </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)   <U>Allowable
Delays</U>. On no more than two occasions in any twelve (12)-month period for not more than thirty (30) consecutive days or for a total
of not more than sixty (60) days (which need not be consecutive calendar days), the Company may delay the effectiveness of the Initial
Registration Statement or any other Registration Statement, or suspend the use of any prospectus included in any Registration Statement,
in the event that the Board of Directors reasonably determines, in good faith and upon advice of legal counsel, that such delay or suspension
is necessary to (A) delay the disclosure of material non-public information concerning the Company, including in connection with the negotiation
or consummation of a material transaction by the Company that is pending, that would require additional disclosure by the Company in the
Registration Statement of material non-public information that the Company has a bona fide business purpose for preserving as confidential
and the non-disclosure of which would be expected, in the reasonable determination of the Board of Directors, upon advice of legal counsel,
to cause the Registration Statement to fail to comply with applicable disclosure requirements, or (B) amend or supplement the affected
Registration Statement or the related prospectus so that such Registration Statement or prospectus shall not include an untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the
case of the prospectus in light of the circumstances under which they were made, not misleading (an &ldquo;<B>Allowed Delay</B>&rdquo;);
provided, that the Company shall promptly (a) notify each Investor in writing of the commencement of an Allowed Delay, but shall not (without
the prior written consent of an Investor) disclose to such Investor any material non-public information giving rise to an Allowed Delay,
(b) advise the Investors in writing to cease all sales under the applicable Registration Statement until the end of the Allowed Delay
and (c) use commercially reasonable efforts to terminate an Allowed Delay as promptly as practicable. Each Investor may deliver written
notice (an &ldquo;<B>Opt-Out Notice</B>&rdquo;) to the Company requesting that such Investor not receive notices from the Company otherwise
required by this <U>Section 2</U>; provided, however, that such Investor may later revoke any such Opt-Out Notice in writing, which shall
be effective five (5) Business Days after the receipt thereof. Following receipt of an Opt-Out Notice from an Investor (unless subsequently
revoked), the Company shall not deliver any notices pursuant to this <U>Section 2(e)</U> to such Investor and such Investor shall no longer
be entitled to the rights associated with any such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)   <U>Rule&nbsp;415;
Cutback</U>. If at any time the SEC takes the position that the offering of some or all of the Registrable Securities in any Registration
Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule&nbsp;415 under the Securities Act (provided,
however, the Company shall be obligated to use commercially reasonable efforts to advocate with the SEC for the registration of all of
the Registrable Securities) or requires any Investor to be named as an &ldquo;underwriter,&rdquo; the Company shall (i) promptly notify
each holder of Registrable Securities thereof and (ii) make commercially reasonable efforts to persuade the SEC that the offering contemplated
by such Registration Statement is a valid secondary offering and not an offering &ldquo;by or on behalf of the issuer&rdquo; as defined
in Rule&nbsp;415 and that none of the Investors is an &ldquo;underwriter.&rdquo; Each Investor shall have the right to have its legal
counsel, at such Investor&rsquo;s expense, to review and oversee any registration or matters pursuant to this <U>Section&nbsp;2(e)</U>,
including to comment on any written submission made to the SEC with respect thereto. In the event that, despite the Company&rsquo;s commercially
reasonable efforts and compliance with the terms of this <U>Section&nbsp;2(e)</U>, the SEC refuses to alter its position, the Company
shall (i)&nbsp;remove from such Registration Statement such portion of the Registrable Securities (the &ldquo;<B>Cut Back Shares</B>&rdquo;)
and/or (ii)&nbsp;agree to such restrictions and limitations on the registration and resale of the Registrable Securities as the SEC may
require to assure the Company&rsquo;s compliance with the requirements of Rule&nbsp;415 (collectively, the &ldquo;<B>SEC Restrictions</B>&rdquo;);
provided, however, that the Company shall not name any Investor as an &ldquo;underwriter&rdquo; in such Registration Statement without
the prior written consent of such Investor (provided that, in the event an Investor withholds such consent, the Company shall have no
obligation hereunder to include any Registrable Securities of such Investor in any Registration Statement covering the resale thereof
until such time as the SEC no longer requires such Investor to be named as an &ldquo;underwriter&rdquo; in such Registration Statement
or such Investor otherwise consents in writing to being so named). Any cut-back imposed on the Investors pursuant to this <U>Section 2(e)</U>
shall be allocated among the Investors on a pro rata basis and shall be applied first to any of the Registrable Securities of an Investor
that the SEC has indicated cannot be included or must be limited in the number of Registrable Securities that can be included, and thereafter
to all other Investors as such Investor shall designate, unless the SEC Restrictions otherwise require or provides otherwise, or the Investors
otherwise agree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)   Each
Registration Statement filed hereunder shall be on Form S-3 (except if the Company is not then eligible to register for resale the Registrable
Securities on Form S-3, in which case such registration shall be on another form in accordance with the provisions of <U>Section 2(f)</U>)).
If Form S-3 is not available for the registration of the resale of Registrable Securities hereunder, the Company shall (i) register the
resale of the Registrable Securities on another appropriate form and (ii) undertake to register the Registrable Securities on Form S-3
as soon as such form is available, provided that the Company shall maintain the effectiveness of the Registration Statement then in effect
until such time as a Registration Statement on Form S-3 covering the Registrable Securities has been declared effective by the SEC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">3.</TD><TD>RELATED COMPANY OBLIGATIONS.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to the Registration
Statement and whenever any Registrable Securities are to be Registered pursuant to <U>Section 2</U>, including on the Initial Registration
Statement or on any New Registration Statement, the Company shall use its commercially reasonable efforts to effect the registration of
the Registrable Securities in accordance with the intended method of disposition thereof and, pursuant thereto, the Company shall have
the following obligations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)   <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Notifications</U></FONT>.
The Company will promptly notify the Investors of the time when any subsequent amendment to the Initial Registration Statement or any
New Registration Statement, other than documents incorporated by reference, has been filed with the SEC and/or has become effective or
where a receipt has been issued therefor or any subsequent supplement to a prospectus has been filed and of any request by the SEC for
any amendment or supplement to the Registration Statement, any New Registration Statement or any prospectus or for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)   <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Amendments.</U></FONT>
The Company will prepare and file with the SEC any amendments, post-effective amendments or supplements to the Initial Registration Statement,
any New Registration Statement or any related prospectus, as applicable, that, (a) as may be necessary to keep such Registration Statement
effective for the Registration Period and to comply with the provisions of the Securities Act and the Securities Exchange Act of 1934,
as amended (the &ldquo;<B>Exchange Act</B>&rdquo;) with respect to the distribution of all of the Registrable Securities covered thereby,
or (b) in the reasonable opinion of the Investors and the Company, as may be necessary or advisable in connection with any acquisition
or sale of Registrable Securities by the Investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)   <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Investor
Review</U></FONT>. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement
or any prospectus, other than documents incorporated by reference, relating to the Investors, the Registrable Securities or the transactions
contemplated hereby unless (A) the Investors and their counsel shall have been advised and afforded the opportunity to review and comment
thereon at least three (3) Business Days prior to filing with the SEC and (B) the Company shall have given good faith consideration to
any comments thereon received from the Investors or their counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)   <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Copies
Available</U></FONT>. The Company will furnish to any Investor whose Registrable Securities are included in any Registration Statement
and its counsel copies of the Initial Registration Statement, any prospectus thereunder (including all documents incorporated by reference
therein), any prospectus supplement thereunder, any New Registration Statement and all amendments to the Initial Registration Statement
or any New Registration Statement that are filed with the SEC during the Registration Period (including all documents filed with or furnished
to the SEC during such period that are deemed to be incorporated by reference therein), each letter written by or on behalf of the Company
to the SEC or the staff of the SEC, and each item of correspondence from the SEC or the staff of the SEC, in each case relating to such
Registration Statement (other than any portion thereof which contains information for which the Company has sought confidential treatment)
and <FONT STYLE="background-color: white">such other documents as Investor may reasonably request in order to facilitate the disposition
of the Registrable Securities owned by Investor that are covered by such Registration Statement</FONT>, in each case as soon as reasonably
practicable upon such Investor&rsquo;s request and in such quantities as such Investor may from time to time reasonably request; <U>provided</U>,
<U>however</U>, that the Company shall not be required to furnish any document to the Investor to the extent such document is available
on EDGAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)   <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Notification
of Stop Orders; Material Changes</U></FONT>. The Company shall use commercially reasonable efforts to (i) prevent the issuance of any
stop order or other suspension of effectiveness and, (ii) if such order is issued, obtain the withdrawal of any such order as soon as
practicable. The Company shall advise the Investors promptly (but in no event later than 24 hours) and shall confirm such advice in writing,
in each case: (i) of the Company&rsquo;s receipt of notice of any request by the SEC or any other federal or state governmental authority
for amendment of or a supplement to the Registration Statement or any prospectus or for any additional information, (ii) of the Company&rsquo;s
receipt of notice of the issuance by the SEC or any other federal or state governmental authority of any stop order suspending the effectiveness
of the Initial Registration Statement or prohibiting or suspending the use of any prospectus or prospectus supplement, or any New Registration
Statement, or of the Company&rsquo;s receipt of any notification of the suspension of qualification of the Registrable Securities for
offering or sale in any jurisdiction or the initiation or contemplated initiation of any proceeding for such purpose, and (iii) of the
Company becoming aware of the happening of any event, which makes any statement of a material fact made in any Registration Statement
or any prospectus untrue or which requires the making of any additions to or changes to the statements then made in any Registration Statement
or any prospectus in order to state a material fact required by the Securities Act to be stated therein or necessary in order to make
the statements then made therein (in the case of any prospectus, in light of the circumstances under which they were made) not misleading,
or of the necessity to amend any Registration Statement or any prospectus to comply with the Securities Act or any other law. The Company
shall not be required to disclose to the Investors the substance of specific reasons of any of the events set forth in clauses (i) through
(iii) of the immediately preceding sentence (each, a &ldquo;<B>Suspension Event</B>&rdquo;), but rather, shall only be required to disclose
that the event has occurred. If at any time the SEC, or any other federal or state governmental authority shall issue any stop order suspending
the effectiveness of any Registration Statement or prohibiting or suspending the use of any prospectus or prospectus supplement, the Company
shall use its commercially reasonable efforts to obtain the withdrawal of such order at the earliest practicable time. The Company shall
furnish to the Investors, without charge, a copy of any correspondence from the SEC or the staff of the SEC, or any other federal or state
governmental authority to the Company or its representatives relating to the Initial Registration Statement, any New Registration Statement
or any prospectus, or prospectus supplement as the case may be. In the event of a Suspension Event set forth in clause (iii) of the second
sentence of this <U>Section 3(e)</U>, the Company will use its commercially reasonable efforts to publicly disclose such event as soon
as reasonably practicable, or otherwise resolve the matter such that sales under Registration Statements may resume.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)   <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Confirmation
of Effectiveness</U></FONT>. If reasonably requested by an Investor at any time in respect of any Registration Statement, the Company
shall deliver to such Investor a written confirmation (email being sufficient) from Company&rsquo;s counsel of whether or not the effectiveness
of such Registration Statement has lapsed at any time for any reason (including, without limitation, the issuance of a stop order) and
whether or not such Registration Statement is currently effective and available to the Company for sale of Registrable Securities. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)   <U>Listing</U>.
The Company shall use commercially reasonable efforts to cause all Registrable Securities covered by a Registration Statement to be listed
on the Nasdaq Global Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)   <U>Compliance</U>.
The Company shall otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the SEC under the
Securities Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final prospectus, including
any supplement or amendment thereof, with the SEC pursuant to Rule 424 under the Securities Act, promptly inform the Investor in writing
if, at any time during the Registration Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof,
the Investor is required to deliver a prospectus in connection with any disposition of Registrable Securities and take such other actions
as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder, and make available to its security
holders, as soon as reasonably practicable, but not later than the Availability Date (as defined below), an earnings statement covering
a period of at least twelve (12) months, beginning after the effective date of each Registration Statement, which earnings statement shall
satisfy the provisions of Section 11(a) of the Securities Act, including Rule 158 promulgated thereunder (for the purpose of this subsection
3(h), &ldquo;Availability Date&rdquo; means the forty-fifth (45<SUP>th</SUP>) day following the end of the fourth fiscal quarter that
includes the effective date of such Registration Statement, except that, if such fourth fiscal quarter is the last quarter of the Company&rsquo;s
fiscal year, &ldquo;Availability Date&rdquo; means the ninetieth (90<SUP>th</SUP>) day after the end of such fourth fiscal quarter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)   <U>Blue-Sky</U>.
The Company shall use commercially reasonable efforts to register or qualify or cooperate with the Investor and their counsel in connection
with the registration or qualification of such Registrable Securities for the offer and sale under the securities or blue sky laws of
such jurisdictions reasonably requested by the Investor; <U>provided</U>, <U>however</U>, that the Company shall not be required in connection
therewith or as a condition thereto to (i) qualify to do business in any jurisdiction where it would not otherwise be required to qualify
but for this <U>Section 3(i)</U>, (ii) subject itself to general taxation in any jurisdiction where it would not otherwise be so subject
but for this <U>Section 3(i)</U>, or (iii) file a general consent to service of process in any such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)   <U>Rule
144</U>. With a view to making available to the Investors the benefits of Rule&nbsp;144 (or its successor rule) and any other rule or
regulation of the SEC that may at any time permit the Investors to sell shares of Common Stock to the public without registration, for
so long as the Shares are outstanding, the Company covenants and agrees to use commercially reasonable efforts to: (i)&nbsp;make and keep
adequate current public information available, as those terms are understood and defined in Rule&nbsp;144, until the date as all of the
Shares may be sold without restriction by the holders thereof pursuant to Rule&nbsp;144 or any other rule of similar effect, (ii)&nbsp;file
with the SEC in a timely manner all reports and other documents required of the Company under the Exchange Act, (iii)&nbsp;furnish electronically
to each Investor upon request, as long as such Investor owns any Shares, (A)&nbsp;a written statement by the Company that it has complied
with the reporting requirements of the Exchange Act, (B)&nbsp;a copy of or electronic access to the Company&rsquo;s most recent Annual
Report on Form 10-K or Quarterly Report on Form 10-Q, and (C)&nbsp;such other information as may be reasonably requested in order to avail
such Investor of any rule or regulation of the SEC that permits the selling of any such Shares without registration, and (iv) provide
any legal opinions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)   <U>Cooperation.</U>&nbsp;The
Company shall cooperate with the holders of the Registrable Securities to facilitate the timely preparation and delivery of certificates
or uncertificated shares representing the Registrable Securities to be sold pursuant to such Registration Statement or Rule 144 free of
any restrictive legends and representing such number of shares of Common Stock and registered in such names as the holders of the Registrable
Securities may reasonably request in accordance with the provisions of the Purchase Agreement, and the Company may satisfy its obligations
hereunder without issuing physical stock certificates through the use of The Depository Trust Company&rsquo;s Direct Registration System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)   <U>Removal
of Restrictive Legends</U>.&nbsp;Without limiting Section 5.5 of the Purchase Agreement, the Company shall use commercially reasonable
efforts to cause the Company&rsquo;s transfer agent to remove any restrictive legend from any Registrable Securities, as promptly as practicable
following effectiveness of the applicable Registration Statement, without any request for removal being required from any holder of Registrable
Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)   <U>Use
of Prospectus, etc</U>. Subject to the terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment
or supplement thereto by each of the Investors in connection with the offering and sale of the Registrable Securities covered by such
Prospectus and any amendment or supplement thereto, except after the giving of any notice pursuant to Section 3(e).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">4.</TD><TD>OBLIGATIONS OF THE INVESTORS.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)   <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Investor
Information</U></FONT>. Each Investor shall provide a completed Investor Questionnaire in the form attached hereto as <U>Exhibit A</U>
or such other form of questionnaire or information required by the Company in connection with the registration of the Registrable Securities
within three (3) Business Days of request by the Company and no later than the end of the third (3rd) Business Day following the date
on which such Investor receives draft materials in accordance with <U>Section 2(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) <U>Suspension of Sales</U>.
Each Investor, severally and not jointly with any other Investor, agrees that, upon receipt of any notice from the Company of the existence
of an Allowed Delay or Suspension Event, the Investor will promptly discontinue disposition of Registrable Securities pursuant to any
Registration Statement covering such Registrable Securities until the Investor&rsquo;s receipt of a notice from the Company confirming the
resolution of such Allowed Delay or Suspension Event and that such dispositions may again be made, provided, for the avoidance of doubt,
that the foregoing shall not limit the right of the Investor to sell or otherwise dispose of the Registrable Securities pursuant to Rule
144 or any other exemption from the registration requirements of the Securities Act or to settle a transaction pursuant to a Registration
Statement as to which a contract for such sale was entered into prior to such Investor&rsquo;s receipt of the notice from the Company
of the existence of the Allowed Delay or Suspension Event. The Company shall cause its transfer agent to deliver unlegended shares of
Common Stock to a transferee of an Investor in accordance with any sale of Registrable Securities pursuant to a Registration Statement
with respect to which such Investor has entered into a contract for sale prior to such Investor&rsquo;s receipt of the notice from the
Company of the existence of the Allowed Delay or Suspension Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Investor
Cooperation</U></FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Each Investor, severally and not jointly with any other
Investor, agrees</FONT> to cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing
of any amendments and supplements to any Registration Statement or New Registration Statement hereunder, unless such Investor has notified
the Company in writing of its election to exclude all of its Registrable Securities from such Registration Statement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">5.</TD><TD>EXPENSES OF REGISTRATION.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">All Registration Expenses incurred
in connection with registrations pursuant to this Agreement shall be borne by the Company. All Selling Expenses relating to securities
registered on behalf of the Investors shall be borne by the Investors pro rata on the basis of the number of Registrable Securities so
registered.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">6.</TD><TD>INDEMNIFICATION.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)   To
the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend each Investor, each Person,
if any, who controls each Investor, the members, the directors, officers, partners, employees, members, managers, agents, representatives
and advisors of each Investor and each Person, if any, who controls each Investor within the meaning of the Securities Act or the Exchange
Act (each, an &ldquo;<B>Indemnified Person</B>&rdquo;), against any losses, obligation, claims, damages, liabilities, contingencies, judgments,
fines, penalties, charges and costs (including, without limitation, court costs and costs of preparation, reasonable and documented attorneys&rsquo;
fees, amounts paid in settlement (with the prior consent of the Company, such consent not to be unreasonably withheld, conditioned or
delayed) or reasonable and documented expenses (collectively, &ldquo;<B>Claims</B>&rdquo;)) reasonably incurred in investigating, preparing
or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or
governmental, administrative or other regulatory agency or body or the SEC, whether pending or threatened, whether or not an indemnified
party is or may be a party thereto (&ldquo;<B>Indemnified Damages</B>&rdquo;), to which any of them may become subject insofar as such
Claims (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon: (i) any untrue
statement or alleged untrue statement or omission or alleged omission of any material fact contained in any Registration Statement, any
preliminary prospectus or final prospectus, or any amendment or supplement thereof, or (ii) any violation or alleged violation by the
Company or any of its Subsidiaries of the Securities Act, Exchange Act or any other state securities or other &ldquo;blue sky&rdquo; laws
of any jurisdiction in which Registrable Securities are offered or any rule or regulation promulgated thereunder applicable to the Company
or its agents and relating to action or inaction required of the Company in connection with such registration of the Registrable Securities
(the matters in the foregoing clauses (i) and (ii) being, collectively, &ldquo;<B>Violations</B>&rdquo;).&nbsp;The Company shall reimburse
each Indemnified Person promptly as such expenses are incurred and are due and payable, for any reasonable out-of-pocket legal fees or
other reasonable and documented expenses incurred by them in connection with investigating or defending any such Claim.&nbsp;Notwithstanding
anything to the contrary contained herein, the indemnification agreement contained in this <U>Section 6(a)</U>: (A) shall not apply to
a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in reliance upon and in conformity with information
furnished in writing to the Company by the Investors or such Indemnified Person specifically for use in such Registration Statement or
prospectus and was reviewed and approved in writing by such Investor or such Indemnified Person expressly for use in connection with the
preparation of any Registration Statement, any prospectus or any such amendment thereof or supplement thereto, if such in each case if
the foregoing was timely made available by the Company; (B) with respect to any superseded prospectus, shall not inure to the benefit
of any such Person from whom the Person asserting any such Claim purchased the Registrable Securities that are the subject thereof (or
to the benefit of any other Indemnified Person) if the untrue statement or omission of material fact contained in the superseded prospectus
was corrected in the revised prospectus, as then amended or supplemented, and the Indemnified Person was promptly advised in writing not
to use the outdated, defective or incorrect prospectus prior to the use giving rise to a violation; (C) shall not be available to the
extent such Claim is based on a failure of the Indemnified Person to deliver, or cause to be delivered, if required the prospectus to
the Persons asserting an untrue statement or omission or alleged untrue statement or omission at or prior to the written confirmation
of the sale of Registrable Securities; and (D) shall not apply to amounts paid in settlement of any Claim if such settlement is effected
without the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned or delayed.&nbsp;Such
indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall
survive the transfer of the Registrable Securities by the Investor pursuant to <U>Section 8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)   In
connection with the Initial Registration Statement, any New Registration Statement or any prospectus, each Investor, severally and not
jointly, agree to indemnify, hold harmless and defend, the Company, each of its directors, each of its officers who signed the Initial
Registration Statement or signs any New Registration Statement, each Person, if any, who controls the Company within the meaning of the
Securities Act or the Exchange Act (each, an &ldquo;<B>Indemnified Party</B>&rdquo;), against any losses, claims, damages, liabilities
and expense (including reasonable attorney fees) resulting from any Violation, in each case to the extent, and only to the extent, that
such Violation occurs in reliance upon and in conformity with information about an Investor furnished in writing by such Investor to the
Company expressly for use in connection with the preparation of the Registration Statement, any New Registration Statement, any prospectus
or any such amendment thereof or supplement thereto. In no event shall the liability of an Investor be greater in amount than the dollar
amount of the proceeds (net of all expense paid by such Investor in connection with any claim relating to this <U>Section 6</U> and the
amount of any damages such Investor has otherwise been required to pay by reason of such untrue statement or omission) received by such
Investor upon the sale of the Registrable Securities included in such Registration Statement giving rise to such indemnification obligation.
Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Indemnified Party and
shall survive the transfer of the Registrable Securities by an Investor pursuant to <U>Section 8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)   Promptly
after receipt by an Indemnified Person or Indemnified Party under this <U>Section 6</U> of notice of the commencement of any action or
proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party shall, if
a Claim in respect thereof is to be made against any indemnifying party under this <U>Section 6</U>, deliver to the indemnifying party
a written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent the
indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof with
counsel mutually satisfactory to the indemnifying party and the Indemnified Person or the Indemnified Party, as the case may be, and upon
such notice, the indemnifying party shall not be liable to the Indemnified Person or the Indemnified Party for any legal or other expenses
subsequently incurred by the Indemnified Person or the Indemnified Party in connection with the defense thereof; <U>provided</U>, <U>however</U>,
that an Indemnified Person or Indemnified Party (together with all other Indemnified Persons and Indemnified Parties that may be represented
without conflict by one counsel) shall have the right to retain its own counsel with the reasonable fees and expenses to be paid by the
indemnifying party, if, in the reasonable opinion of counsel retained by the indemnifying party, the representation by such counsel of
the Indemnified Person or Indemnified Party and the indemnifying party would be inappropriate due to actual or potential differing interests
between such Indemnified Person or Indemnified Party and any other party represented by such counsel in such proceeding. The Indemnified
Party or Indemnified Person shall cooperate with the indemnifying party in connection with any negotiation or defense of any such action
or claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Indemnified
Party or Indemnified Person which relates to such action or claim.&nbsp;The indemnifying party shall keep the Indemnified Party or Indemnified
Person fully apprised as to the status of the defense or any settlement negotiations with respect thereto.&nbsp;No indemnifying party
shall be liable for any settlement of any action, claim or proceeding effected without its written consent, <U>provided</U>, <U>however</U>,
that the indemnifying party shall not unreasonably withhold, delay or condition its consent.&nbsp;No indemnifying party shall, without
the consent of the Indemnified Party or Indemnified Person, consent to entry of any judgment or enter into any settlement or other compromise
unless such judgment or settlement (i) imposes no liability or obligation on, (ii) includes as an unconditional term thereof the giving
of a complete, explicit and unconditional release from the party bringing such indemnified claims of all liability of the Indemnified
Party or Indemnified Person in respect to or arising out of such claim or litigation in favor of, and (iii) does not include any admission
of fault, culpability, wrongdoing, or wrongdoing or malfeasance by or on behalf of, the Indemnified Party or Indemnified Person.&nbsp;Following
indemnification as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Indemnified Party or Indemnified
Person with respect to all third parties, firms or corporations relating to the matter for which indemnification has been made.&nbsp;The
failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not
relieve such indemnifying party of any liability to the Indemnified Person or Indemnified Party under this <U>Section 6</U>, except to
the extent that the indemnifying party is prejudiced in its ability to defend such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)   The
indemnification required by this <U>Section 6</U> shall be made by periodic payments of the amount thereof during the course of the investigation
or defense, as and when bills are received or Indemnified Damages are incurred.&nbsp;Any Person receiving a payment pursuant to this <U>Section
6</U> which person is later determined to not be entitled to such payment shall return such payment (including reimbursement of expenses)
to the person making it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)   The
indemnity agreements contained herein shall be in addition to (i) any cause of action or similar right of the Indemnified Party or Indemnified
Person against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject to pursuant to the law.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">7.</TD><TD>CONTRIBUTION.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">To the extent any indemnification
by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect
to any amounts for which it would otherwise be liable under <U>Section 6</U> to the fullest extent permitted by law; <U>provided</U>,
<U>however</U>, that: (i) no seller of Registrable Securities guilty of fraudulent misrepresentation (within the meaning of <U>Section
11(f)</U> of the Securities Act) shall be entitled to contribution from any seller of Registrable Securities who was not guilty of fraudulent
misrepresentation; and (ii) contribution by any seller of Registrable Securities shall be limited in amount to the net amount of proceeds
(net of all expenses paid by such holder in connection with any claim relating to this <U>Section 7</U> and the amount of any damages
such holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission) received
by such seller from the sale of such Registrable Securities giving rise to such contribution obligation.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">8.</TD><TD>ASSIGNMENT OF REGISTRATION RIGHTS.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company shall not assign
this Agreement or any rights or obligations hereunder (whether by operation of law or otherwise) without the prior written consent of
the Investors holding a majority of the Registrable Securities then outstanding (measured together as a single class); <U>provided</U>,
<U>however</U>, that in any transaction, whether by merger, reorganization, restructuring, consolidation, financing or otherwise, whereby
the Company is a party and in which the Registrable Securities are converted into the equity securities of another Person, from and after
the effective time of such transaction, such Person shall, by virtue of such transaction, be deemed to have assumed the obligations of
the Company hereunder, the term &ldquo;Company&rdquo; shall be deemed to refer to such Person and the term &ldquo;Registrable Securities&rdquo;
shall be deemed to include the securities received by the Investor in connection with such transaction unless such securities are otherwise
freely tradable by the Investor after giving effect to such transaction, and the prior written consent of the Investors holding a majority
of the Registrable Securities then outstanding shall not be required for such transaction. No Investor may assign its rights under
this Agreement, other than to an affiliate of such Investor, without the prior written consent of the Company. The provisions of this
Agreement shall be binding upon and inure to the benefit of the Investor and its successors and permitted assigns.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">9.</TD><TD>AMENDMENTS AND WAIVERS.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The provisions of this Agreement,
including the provisions of this sentence, may be amended, modified or supplemented, or waived only by a written instrument executed by
(i) the Company and (ii) the holders of a majority of the then outstanding Registrable Securities (measured together as a single class),
<U>provided</U> that (i) any party may give a waiver as to itself, (ii) any amendment, modification, supplement or waiver that disproportionately
and adversely affects the rights and obligations of any Investor relative to the comparable rights and obligations of the other Investors
shall require the prior written consent of such adversely affected Investor or each Investor, as applicable, and (iii) any amendments
to <U>Section 6</U> or to the definitions of &ldquo;Filing Deadline,&rdquo; Effectiveness Deadline,&rdquo; or &ldquo;Registration Period&rdquo;
shall require the written consent of each Investor. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof
with respect to a matter that relates exclusively to the rights of one or more Investors and that does not adversely directly or indirectly
affect the rights of other Investors may be given by Investors holding a majority of the Registrable Securities to which such waiver or
consent relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">10.</TD><TD>MISCELLANEOUS.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)   <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Notices</U></FONT>.
Any notices or other communications required or permitted to be given hereunder shall be in writing and shall be deemed to be given (a)
when delivered if personally delivered to the party for whom it is intended, (b) when delivered, if sent by electronic mail during normal
business hours of the recipient, and if not sent during normal business hours, then on the recipient&rsquo;s next business day, provided
no rejection or undeliverable notice is received, (c) three (3) days after having been sent by certified or registered mail, return-receipt
requested and postage prepaid, or (d) one (1) business day after deposit with a nationally recognized overnight courier, freight prepaid,
specifying next business day delivery, with written verification of receipt:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">i.   If
to the Company, addressed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in">Oruka Therapeutics, Inc.<BR>
855 Oak Grove Ave., Suite 100<BR>
Menlo Park, CA 94025<BR>
Attention: Paul Quinlan, General Counsel<BR>
Email:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;&nbsp;&nbsp;with a copy (which shall not constitute
notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in">Davis Polk &amp; Wardwell LLP<BR>
900 Middlefield Road<BR>
Redwood City, CA 94063<BR>
Attention: Alan Denenberg, Beth LeBow<BR>
Email:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">ii. If
to any Investor, at its e-mail address or address set forth on <U>Exhibit A</U> to the Purchase Agreement or to such e-mail address, or
address as subsequently modified by written notice given in accordance with this <U>Section 10</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Any Person may change the address
to which notices and communications to it are to be addressed by notification as provided for herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)   <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>No
Waiver.</U></FONT> No failure or delay on the part of either party hereto in the exercise of any power, right or privilege under this
Agreement shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude any
other or further exercise thereof or of any other right, power or privilege.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)   <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Governing
Law; Submission to Jurisdiction; Venue; Waiver of Trial by Jury</U></FONT>. The provisions of <U>Section 8.6</U> of the Purchase Agreement
are incorporated by reference herein <I>mutatis mutandis</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)   <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Integration</U></FONT>.
This Agreement and the other Transaction Agreements (including all schedules and exhibits hereto and thereto) constitute the entire agreement
between the parties hereto respecting the subject matter hereof and supersedes all prior agreements, negotiations, understandings, representations
and statements respecting the subject matter hereof, whether written or oral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)   <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Headings</U></FONT>.
The titles, subtitles and headings in this Agreement are for convenience of reference and shall not form part of, or affect the interpretation
of, this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)   <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Counterparts</U></FONT>.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or
pdf signature including any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall be considered
due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not
a facsimile or pdf (or other electronic reproduction of a) signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)   <U>Further
Assurances</U>. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute
and deliver all such other agreements, certificates, instruments and documents as the other party may reasonably request in order to carry
out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)   <U>Contract
Interpretation</U>. This Agreement is the joint product of each Investor and the Company and each provision hereof has been subject to
the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)   <U>No
Third Party Beneficiaries</U>. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors
and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. Nothing in this Agreement,
express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any
rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)   <U>Severability</U>.
If any part or provision of this Agreement is held unenforceable or in conflict with the applicable laws or regulations of any jurisdiction,
the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original
business purpose of such part or provision in a valid and enforceable manner, and the remainder of this Agreement shall remain binding
upon the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)   <U>Non-Recourse</U>.
Notwithstanding anything that may be expressed or implied in this Agreement, the Company covenants, agrees and acknowledges that no recourse
under this Agreement or any documents or instruments delivered in connection with this Agreement shall be had against any current or future
director, officer, employee, stockholder, general or limited partner or member of the Investors or of any affiliates or assignees thereof,
whether by the enforcement of any assessment or by any legal or equitable proceeding, or by virtue of any statute, regulation or other
applicable law, it being expressly agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed on or otherwise
be incurred by any current or future director, officer, employee, stockholder, general or limited partner or member of the Investors or
of any affiliates or assignees thereof, as such for any obligation of the Investors under this Agreement or any documents or instruments
delivered in connection with this Agreement for any claim based on, in respect of or by reason of such obligations or their creation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)   <U>Specific
Performance</U>. In addition to any and all other remedies that may be available at law in the event of any breach of this Agreement,
each Investor shall be entitled to specific performance of the agreements and obligations of the Company hereunder and to such other injunction
or equitable relief as may be granted by a court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)   <U>Cumulative
Remedies</U>. The remedies provided herein are cumulative and not exclusive of any remedies provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>IN WITNESS WHEREOF,</B> the parties have caused
this Registration Rights Agreement to be duly executed as of date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: left"><B>COMPANY:</B></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 60%">&nbsp;</TD><TD STYLE="text-align: left; width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD><TD STYLE="text-align: left; width: 31%">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: left"><FONT STYLE="text-transform: uppercase"><B>Oruka Therapeutics, Inc.</B></FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD>Name:</TD><TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD>Title:</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>[Signature Page to Registration Rights Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in"><B>IN WITNESS WHEREOF,</B> the parties have caused
this Registration Rights Agreement to be duly executed as of date first written above.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><B>INVESTOR:</B></TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left; width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><B>[NAME]</B></TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Name:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Title:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">Address: [&#9679;]</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">Email: [&#9679;]</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>[Signature Page to Registration Rights Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Investor Questionnaire</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Attached.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>ea025786501ex99-1_oruka.htm
<DESCRIPTION>PRESS RELEASE, DATED SEPTEMBER 17, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.75pt"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.75pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Oruka Therapeutics Announces $180 Million Private Placement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka
Therapeutics, Inc. (&ldquo;Oruka&rdquo; or the &ldquo;Company&rdquo;) (Nasdaq: ORKA), a biotechnology company developing novel biologics
designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that it has entered
into a securities purchase agreement for a private investment in public equity (&ldquo;PIPE&rdquo;) financing that is expected to result
in gross proceeds of approximately $180 million to the Company, before placement agent fees and offering expenses. The PIPE financing
was led by Viking Global Investors, and included participation from both new and existing investors, including Affinity Healthcare Fund,
Blackstone Multi-Asset Investing, Commodore Capital, Cormorant Asset Management, Deep Track Capital, Fairmount, Great Point Partners,
LLC, Palo Alto Investors, LP, Perceptive Advisors, Surveyor Capital (a Citadel company), Venrock Healthcare Capital Partners, Woodline
Partners LP and a leading life sciences investment firm, among others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Pursuant
to the terms of the securities purchase agreement, Oruka is selling an aggregate of (i) 10,933,405 shares of its common stock
(&ldquo;Common Stock&rdquo;) at a purchase price of $15.00 per share and (ii) pre-funded warrants to purchase 1,066,666 shares of
Common Stock at a price of $14.999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share.
Following the transaction, there will be approximately 67.1 million shares of the Company&rsquo;s Common Stock and Common Stock
equivalents issued and outstanding, including shares of Common Stock underlying pre-funded warrants and Series B non-voting
convertible preferred stock. The PIPE financing is expected to close on or about September 19, 2025, subject to satisfaction of
customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">The Company intends to use the net proceeds from the PIPE
financing, together with the Company&rsquo;s existing cash, cash equivalents, and marketable securities, to provide financing for research
and development, general corporate expenses, and working capital needs. The Company expects that its cash will fund its operations for
at least one year following the ORKA-002 Phase 2 and ORKA-001 EVERLAST-B Phase 2b data readouts in 2027.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Jefferies, TD Cowen, Guggenheim Securities and LifeSci Capital
are acting as joint placement agents for the PIPE financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.15pt; text-indent: 0.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">The offer and sale of the foregoing
securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities
Act of 1933, as amended, and may not be reoffered or resold in the United States except pursuant to an effective registration statement
or an applicable exemption from the registration requirements. Concurrently with the execution of the securities purchase agreement, Oruka
and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file a registration statement
with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) registering the resale of the shares of Common Stock and the Common
Stock issuable upon exercise of the pre-funded warrants, in each case sold in the PIPE financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">This press release shall not constitute an offer to sell
or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any
such state or other jurisdiction.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">About Oruka Therapeutics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Oruka Therapeutics is developing novel biologics designed
to set a new standard for the treatment of chronic skin diseases. Oruka&rsquo;s mission is to offer patients suffering from chronic skin
diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance
with dosing as infrequently as once or twice per year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies
that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory
diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><B>Forward-Looking
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Certain
statements in this press release, other than purely historical information, may constitute &ldquo;forward-looking statements&rdquo;
within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States
Private Securities Litigation Reform Act of 1995, concerning Oruka and other matters. These forward-looking statements include, but
are not limited to, express or implied statements relating to Oruka&rsquo;s management team&rsquo;s expectations, hopes, beliefs,
intentions or strategies regarding the future of its pipeline and business including, without limitation, the intended use of
proceeds from the PIPE financing, Oruka&rsquo;s cash sufficiency and runway, including as it relates to the anticipated timing of
clinical trials and data readouts, the expected timing of closing of the PIPE financing and the completion of the PIPE financing,
and Oruka&rsquo;s business plans. In addition, any statements that refer to projections, forecasts or other characterizations of
future events or circumstances, including any underlying assumptions, are forward-looking statements. The words
&ldquo;potential,&rdquo; &ldquo;pipeline,&rdquo; &ldquo;can,&rdquo; &ldquo;target,&rdquo; &ldquo;believe,&rdquo;
&ldquo;expect,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;possible,&rdquo;
&ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; and similar expressions (including the
negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not
mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs
concerning future developments and their potential effects. There can be no assurance that future developments affecting Oruka will
be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are
beyond Oruka&rsquo;s control) or other assumptions that may cause actual results or performance to be materially different from
those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to,
market conditions and the satisfaction of closing conditions, as well as those uncertainties and factors described under the heading
&ldquo;Risk Factors&rdquo; and &ldquo;Cautionary Note Regarding Forward-Looking Statements&rdquo; in Oruka&rsquo;s most recent
filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of Oruka&rsquo;s assumptions
prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in
this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will
be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue
reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in
their entirety by reference to the cautionary statements herein. Oruka does not undertake or accept any duty to make any updates or
revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other
attributes of an investment in Oruka.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Investor Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Alan Lada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">(650) 606-7911</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">alan.lada@orukatx.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>6
<FILENAME>ea025786501ex99-2_oruka.htm
<DESCRIPTION>PRESS RELEASE, DATED SEPTEMBER 17, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0 0pt 9.75pt"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.75pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><IMG SRC="ex99-2_001.jpg" ALT=""></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Oruka Therapeutics Announces Positive Interim Phase 1 Results
for ORKA-001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Half-life of approximately 100 days
increases likelihood of once-per-year dosing</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Pharmacokinetic profile supports the
ability to achieve exposures that could lead to higher efficacy and extended off-treatment remissions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 111.55pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Well tolerated with a favorable
safety profile consistent with the IL-23p19 class</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>EVERLAST-A Phase 2a trial enrollment ongoing with data expected 2H 2026</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 111.55pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics,
Inc. (&ldquo;Oruka&rdquo;) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment
of chronic skin diseases including plaque psoriasis (PsO), today announced interim data from its Phase 1 trial of ORKA-001, the Company&rsquo;s
long-acting IL-23p19 antibody, in a late-breaking abstract at the European Academy of Dermatology and Venerology (EADV) Congress in Paris,
France. These results, as well as additional details on the EVERLAST-A trial design, will be presented in two oral presentations at the
conference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.85pt">&ldquo;ORKA-001&rsquo;s
approximately 100-day half-life exceeded our expectations and has the potential to enable multiple &lsquo;upside&rsquo; scenarios
for the program,&rdquo; said Lawrence Klein, PhD, CEO of Oruka. &ldquo;We are increasingly confident that ORKA-001 can redefine the
standard of care in this important disease. I&rsquo;m very pleased with how quickly our team has progressed this program and by the
enthusiasm we are hearing from investigators and patients.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Interim results from the Phase 1 trial support the potential for ORKA-001
to change the PsO treatment paradigm. The ongoing EVERLAST-A Phase 2a trial is designed to test whether ORKA-001 can enable annual dosing,
higher rates of skin clearance than standard of care, and long-term off-treatment remissions. Oruka expects to present initial data from
EVERLAST-A in 2H 2026.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Key Phase 1 Interim Findings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Phase 1 trial is a first-in-human, randomized, double-blind, placebo-controlled
trial designed to evaluate the safety and pharmacokinetics (PK) of ORKA-001 in healthy volunteers. The study enrolled 24 healthy adult
participants into three single ascending subcutaneous dose cohorts of 300 mg, 600 mg, and 1200 mg. Interim results from the Phase 1 trial
include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -8.15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&#9679;</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PK:
</B></FONT>ORKA-001 showed a half-life of approximately 100 days, greater than three times that of risankizumab, and a C<FONT STYLE="font-size: 10pt">max</FONT>
that exceeded risankizumab at an equivalent dose, based on previously reported risankizumab data. These properties increase the likelihood
of achieving once-yearly maintenance dosing and demonstrate comparable exposures to the KNOCKOUT study, which could lead to best-in-class
rates of skin clearance and extended off-treatment remissions.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -8.15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&#9679;</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Pharmacodynamics
(PD): </B></FONT>Single doses of ORKA-001 demonstrated complete and sustained inhibition of STAT3 signaling, a downstream marker of IL-23
activity, in an <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>ex vivo </I></FONT>assay through 24 weeks (the longest follow-up
available).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -8.15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&#9679;</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Safety:
</B></FONT>ORKA-001 was well tolerated at all dose levels, with a favorable safety profile consistent with the anti-IL-23 class. There
were no severe treatment-emergent adverse events (TEAEs) or serious adverse events. The only TEAEs to occur in more than two subjects
were headache, upper respiratory tract infections, and transient erythema at the injection site. The study remains blinded, and all subjects
remain on study.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">EVERLAST Phase 2 Trials of ORKA-001 in Plaque Psoriasis</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The ongoing EVERLAST-A trial is a randomized, double-blind,
placebo-controlled Phase 2a trial designed to evaluate the safety and efficacy of a single dose level of ORKA-001 in
moderate-to-severe PsO patients. Enrollment and dosing at sites across the U.S. and Canada are currently progressing well, and the
Company expects to share initial data from EVERLAST-A in 2H 2026. Data presented at that time is expected to include PASI 100 at
Week 16 for all patients and preliminary durability data that could show the potential for yearly dosing and off-treatment
remissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -8.15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">EVERLAST-A will enroll approximately 80 patients randomized
3:1 to receive 600 mg ORKA-001 at Week 0 and 4 or matching placebo. The primary endpoint is PASI 100 at Week 16. ORKA-001 exposures are
expected to match or exceed exposures in the KNOCKOUT study, testing whether higher antibody exposures can lead to greater efficacy.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -8.15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -8.15pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -8.15pt">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">At Week 28, patients who have achieved PASI 100, or completely
clear skin, will be randomized 2:1 to an arm where either (1) they do not receive another dose until disease recurrence or (2) they receive
300 mg ORKA-001 every six months. The &ldquo;no-dose&rdquo; arm will evaluate the possibility of both yearly dosing and extended off-treatment
remissions (defined in the literature as clear skin over one year from last administration of a therapeutic). Patients who have not achieved
PASI 100 at Week 28 will receive 300 mg ORKA-001 every six months.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">At Week 16, patients receiving placebo will cross over to
600 mg ORKA-001 at Week 16 and 20, followed by once-yearly dosing of ORKA-001, providing additional data on the efficacy of yearly dosing.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, Oruka expects to initiate a dose-ranging Phase 2b trial
of ORKA-001 in moderate-to-severe PsO patients, EVERLAST-B, in 1H 2026. EVERLAST-B will evaluate three dose levels of ORKA-001: 37.5 mg
at Week 0, 300 mg at Weeks 0 and 4, and 600 mg at Weeks 0 and 4, versus placebo. The primary endpoint is PASI 100 at Week 16. To expedite
development, EVERLAST-B dosing is projected to begin enrolling before the completion of EVERLAST-A.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Details of the oral presentations at EADV:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -8.15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>&#9679;</B></TD><TD STYLE="text-align: justify"><B>Phase 1 Clinical Data of ORKA-001, a Novel Half-Life Extended
IL-23p19 Monoclonal Antibody with Potential for Once-Yearly Dosing in Plaque Psoriasis</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0in; text-align: justify">Author:
Dr. James Krueger</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0in; text-align: justify">Presentation
ID: D2T01.4D</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0in; text-align: justify">Late-Breaking
Presentation: Thursday, September 18, 16:45-17:00 CET</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0in; text-align: justify">Location:
Paris Nord</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -8.15pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">EVERLAST-A: A Phase 2a Study Design of ORKA-001, a Novel
Half-Life Extended IL-23p19 Monoclonal Antibody for Plaque Psoriasis</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0in; text-align: justify">Author:
Dr. Andrew Blauvelt</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0in; text-align: justify">Presentation
ID: FC02.1l</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0in; text-align: justify">Oral
Presentation: Thursday, September 18, 11:35-11:45 CET</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0in; text-align: justify">Location:
W05-W06</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">About ORKA-001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ORKA-001 is a novel, subcutaneously administered, half-life
extended monoclonal antibody targeting IL-23p19. Inhibitors of IL-23p19 have become the preferred first-line therapy for patients
with moderate-to-severe PsO given their strong efficacy and safety profile. Currently approved therapies are dosed four to six times
per year and deliver PASI 100, or fully clear skin, for less than half of patients after four months. ORKA-001 has the potential to
be dosed just once or twice per year and is designed to achieve higher exposures than currently marketed IL-23p19 antibodies, which
could lead to higher rates of disease clearance and extended off-treatment remissions. ORKA-001 is designed to match the validated
biology of risankizumab by binding to a similar epitope with similar affinity, but has a significantly extended half-life of
approximately 100 days.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">About Oruka Therapeutics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Oruka Therapeutics is developing novel biologics
designed to set a new standard for the treatment of chronic skin diseases. Oruka&rsquo;s mission is to offer patients suffering from
chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease
clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class
antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic
and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Forward-Looking Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain statements in this press release, other than purely historical
information, may constitute &ldquo;forward-looking statements&rdquo; within the meaning of the federal securities laws, including for
purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, express or implied statements relating to Oruka&rsquo;s expectations, hopes, beliefs, intentions
or strategies regarding the future of its pipeline and business including, without limitation, Oruka&rsquo;s ability to achieve the expected
benefits or opportunities with respect to ORKA-001, including its anticipated half-life, potential dosing intervals, ability to deliver
off-treatment remissions, anticipated rates of disease clearance, and safety and tolerability profile; the competitive outlook; and anticipated
trial design, enrollment targets and timelines to clinical development and data release milestones for ORKA-001. These forward-looking
statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance
that future developments affecting Oruka will be those that have been anticipated. These forward-looking statements involve a number of
risks, uncertainties (some of which are beyond Oruka&rsquo;s control) or other assumptions that may cause actual results or performance to be
materially different from those expressed or implied by these forward-looking statements. Such risks and uncertainties include, without
limitation, risks and uncertainties inherent in the drug development process, including risks related to the design and conduct of clinical
trials; risks that the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical
trials, and interim results of a clinical trial do not necessarily predict final results; risks related to the regulatory approval process
and the timing of regulatory filings; risks related to Oruka&rsquo;s ability to successfully establish, protect and defend its intellectual
property; risks related to other matters that could affect the sufficiency of the company&rsquo;s capital resources to fund operations;
and changes in the competitive landscape. For a further description of the risks and uncertainties that could cause actual results to
differ from those anticipated in these forward-looking statements, see the uncertainties and factors described under the heading &ldquo;Risk
Factors&rdquo; and &ldquo;Cautionary Note Regarding Forward-Looking Statements&rdquo; in Oruka&rsquo;s most recent filings with the Securities
and Exchange Commission (SEC), including its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q and subsequent filings with
the SEC. Should one or more of these risks or uncertainties materialize, or should any of Oruka&rsquo;s assumptions prove incorrect, actual
results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be
regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated
results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this
press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements
herein and in Oruka&rsquo;s SEC filings. Oruka does not undertake or accept any duty to make any updates or revisions to any forward-looking
statements.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor Contact:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alan Lada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(650)-606-7911</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">alan.lada@orukatx.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>orka-20250917.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qpZs7xRiXgen8uBYXYsWaGM2aPtyJ1xKYkxuG93fcnqXywtmxPB7CjsUakWAfsK -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:ORKA="http://orukatx.com/20250917" elementFormDefault="qualified" targetNamespace="http://orukatx.com/20250917">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://orukatx.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="orka-20250917_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="orka-20250917_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>orka-20250917_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>orka-20250917_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="orka-20250917.xsd#Cover" roleURI="http://orukatx.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://orukatx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !> 1H# 2(  A$! Q$!_\0
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M7\J^@=._Y!=I_P!<4_\ 017S_P#&($>/YL][>+'Y5[_IC!M*LV!R# A!_P"
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M)\ME8*?-=W+%%%%9&QA>(-3U;2HFN+;1UU2T ^>.*3;*OK\I!##Z<^U>>/\
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G **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex99-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !> 1H# 2(  A$! Q$!_\0
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M7\J^@=._Y!=I_P!<4_\ 017S_P#&($>/YL][>+'Y5[_IC!M*LV!R# A!_P"
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M)\ME8*?-=W+%%%%9&QA>(-3U;2HFN+;1UU2T ^>.*3;*OK\I!##Z<^U>>/\
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G **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 17, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 17,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-22873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Oruka Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000907654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-3855489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">855 Oak Grove Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Menlo Park<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">606-7910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ORKA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0257865-8k_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orukatx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0257865-8k_oruka.htm">ea0257865-8k_oruka.htm</File>
    <File>orka-20250917.xsd</File>
    <File>orka-20250917_lab.xml</File>
    <File>orka-20250917_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0257865-8k_oruka.htm": {
   "nsprefix": "ORKA",
   "nsuri": "http://orukatx.com/20250917",
   "dts": {
    "inline": {
     "local": [
      "ea0257865-8k_oruka.htm"
     ]
    },
    "schema": {
     "local": [
      "orka-20250917.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "orka-20250917_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "orka-20250917_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://orukatx.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-17",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257865-8k_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-17",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257865-8k_oruka.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://orukatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001213900-25-090129-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-090129-xbrl.zip
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M]@[9-ZAZ2\J@LUW+T+5=(AL'EN=9DZ!=F;>CEL^[^G<P(?!MMOFO?RCUTJY
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M.XW)OWD> <07$V#H-W'S&/F,M (#Q::J/-VKB&5!\":")$0+-B($PJZ7J2O
MDIDKE1>*,<P%(%":I6Z5^NVMB.^R]X#9 [#IH+FA(\ &;R[4-:*NQ<VTE#E=
MB$*$,CDTL_@9C_2"'&E",<?MS[P3%]!YM_FD@(>FBSH:D%X:^3= ]I;A6@N>
M2.@T1L@8N'P9Z?(%)Z>YKWBFC\:P*Y)=OI4]X_[;(E.$:9'9 [00L#,B.&6X
M9@NJ'#+?X5(CQ<J$;$^SA,)_"Q:L8Q7PFZ\[XIPBB)R-]@RA#/&F( V3*[BR
M#+_'P1<?+B7B%N.H,+<1N7-H6L2@ GE0<2>J9W$.U (.<)Q%H@85)J_N.E(]
MHL8!!Q?5.2@RRT'3:V7&]([%4C^<[G/L0%49%-<DE!^&0(@P**5&B6L;' R@
M44_F0"\.;J2*#)QKU%TVWPAO0/JC#,<$&<7=0%$ZD>Y ?Y"?D=0*2*016"H\
MCC$Q=7E(-2JO\%EWY.4,_*R!\*@8:@"@$?I&W./T3-XXX;L-_Z FM.)?W"L5
ME@>'S*VC#%HX ZF&.3='J#TF[I "&>8E_!3&#QUK$C(1X X >"B;-A@T$"HR
M9/(+-K69Z:*G#?P6UQ]XXL\ UTIV$YLLXS*#'],5>&^XFT)JL3/'Z=X1A\PT
MW>6I00$_&*6&>\'=1)/*'\&Y8-Q"YWU^$CBZWJB"R2PJF%\TE[]"'-VYUD _
MC&F"7D#=Q7@*9&!.A033R=4C>AP#%CW0D'HL5=9@<EBYH1.1$8YJ\GCW4'7K
M9L9A(%!X?T":4?"D)EQ'"*F+2628# :?)\@!5S?HYD9Y,[DVE$,/:W[.FTMT
ME$H&O1>J.Q/L9$1'Q-?<'UN%S8 'G; C<&/BB 7G MBF\=QZG/#"5$20"!SA
M <M8>+@'IW<$UW1!DPN3IQ_XO3V@[\ 5SZ:*X"+C%]LV=%6H]16(2]N$C 9L
MCID>Z"B7M#&]8'H9^5PLO-HNS^#G $='<FBL#[@/[GD04 %BJ/51Y8FB'E\$
M]XQAHQ(YR!5'1L.S^-%^ U_0*$(3L-FJHP_ :4#8^NO$6#_#:C!S1/$.S4>T
MJ0XN_>BH#8 [T>>Q;5ST6YNBX;T_ G, QF(2Z9##-K[7C_0AZZLZ:5,;B&V(
M[]U(2DP8$Q[P)J:8XHX,MVN!2<N@II][M7.8H>8'3DT&ON.RB,67MD!NST5$
MWH@?@#GUD85&R?4GG#I!"F\Y?Y59-#S+/G"ZNPD[PP*$45W8OL/W*&X@)@IM
MS!-.)NS#;S[>Z9T_-PJ=<-CSW@P54OA$[<P#:3:LL4:?2;4:W:!W4H9%M6P9
M8 G/'/UA](7!1.'S!J5&44H%)8<_RQQHM: (PS773"1),X'6M>>)5NY" /CY
MTT"$Q0A735Y1I_SL6E1YEWS&+.7K5:4>O\*D8VK1V4H)D_'*TS.+N_$"I8 4
M>^^ (-HNP8?,[I"6 XZN&KR*  E[;"$-E5B-*QC%*ZSSHO&?(MS+SM$+[^9Y
MJ8623&C%XOD'M&+5[5QENYI3:J6TM%_$8XYF +DVB>5^ZUN@EF3N=PE89B4P
M&(!Y?TL<7D$/4@]S%2-07VXDK\@UJ@\>E&J9\KU%:96)OO <]C/'EIG_;/&8
MJ<U'>3HZ@Z=<]3G<A0R*%R2M>!%Z[ +FXN!($8,O.U:&RHC4 V8%8-GH=5)'
M$Q8J2,YB:A96,]9MB"0G>N K\P0->L+\2W$UE(>9W)0&[H0,<,6\R?BA21,4
M\T1J5G((OHZQF\IFS&-+FP$\FS WB$)$4AI=5?1B(TQ,J,FLV92L_RA[="I>
M :\42F6(.R*Q7Y\:0M"[$#UXLXC[^4;*W^?6_$23-T_@@><P]S1XJ4-W4?_X
M(%49D,GY@0$ZP"<F+;D>PMN(>2!O3UZVD #@)OJ&<!)['=()Z?1&!"3E?$34
MU/"0G]Y1W< H/(/*'JLU#C.8*,.:EF^J@1E+B+Y:Z"F'X4-\-'C!0]\Q=7?,
MW68BW6;2:#SH)V= >M^ O_O8BD.<#62!#9D(&P++HAHZWG8RL)!)1<X$ Y)3
M'A4I\V:/'P("]N"Y]SR83FX'[S'3 ;^);ZOXLA6( U5=/I2/Q)-"L@[1]1W+
M9N#%ME3 =<(YWF%XHM4RK-&,9V@_@]%T&/^,YGR$:WBVA)0?$4F] 0G!:%PW
MP]?[D4!!<_T4G-9>%4O.']GC+8-:HG@D";:X(47=YDGTS\49&!QY19<FMHB@
MOTCOCND\5ZMA2*X%65<>8$N'+4SY\+R!3,F$!VFW$_*G"P?A,W@0/IK@S85/
MX[Q'3RE2[T% T3(!AXT.EYBN0'J^@^.P0B\V[A-9EDEF61*H-;(LPV=/HK_(
MR:0G("1>XBDEBV7GU"S[V_,:&LCB7G@"O!]4G-PH*U[4OWSQ(Z/X!HT T=_U
M63$_\(15D:1X\$)G0EX)HEZ/Y7%)#%^K>.]0.RXM!AMZ(9H-<6TQV)W'5B'U
M%J6DRCQ_(N[#!^M]TN7*Y^"]<..R41*H=WA)@]=D5MVI7+X^Z8P&&^52-5>N
M;.?*M=KFZGN4DFI)2";>Q*T6E$1"I#%Z!>T2KX,F[W]*Q+L@&07?;6N[7BLI
M;%K-*^)5K(6Q-\&43UHZ&7A/GT# 2R3&RU(-$]7<L%8?1XI7H)Y2BI-OY<GJ
M'#^PIR4ZTF"I4/L.F'?/F)EZ_%O4^O%$97!8TB'A6S!Y!;5EFFP*_JHGZH.<
M:ZL?2OO:PH^5AE^(?^4D\5]9>_GY.P$=IU^%A(U&? N<<K_O3/A]Z2+_1"*N
M5R31[_R%Z%E>/SW7HIZKKT]#?H/#@OZ\KB-R"$G9^O3X3]YI%5=-0,GB.^L)
MOK2^\%:>Y?]#SP/23?%6Z%4/"UIEE!.Y%M:>P9P5+?'J9\W'5#<_#CE $VA-
M=,Z4Z!U4'K_42PH>/ZIM2D4=9#_[^4-QD")ZB1:,X$ &=QZ]%24)&>Q#\&S;
M!M?H_'SFO%H>>3QE@ 6+8!Q!U[?ET1Y\?9T\=?3P,=+=\%!5CHRM>W;'C]L'
MIV4CZ&-M)H"N6N90F'J>$6-4'"]<>DA0N8IWY%.>$"3N7,SFRXD1W[7FB9!7
MDOYU7,!=+,=7_I3C7[H<7_Z?+<>_]C.N#MX?M\XOSKK]7S<?\\AKA=$3D,N9
MS\3WG^:2'HH N@J4-?7Q("A/%(H7ALK\GPM(B$@(U=N C:DQ##0S5XJR UH&
M'^]&<'#4]\:6 YM"6],!Y%\ZGQ1S )+\LD1?#:#C5G^7K7!)37_)XS/?N? L
M1#;FKPC87.NLJS$IO\B;8!*3:EG^'MV=QV?AHJ^>+9>#5\\^?O3^;"=UE8\U
MH=EFT2V2(WHO4O&'!M/-'R*-%/SZH][,4ZL^[@4^CP/V5Y8_R&U'="6K^E8P
M\?D"J_X1H11/Z(NSD >5XNH&NJCML<Z&X"@&KRLY$3=B?A</\$?!/=L'J[S]
MUQ4D^==]Y@4>X52;[I*##O_CNK2]?\T/\O#K01P!/HQ]G/9NM-+A_4WKT_BJ
M,=J:[M>/!I\&1;]V,JY:U;.O],#;_MP[O-PZ[I_<79P5#SSGS-/;!^>W9KOQ
M0?]8^UKZ?/AE]J%-:]-;U3VTCVIG^[.[=OOFA!Y7[!/ON&5N3=CQETOW_-#_
M\J4QZMNU_>_5[^W+4V.K7IZ5IOV#_1.F?+BM5+?W.\9!;7\\N9SVMAM7YY_.
MSC3+['TU#GNG+?.;,;FYV)I^*WKW%]WMV>>C"K7;)S/E\K]]O7MT-;O\]\'5
MV7GG9NPH!T>UJ]G1QXO]HW*YY?1TWQLR[\NH?MS;[O?TSY>G;JW<./IWI[,]
M'O2-K^\$18H#2YOA[[$W,9K_#U!+ P04    " !!@S9;0Z!/[CJC  "4A ,
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M'['E[AO /WX^N3@YNL0(9*)T'3')4_[ SE=$(A"E'],)B0=)#+Z?IO/LEL9
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MJU\Z&4BQ+7[;@,L4BM=$R&A</N!0TR:[.X=/]J8C4R4:M!W#*"7O^&3ZZ,E
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MRV.WH9[?VH(1%?.E.\[%Y&BI[%@I1OE#H [R5*[<JT:"AY$)Q0$V7K5_:]O
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M=MC;#RCSDWIVB#/Z# $=!-2.=!6[#_UI:\^85X/CWT>6J'^%C \K4TA2@K"
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M>Y;P39(#%NP!DG/! 3GK?'=G'4+%ZZ#=,LV[@Q"G6_); 6C?\HVM6SXZLG$
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M2I RJ<VU52+DRZ11^%\JTXS/WTK+>FEY*J58"(C()C6K_4F83V$RX.#L0L]
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MI1]JPA<;/(\I*#/F#'(0=LBMRNV@3"FZ;K)I"_K8.])[*T.9BS@Z_"YZ3VO
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M*1 U-41M+5*35ZFEBRI,FS/;BC36')G/Q"2[5+-F=J.)1-N.!WY88(T*5S?
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M;4"G<#W=F*.7J?RG6KD@!G#%"I^AQ+[#<WF#U-.E?*R'LP=+;]7,31M+"*=
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MN63MK YXMU79=9]WPV.S6'X>[TFW#)\Y@RN:@2YD3(@-8-<R)^)55L&#VH8
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MP_3X71L'6UE"6[LZ)RZ<:5O6XW):46&]?1_ *8!U H_=-$Z3M0+<3[<![B#
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M28TOBAR YA3'M<!KEBJ^)3:D#+WL H<_D&OPF=ULNHA#AU*\2$U'N5Z3T9Z
M\C,;RHP'BPM*74O8I=KOZU**.$A4$B/=_9B?0H>N,PQ'DF-[Q& Y3U9!*(-:
M>Y(?1/UDQA( J,P]^-]P4%*;%.'380=UH +6;G3;L*&WXWE"J8+2S"CW594\
MO^ZM9]9SX?1ZD);J57&\R?YL6HQ*^/J2IMXO9Q&_B#JD<Z&6*F!Q825RA%8&
MC@FWW#N7V*F4-JIAC,+O2:[KL"-EXC[8DJ>-BDUE*2F#1FD4_XTXV$ Z->LN
M1#,C0ABG4^Z!(&<7FWT,BZA#M;:>U177J$%Z(1'/QTT%M OGZ@56W_9B*.X:
M\KGI,CS@%Q2#ESRI'*4#[7H1N9UA\9<?_$OI\"LSSIUW1M"["6L7N8.=9'*@
M;5XY5=GB2MKP"2S3;__!FH!#"([*B86>8@@\+LB9T:A$1.S 2D7>XS6O]_*X
M>E1;SI<5)Q92E7U 3&U6K>UG6+1G7#6K_(X ]Y6%QXN^#)7I0WVUIF(]9\PJ
M9OZ)@*CC]?\^NH%;9 ^$XS2,&FL[F?<<8XHA+-:HJG5PL185L#6BEHLD\I6]
MF<_F4(7^LLTFH,]N,6$3]FP"Z:$@/QN^/<U-1E1XW))(ASH.8I?DW?A,#I?X
M0I:0C P*9?4DED'\4I]PHKX5F(9/44?+-R'=G)UG<"*H1/BV#](Z\D:4/NVE
M(,MV=UX7];E1&F^53;J.W?Y*JDVNFC*7ZNV\F8^88\2NI<LU2#$,I$I<F@B5
M$PF=/2N[B*)#3R\OJ R"P^]<!82>FWNG^Q6]DC:SMW*Q5"X>(B?&*R*[--Y<
M9XXCY,M<1Q2.0]+#G)PNMG'(E< < ]D^N817E!%$1Z"YCQ!N H&/J"+RBUPT
M@?T"'3YQ-R#/4;M;&G>K 7>D: 18UPG$35/*^R7?ME]T@G3.S&\T-@?B(A'K
MG0C"N1)%VLS1CJ#LSQ![D%C3:],I"A'-K8MVB.=<D95XN,U*!%F)A]NLQ)"^
M>7!G@&%^\J_/_W[R-OGCY.SM\8</R1^_'Y\>OWOUZP_/_Y[Z:$0VW#& :^,0
M_7HJWJ1 )PJ;>%% KXRR!<MD!+VXV9F_/5@J_O<1OXE,XW.W^<^.GK\^3EX<
MOW[]X?W1BY.WO_W7O0?W\._W1R]?RM\W'L-UF<\NX-('?[-;==Q453;MC+#*
MO^ZAC/UZ=BH/N +5.\XJ61HCR/=$#L]>VO&;?]H/DQ?O8.AO_^O>HWLKCAXS
M R_>O3'7_O,7F@/6@^9VYC^GMS"8%2-\>$]?<$O/7'L"6,#Q@(!S])=D/C5'
M*M01X-P,]HS_?N9JA8 \AYYI[D6CH[+J=_7YL_19/W0_)*^S:\HD_J^J*.O_
M;([E*MYY3Q[\[5Y\AOWK'JUWV>._K7H?/-7BLQ<\\:&Y5[+\9K<Y,>L+WXHW
M/(.L\2])]!U7_/3%\;OX2_R ^O>V[+#/=$"2!11S3>*ZY$NX)S<=TTUP,X^^
ME%WZR6;F@*GV_5J'WX,(_LN%S#[8A#3,69>\,@91<_WOKVN\*^8P)KPW'>?:
M8OZITW$+.VQS'[U"3?YH'?G#[]"1_YYUJSQQN:2-FBJ_'9T3NM;@CA[_G]]/
MGI^<)4>_/@=;B/Y[\O:_CS^<O3O]<+O^+_KR4:?_UD,+V^?=Z?-6J*S'SY)W
M6';2_0+/9[#"]ZS'CNY_2DAR0W'2:PK;YU";0X^.*M#[')P4'?K\;E3X71X?
MK]Z=ODG>O4K>GQ[??_6/MR^/7R9_')V>'KT]^\S6\V<-1<M#_O7JY+5YHP_'
M[X].C\Z.7__SW]_#6VT?\A\\9,7)]F3C3K;G&WRR?<$SYJL[[%YL[F%W>OS;
MR8<S<R*<O'N;G)[\]OO9A]V=H]].CX_?'&\/OJ_WK;8/^7P'WT\;=_"]V!Y\
MWZ&.E^/MY=T\_E83*U_'4%VZY=1G\GR-C'&?&P:WO>%MWO +9)M>WC^\Q1>)
M99I/YU5Q7]2;5K,*+G7/^T(C"=2)A"\2.8YD]D"S\G^U9O6>_WD6[(?G[U[^
M$^+Y/_Q^]N;UW_\_4$L#!!0    ( $&#-EL85A[%+T<   !] 0 ;    96$P
M,C4W.#8U,#%E>#$P+3)?;W)U:V$N:'1M[;UI<]Q&\B?\OB/Z.V"]NQ-D!$B3
M.GQ(&D50$B5S5Z8T(FWOQ,2\0#?0)"PTT,9!FO/I-Z^JRL+5+9$ZQN3SQ/['
M:@*%.K+RSE\^^>GTY]=/IY,G/QT>O(#_#?#_>W)Z=/KZ\.F3;_E_X:_?RI^?
M/'OSXI_!R>D_7Q_^_9M%D=>/@OV]51V<ILND"HZ3R^!=L8SRD'\(@Y.D3!??
MP(OPZEOS7IW\6>]$67J6/PK*].R\?APLH_(LA7_N??/TR;.GAW^>I[.TAJ%W
M[SWY]AE,Y&UK"/7\W_)9M7K<?633V:F/PZ-[CP,]O7F2UTE)DWIW^.KHY/3=
MP>G1F^/@W=&KGTY/@H-7[PX/?SX\/NV?Y8U,X?>FJM/%E?R8YG&"@^[M/DQS
MFI=9_Q>;P.E/1R=!S^Y,)][V!%OU>5H%?\OB/YKB,;QW<%8FR1(&P[_^K:2?
MM\,@CNHD#J(J*!8PN56=+&=)&>Q_'P;W]NX]# ,8@PX%'DKSN@AF5T&4PPO+
M(C\+WI3-^R@X/4_*:)4T=3JO@J-\OAM.)U'P(LFBRZA,@GE1KHHRJM,BQTDE
M:D[/B^4JRJ_\&>'P^%B57,"X&7SV(JGJHJR""C8H@O^Z"N"+"4QF"[8GO4CC
M)LJR*UQ$E*O1C^1%-3Q,#$:?%UF6S.OT(H&WZN(L@<^5P65:G^.'TS(HDVK%
M#P2KI%RF->\1?A_.T%^#^4JE5['+9/(\6J4UG.M_X'78PV45-!7\)\X^S7DN
M>5$'!7[_,JV2($X6:6Z?"*IS6%AP'L$\\*-J6LLDRM/\#/8DJ8-%4<+4X7E\
MZ"29-V5:IT!^;YMR?A[!L/;L_>/#QU=1B<].)[RE/D'@ _AOF@_\>PNW&,:)
MDSC$V=3X;!A4S6J5T?CP9E&J]2R+.%VD\.NB+)9!#7< ]IO^M[V-9JY QGV$
MNOLE;MOGXG6__73X[O#@Y-$GY"KF:Y]T2:.;>; +HNZ750%TCR?/UP%IL6IF
MOP-5$V&<([N .XW,PE)@EXR9>(1[P/V @?!/,8Z15E63F,'LY71LQ?X$)(\7
MR[VYDN^$AO5D?%GPBOY> /?+KG 8> ->.<-K42QX/YL5OO^_]G_8"_?VZ/_A
MW+?^W,8;#/>DS?>.<E@AL+83^JNF\^E$%BV+^UM9X>\5;,L2[FP ,Y^_#_'6
M!A=1!@O]7WN[>WO[R*;X6STL%M\[P??TAW!EW\)=W;K:#E9ELK-H\%8'P+'+
M**]YQM.)NI_PS$M^YC=YQAM.[9]9-*Q$?SU$#I5$\_-@3IL,CU<-C&/.JGO,
MNRA: MFLZ81W2PF(WL\0 42S+ D:(+8@^3,IY\B*##%UUQ&PE%(RH4P625DR
M50@K!AKS-]:=W:YLPE^.18U^^1G>Y]-B.H'?FWGBWRW<..(XK#1\^"U>E07(
M=3B6I*PCV'ZX<&E5BQ9!6BS(4IA026/\LGNR"_3A)-\!\!,X\/T?[]\/ RVT
M#.V4398P^X&1FRQBAH-R*Z%A0Y1C.*TJ7:89W+:JF<^3JH)?4>HU</FW-,FT
MQ9F;"PBT>=W5<"(0F>F<Z)3$*/ <.WM0G*J_GL!;I]@>O_D-1D-1^/+-N\.0
ME%C4DD @5$ *<O9RC8$^EG"K*WN@RZ8&+1"N\462TZ6&UY!RG#*%3Y)F$IP5
M14S_1!9*1^!](Q1E:YZDL H648M%.D^3?'Y%#/KR/ 4VAFP#QT:=:OX^+RZS
M)#Y#(M-DW1$[]A6D=:3-!9!1<5D]^@H._/3@V>O#X/GAZ]=O#UZ\.#I^]?=O
M]KZA?Y^\/7AN_OW;T8O3G_[^S?[>WO_^QI_JK,CB#YCO3EVL:,[VAUE1U\62
M?@.:.'UGA@=Q#-9%E)E%P8MHYCXY?6&>N$SC^MR1T[>G+Y[V_?4>_7E_USSP
M],7ARZ/C([2C3N3';T_?X?_!K?A\Y['_A:X???<E<#60QJNB2D3I JO/L6E6
MV)A,4S0;2'5KV2;NS\8T^;P$_44W<"O:!F'HN/_+-(,=F$Y>)%$,_Y4H]D_;
M ]\C:U,,.J>MLEKX3@N[$Y0.9+N5R1]-6@I#$RF5%R M:A*#H)F^F=<%F>\/
MV7Q'[@/'U_X6\B7:@=[O5-:$&YK((LW\6>#D[^_5J-EE(&A!7,;1E:88^#M-
MTZJW6^DV6Y8P,'-3S32!_)S=#;SRY/!Y\*I)XRB?DVJ/$T")?#ZR#%AP1J:L
M;*YY"MF]EL[(H+?2T>G,$M"^4=:0/T-6D">H#Z3U%?ZPH ._QI2T]O)Y1?^7
MO3@S_^*\3<JJR#V'#=T7(EGG[$$*A4%P\]-\GC4Q;OZLJ<E4RT!CDTW&MY3[
M*;1_R])H!D=6XY_IC%%+K(IY*L^A5R2'N9RG*]0$SX"C_8?_-)W,F@JN=%6%
M:D(AZ!0@HW(\99[>JH#A462A?8N/54@*M3A24+GT7XG.4+NX34<_]X^>+T-"
MWKK0GG[W[TFLGR#]JOT0G[9FNF30$47XED2R6 !/9"8#5C <.U(2CBDWNLCA
MP@/;6A9EXK]:*7ZY\+E73E0%-(;LRK@5@Y9Y@A]A*P>_LT">"Y.A[RM3 #X4
MD2J;YDW1 +N:156J;. XF8-U(JHQ#%'&/ 1,B=<&U@D2*_Y W*E_#5O5-FZ!
ML:7T7/%+AW^"Z9:?T1)![492GDY:C@;@T5_.8?=%*=E^\7_L[ 0OTR2+'P5O
MX3X_AF'_:.!:)_!@L+,C\9XG+XY^]0,KK ?OW^M1A+_#WV9TK/:W9QF8&\'^
M[D.8905L)H8I=$,UJ$&['7GR+7RU9P*S,HG>[\P2H#^8Y8IFK2?U7<^<<*(?
M^DFU-=_BWO!VW ;JV(K[^%Q'Z'=41.89[.(BAP%PEHZ?B_WMUN/5IU2:(2KB
M?563D6>$7!LT3 6,J@:]K-2"*I0_DGP#C0Z]_7,3S! 9F1BF@*^*ER2Y(+==
MOZXE)L,\02\0AI*&E;(MP]\,3^574;S/$J<(PR!+L/')0X1/=U@>27:8'RF,
M44Y:;3BDG5F%UMM'LGXP-++-#D7Z3E1F,$_:XV(.TR9W+^B0-F#BZ9'.]E=&
M$PR/UC+^>U@])7]&2?*)K;#^J8>LP7:_3BQ_8&B:Q2Q)<I1\%RE(E^PJH#FA
MLV0.>E/L!-B[!E[>?_  ]!_XU/"WE.ABK3E(X(:D^&D4<;#H2.BT '7MHLB:
M)1$07#?0MW:*Q0X]@+&E,IVS5TX[BLT\6&\WX["_AHB"#92B]*B'B6U +L.$
M2WQIU<RR= Y/P=M+<32J,9DR[#X$;#=<;$\G"PS(;3W<#JZ +N":+6IQ2_+^
MM.WI6R09MY)^WE>3 G'XYRK)JS[6AY?"4U241K9(@*;D3=3^FY+O1UL%$UY
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M/;0)CT\XQ7>M?KL=N@U)65/&4=CW8C35X&1L6:C&BT,=*2QL&=(1YEYP&NR
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M3B[A- IX)Y_B$C+ W,4L'$?(9VA+Z=3?DLQ1AO6*(,7WIPQ 6 $,'TX!CVG
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M%Y 5@)_!E$MVZEDN6_Q89+ Z/"G@S2!VRH\1JEZ7</+_PP^RYXHY!NFKXC(
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MD@W"H@C'5Y361WB!?R\!W_9U#EB1EA+E/*.GJ\.0N!<A"A)S6((HP@I$6\5
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M!1A+3,B([R%H"B%F3VFK&WHI?<U$B!" AM->IH6&S)+%]1V3^X>&OA"K52$
M0OF*BI2@OQ)08<5%*O3DD:ZJBX8@1()Y0LX7"ILB8U>I3!F=HAL#%^?6T]Z-
M#-4)5Z1CL-9I&]+D<+6<C?O2&&+W!K"!1#-JG1HS <;1)"H]5V$VT%8#5G^M
M/3W<^=*=_UO-G<^C[-HD>OG=*:HR*]'(D'#/!HX8I*P24@'Q]-DB!XQV%I7(
M!0@25!""=,*,YF:AY4L4+8QZ"4M9:GYD B+@"S2KADN02#+8W82NZC*QG(M&
M"5\F,O[$2\1%(^]L595K&.&EHD*EA85::UE,17JC- )0\D+;BS#QO>\(0C0R
M27[GC&4INMV6-,=0T7$DI?DY*M+0L"FJU13BO\"PQ@4KSQRR[]@\N+@Z26<Z
MYE4]-T5EG.K7.J*"B:O<*<(O!*\$#5,2O4%GIEL_J9ICEBL?QK7L%=2+I+46
MPQ"K/+#EJ083\P@+3LI+0-"*;=&8SMN-3*\/L:V)N+9U_3:Y6#$ G@CS-5S4
M"7[0"-JV'=^8!K%B^1(_)FFR&U*M=YS=!0#% E PNVXG(Y8Z0#"1%RT>E$1H
M_ ^) 6%D=$YV#QV)6J,%R#AJA59$L:"PCM"P;6B>1"Y&'U,RA_@OQE7@@R+W
M,B+(RS55G$(=0(-%F"2FA<)S^"!KJCG))KB.DPO$Z3(KJ%9\-<%"V=P8IM@S
M@;5<;S*T;B?: .O%:O&I:-,IFZZ3,9Y&) B6F:*=9KW*R&3GX6PDDO>0CVUA
M17KQ8$6Z<RO2BP<KT@\9);NM>/>RVGS$W9":C8YAR*Y0Y^>5(&.JDU6T8+)>
M!O)B'$_K<F;<@,<L"BI[1U9W-G.<=UYZ,8L4#R'4Y1!JA!$R(:S>S*6163P;
M8&'DG'.RW;+5[=OQJS9%+BXH#L,KPHS>=I3>;>Y-[D(CLL^!M>*+=F$/5?![
M/ .Q!I%H'"YBM!GF=G,X$OW-,I1GOZHTFT1_>*(=:Y LVVG3H1TD4#54FCGE
M"E66D67(JY:\I$T%H#L#)^? $K-^\M55B6PL:(/0E5W"E=H4-=&6?A1<ZKH\
M39U@*+/D6#L*Y:>-T1D44WDM,944*0Q*/!Z829-R7G;/D(2IB7*IU\[A1IY)
M<) RE6@3"AU6B>1HM4&;MI>S(@:LEV1^(#(LSFEM#3L*D"#K1[)N%Z]B0SF>
MH_N42I5+=!)'4%VKTE$4PA@E*7G-ZR:M.NUF8ZM)F3%;L^X%'8*YIK%DZ;>]
MFG!Z:)?#VZS(._9&NLS"A5D6Q9+J</1FH[Q1%96033A&4RG=;JUXW!)N@$-2
MK60$*\*5R\%K6I(Y1*)M&^C;S89MFI=K.55)>68Q5G;I*,+Z:/%O0DK<R23V
MVU+?[.*1_!99QZ>IU*=@_*LPJ-@6\S'7&IL(*8)#FZVL:-OQ3*P2HV6.ES?7
M/0OL/0CZ@/REX5W+;ZWR^:I>ONO(=@[9K(2+ TQ5O21+@7;@E)>PJHQ0S092
M/D67%-G8%L,J;A(90_3O*@Z8R3>35^ZDYE;[!U05L\!#M)<?X0LRPGF6-AO]
ML B#(^N2:?F@O5VEB++1?X),(9-4#]&B[2LM=;HRN/4XN5O?2QG_<A#]<LJJ
M%C,5F9[(S& ]T**0=Z$G:QCD"$.N5AP%7RRSQ.9.CFQB]1 TJ2M6-$NI(AF/
ME%^I?A.FQX2V?U!\Z0)$=.!FW+,.OM(^!MPPG.$([BE??]MLQ[NDP&-9?VBW
MNUA@1CX&;?E\N*TKGI,!R?3!@Y?&5Y%<=//UVM88Y"JA^KS,FL/K-)XH[^LD
M78X*K/%KNW)] -7%D59&-KV4\.]J6)_KH-8^XP574)AR$3\.YJL;=\QAY:I$
M(_8R1JFNX**:.B;[%B-.6C0DT#L[/-J^3E[26I2TR\),N^Q;P:HQ%GO4Z4A%
MI*M(VK/H;!JNG< 1G'XM*>XN1HS0&L_TM(T=Q_!5B ;"V:1.*'&/DJ^FUAK1
M&">1]/7ZH[I>G&VD@A[MV$U.*K-,RO7J:-N$H55'H>$VRIW$*@Z[5254:3E
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M6=]T?]^==G_U*K8"_><UH.=>7;4'X(NE*IS#59I(.QY%%%<@U'?RAX/F3W1
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M:(0.)$?&F\?(=UE_83RC:600C<#'2<*J! (CZP3OV :_F[DA2@S4"RXH 4W
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MWP%'\; U>F9NMLR=*W%I)%O^W1[)KM'_RJ9X0/_1)_S/'_H/0O\!4$L#!!0
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MF"1IF008Y#+-=:%OE3A-"KP=B\N)S)7HBRN5EU&1MUNCU(B+J_>'73#B[\C
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MIYE7QA5S.[UP(E)+Q8*STB79FU3^C+H/E&)C61H'3IZ%V&V((.])EI(AH,V
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M6-Z[14'7:9C*'6L.1MXLV2+X'=!^,@2D61TQ9+<$;C/LPZV&QF&]1I$AG1^
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M#/F<0^HZ=M_6\F8@J)6T7E.[Y9AI;=&<P$&HO:C[S$680FB)?@:+0MZPJ$N
M?F89'Y;6$,1TBRZ466@=93H9Z>,L;KJ>?LK!?"81_RE_%@JT'6$8Z.#*AK8O
ML^S'9#-AO<29#.43CKF^L[VYT=W9W.F^WNT_9>%18K&]"(O]GT:FZ)OZ_- C
MDC.^"/"DM>ZU-Z^>D(QEM9>K,E)=G[5O5@]F6VH:-YJ?5&F469B,)346SSLJ
M&+A_FP6#F?F_S':]I,^ V^^"T^?#_Q]02P,$%     @ 08,V6VDR'<XH P
MWPL  !$   !O<FMA+3(P,C4P.3$W+GAS9+56VW+:,!!][TS_0?6[+0Q-4@@D
MDY!)AH8T&6@2TI>.L&6B8DN.) ?S]Y5\XV)P@;8\R;OGG-WU[LJTS^/ !^^8
M"\)HQ["MF@$P=9A+Z*1C/ [-BV&WUS/ ^=G'#T#]VI],$UP3[+LM<,4<LT<]
M=@J^H0"WP VFF"/)^"EX0GZD+>R:^)B#+@M"'TNL'&FD%CBVZ@B8Y@ZR3YBZ
MC#\.>H7LJY2A:$$XF\TLRM[1C/&IL!P6["8XE$A&HE"KQ;7LMQO]C@BG(,.W
M\(<XB0=D-,'T2W3Y,GH1S^CFKHX>Y/RK'=^^3./HIMGP'/HVFL]D$#]<GG1_
MB4<T?;[PQ&T:LBV<5QP@H'I!1<?0]67ES1H6XQ-8K]5L.+KK#Q.<D0);L4_H
M=!/<;C:;,/'FT!(R'G,_EVY [1XC@0MEY245>$*%1-19P;NR("R#CV#J7(&2
MC=#C%$IRJ(O7< ([UH2]0^50^/I1#HR$.4$H+, >$N-$-'.L@ 679: RKH-,
M.0^QV A-72N$^\'M18%E/)HB&>N13$"UIGVB]LK' :;RFO'@"GLH\E4>;Q'R
MB4>P:P")^ 1+/6,B1 ZN%LOG%%'*U#BKE<HLVA:&1,UK85 FW=\69S[^KA('
M^J#V:6,$[8-=IFX$ Q"W8Z3'):U<S<4>H22)G*V/#4R]+)$N4AT39ANN@\M*
MD<#N/3U+SB''0M&3BOK*D/$S2#770;X3^0=1%_E5,3-[_AY++SC?H@'V0+)]
M+3TG'4,0??T9F>V58Z]CJ"L+F7D[?ZJR+35'.41'J-B^I$?K;RH+G$L@[I14
M2K>#$F$AYI*H85ZZ M+4B=3TAZ4P0,<1!H#_L'(?C?>M7%&P_Q]+[FO]<JUM
MN+I8ZGE]^=JJ7,8EH*4EKKI"T\N_SYQ$JH*BG\R<9VJ3:=?-AFW%PEUDND\2
MBS>P7Q(Y[X DMESDF^*+;7!]2$9HUZ!;/@B503=R(/:ER"T'I[#\^?B+'!*9
MO9)8::<K.=026O2S6;-5$[>G\R=F\BP.&@*'153R^3Z#L$S)'P[KQN+#OULC
M<GS:!/U?X-"P!TQ!.?BF$6C#5$T=?P-02P,$%     @ 08,V6ZRL0;+\"@
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M6Z<>ABXH3@!S\"E)I?=+RN*1I*F\'8!I_X!B$[NF!39L\M)6!D4,: ]DIHA
M94@XV%R^R-6Y6"8-;&Q-[Q.>ENTN?BIQL B9#@=25(0A&>>)I-IMB!Z&6DK7
M] !636X,65#$V+V!K"@Y*O3^(;FD\2!$*IT?0 R;=CQ*48!P-)WUH2'4/L&X
M2K((I\K+E=B6=33/HG4-"&C7A*0E# H4R!T(BPK0S!0A7H'Y%\%\&"XUI1]8
M6E;MJ%2R $$QO?5A(O5>()EM.6^XAF<<6.KLIFR/V>K^+* + I0><ZV[MDK>
M ,73#'1)\R3?R\?I;K:;%>&6QK4EKMB S&DFS/(@6 !,F0PH&9(ZI(1>>E[?
M):"Y?(@1;(XI<TN W623@J8F(!*LQ@ :#MKBF5(O1,S$R,1Q.J<QV?U"]F"[
M6CJW3  VFU 8HH"HL#L#L"C%J% C(?<"QAU/-ICO%TG4,U6TA6[1@(PVV3!5
M <$!6 /H*-5H,9_YG$F6>#>/!:C)0Z*>!^^A!-2[A:7'=I,90!P0.MT. 8)$
M$&I&^01I3B/&GUGM<8<9VXH!<#]C,;Q"Z8ER"]6@)C31Z@P)"+ A/@',&J$?
MU#,IB,G7>(H*D*S!"W$7<2P.5%;^<YU0<@RVWZIU2U>'W293%F% ),'N 'Y*
MY0?] <D8=$M#@6;ZAJ9._4,S'0K--&AHIN^!9OG* H'FY U-/?$/S<E0:$Z"
MAN;D7="(CO<ZULS$QUN^9*^VA[-!I1=DVE:MP!QDX>'2\M8'BPR0ZQD9XA.3
M8F%UR^\X>TEH!"^9(;D78 #35FH,;7CHV WV\5,MB'6<U[%&+<I[OR1:YF>4
M:9JT#S%*$QXD36.]@XM2^T3BCF4Y3O^=/'>>B-O%7O"P&K9"TE"&AXK-7A\P
M*@:)(!\GUB6N\H:&]54RH]S=*\ 66X=7@&N%04!@<]1^!5A=/5$BU]TL&>4$
M R-"L]A9)UM,57U<*PNCB]N&6CU<?*^%QL<7669W2>\>&84?$&A+7/4T9$[W
MMED>1(\#ILQ>+V2HT'FZ&B\S3&3VX;M6YFQF-^U4$[DN"*)W33>M:5J7.^[-
MWWB2BSW/V&:SI>5='MMS@X#.52]WVM0];A4%T?M=SDP22BUJBAUCL6!I$B5Y
M0M>_BI-/GF!;JVPB5T# !C4-;440*("V3 X.0J25CB&XXT1"2$1'%"\!RL1"
M_/;AP3K;=XE=0=%O6,,!*X. I->>"8L(&$>U"*1"4!'C%YMYEFT)?Q,\EA!/
M"('F 9!:^A!Q@DSV0J4"?;*U(-%6S(_[X^EJF>2I[>2R+7$V)P'FJAG)* ^"
M#<"4R4)1AM@#.I[^;?5WI*,<=_\-6W(L<\<N]IL52X'L4U:5*P@Z+&H.+)(@
M4(!]F33<,%1*D=+ZR$[5,&MICE'N"@"K+=WUC<(@.MWFJ/7E;_2UIR'_<A<]
M"E,$>"'!+G,]]-M,FL-_71,$ AW&6B<EI11IK8\7$@Y3UKI_$;#VM@A8]RP"
MUB$N M9#%P%K;XL O5N5(D2,2[>K-%EC(#EAI]HU%!V633XLTJ!0@?V!8T85
M@@XQKC-:%BG.9'I^OBGV?R4^6%H)Z)SEM.RR626UM(F"8*3+62NMI4HZ5Q,C
MJ7;-Q39.<A(K,U<)Q31*<%JE1[1=$>\/<4;+0/,5.#WZ,!@:9K*%DPK3N0RK
MP$.J2]>7TM4#&+^1-/V%LE>Z(#ACE,3J6HKM3E&WWNT3,SVVFP_- .(@<!KB
M$'AT1@:-GV04TF'EE3 O)'UCZ9;FF!?ODG/;R 3HW)(#V&P28X@"(L7N#""D
M$B.E]O."MLH>42VRU.\.@0V$Y(Y?U^XT;;RU;=4&Q$RG0>@=[C+GQV%MK*(\
MO6*9$_E[$<D+^8)S7'H#VPO)7;]4V67:?)O2I@T(H4Z#X/N358Q,%8,U4]Y2
MQO"96&JM6<=3XH;*?>*8EL5V[IA*$A >-E\=&60XTEHO+"PV.$T_;[.$D@R>
MB R56Q:L%ILL-"0!L6#S!;!02)'6>F'A<D/X6DQO/W/VFC^6^5G!M@%JMVQT
M6FXR8I4&Q$J7/X 9'8)4C$ZIZP>>W2&AN,JR"+?4(G6,#6C68*:E"PD8R%R+
MEI1$\GK+#<O1DJ&O&4'Y(T&7Y<_0U3/!JWI\_=)(%,D7(M2JG,:8VQ#J$CO_
MU1'0<.NW1UK*($#JM0?_#DD5@72(8VIN!<.\?AY7F)CG9 .^[= ?XHJ@H>8U
M1WWZ(&@::-)DJ@AKGEP7@4A&^LQF5$]N#R_Q&B+'*V.+06-A7%,$P0AH"UH6
MUW\KP$_NO.TJ3:*KE&'X*DM#XSAC7MN>D2SO( B(@+8K*$5>(42%TDO_?\;T
MB6^?\VA_QUE$B'S**JM&J[[K;P.CW3+SIB8U:1H4&A!G;_$+$'BH M7J^%";
ML7Q>S),/C<ML;BQZ6CQB<0!OMWDF9U!A#+X*WAGD^/;"@ 88-QDZ(@)";X!-
MZ(9#$8F*T ](!:-:M*?SL^R0!9#$G_?WY(%P^=[!DNSRSV)'3QUG& -B79^]
M#6Z.>3+7&Q@$A&]U"YWJ9:A> 5K)9\3**M#OLA)4U&+[_?+ZIFOQ26S6F\1?
M*YP1L>6_4$L#!!0    ( $&#-EO>5R$^6 <  -)7   5    ;W)K82TR,#(U
M,#DQ-U]P<F4N>&ULS9Q=<]HX%(;O=V;_@Y>])@2R;3<TV4Y*0X=IVF1#VN[N
M34?8 C21)4:2 _S[E6Q,^;#DDQN?Y"(AYM7'^QQ;]K$E7[Q;I3QZHDHS*2Y;
MW9/35D1%+!,F9I>MK^/VU7@P&K4B;8A(")>"7K:$;+W[Z]=?(OMS\5N['0T9
MY4D_^B#C]DA,Y=OH"TEI/_I(!57$2/4V^D9XYK;((>-410.9+C@UU'Y1--R/
M7I_T2-1N ZK]1D4BU=?[T;;:N3$+W>]TELOEB9!/9"G5HSZ)90JK<&R(R?2V
MMM/5Z>:G*'[!F7CLNU\3HFED<0G=7VEVV7+M;II=GIU(->OT3D^[G7\^WXSC
M.4U)FPF'+::MLI2KI:I<]_S\O)-_6TJ/E*N)XF4;9YVR.]N:[;<LH-_IB69]
MG7?O1L;$Y%&O;2;R*MQ_[5+6=IO:W5[[K'NRTDFKA)\35)+3>SJ-<IM]LU[8
M/4DSMR.T-MOFBDXO6S9XQ%;4>W5ZWGWCJOE](.W^V8I<!3;LV^Y*E3T2LW*!
M[KCO.AM=9Z_9A:*:"I,[O;$;]MJG*V/W)IJ4/7#5U-:_J8 9I]WL*MVH[?:K
M++5-V8^%<M./LB=<QGN-<\=?JGWWY;Z<4]8T/IG)ITY"6<<1<1]R-#D6^\^/
MO*&KB3:*Q*:LB9,)Y7G]/ZSF0-)IH%<EB0=;8W6G]A6'?=J-V96*(ZD2JBSK
MLBZBXKU('>^6&T5G092MJ!W/&=\&>:IDZJ.S(2$]'=T%99MHAN:5;3]Q?1AR
M,JO&>2 !\NQB *UT@T7T ]6Q8@O'I0;LGA+(MX?*M\);PYC+8^>>SICKK^N*
M.]E2MS$\+GB* ,&?88X40;=($;@2(B/\GBZDJ@&_KP3R_@.3=Y4W),Q_9T09
MJO@:0OI(#(3]"A.VQR$2[P=%A&:.#P3XL1I(_#7JA8?'(Q+R\9QR[O(W(D![
M>94>B/T-)G:_SQ< _OK)G=_MJ07.?J<($/^?+P7_D5ND"-Q1Q61B3^D*P/Y(
M#*1^CDG=XQ"5][5(H+2W4G#^@P_[P!X2ZB'3,>%%CX9VFP[CKI!#D:/DG+4V
M4;'_2XD"0]\10Y&CI*$U%AL&/LB4VNM,<%3QJZ'(41+0.I,-,[\6AIFUN^'_
M)4LG/V^<[K,^5D$9HR2=/E,H;,L[#<*X!QDAOH=**&.47#-D#H7SP/I1A(]$
M0E>?Z#H$^D@*)8V28P;MH:"^4RPE:CUF<?V@<:R%PD;)+,,&46@_D-4HL:[8
ME!6/ NNA>XM V:.DE2"[*"$8B5BJA=RY73R0F3T>UP.9!(?TFH+0<*#DF\^P
MCA*4JR2QN/3FSPT3M!L*1:4<_(P(+P !FR\$>^]YV'MP["AY:*W-%X+]['G8
MS^#847+16IN8V ?VXZUZD$O/$VBO&(H<)1>ML8@)/#_3W*H[)9]8,2.JCOI1
M"2AZQ!0U;!9UAR].\I"]O51">2.FJ]7F,#G?26T(_X\MZJXDJ_50YHB):\AH
MTS<8B[B[FQ:^J40'$BA?E%RUTD[32%V$%27^W7=? 06*DH!6F6F8YXUTSS[F
M4@3OQQZKH%Q1,DF?J:8'7C>/6'L/_9VOP3/84(;50QL-8_RNF+$]&,@TS<3F
M'HWGJ9A'"L6+DOX%[36,>BPYBYEA8O;97B$J1G@UYRH=%#)*LN<WUC#A.T5=
MI*F][,[G<;F%!NIV.O6-O"$]E#A*KE=O%)?\2.N,JN?RKR@%C0)*V@<UW?0X
M0^/,#GOK;F_RX%;,>$:9(Q64-4K*YS/5,-LO\D$1MU!OO$XGDON7AU0*H811
M$KR M88A[_6C&N^!! H6);.KM(,T)EROXCD1,^J?O5"MA )&R?1"YM#&WAEH
M[)T]<^Q%R?A\II#8%G/#[1%U.^%L1OPKR8(%P.ML,(D'K#:]?B]?\N/6<*LT
M[\?0?JC&[I%"@>,LD0S9:QIUEC!#DZ)+0R:(B&U*M5W7YLG.ZTM! X"SAA)H
M&N7V_G?*^2<AEV),B9:")L6E?N@.O[<(- J(SQ!K[**$X)ODF:6D\HF@RG,,
M>*10Y(C/#CWV<.9>%I.:M^>>XF4=(>*^$E#PB \1PV:1YJ<9ZOK,GN@'8LBF
MAR'^OA)0_H@/%,-FT>;/JX$]\<QD^)GY@1!*&W$J;*4U%,CCE'#^/M-,4!T<
M6PZ$4,B(<UXKK:% ODZIFME![:.22S/?K.T,P?84@$)'G-D:M(H#?_5S'7FQ
M_BU(OD(-?CL!(G:O2:S7;L2QFTA1G,E%0I2'>D@/Y8ZZL-)OM&'RMV9.U>[U
M4]Z9D<W;0I,>ZDM!HX"2KD)-XYQ;=U;R!T^M>SHH;\3$M,H8SIJI;,)9/.22
M!*_+]V10OHA9:(4M%+SOB7A4V<+$ZSLE8TK=XQ.]/=H "1&P FA($//39Z'
MN5T@T]0M)I+QXWAN3>O;S.2O+K7]"]XT"):#A@9S$2? .-)5D/ZYT(LF[]?W
M=$J5FZ;P0%?FO6WH,7Q1!"@.C0_J&X7 &"K"=-$Y\G5C-[BWTQ;?N%_N#:QV
MR_]02P$"% ,4    " !!@S9;^;VP]QX;   CD0  %@              @ $
M    96$P,C4W.#8U+3AK7V]R=6MA+FAT;5!+ 0(4 Q0    ( $&#-EM#H$_N
M.J,  )2$ P ;              "  5(;  !E83 R-3<X-C4P,65X,3 M,5]O
M<G5K82YH=&U02P$"% ,4    " !!@S9;&%8>Q2]'    ?0$ &P
M    @ '%O@  96$P,C4W.#8U,#%E>#$P+3)?;W)U:V$N:'1M4$L! A0#%
M  @ 08,V6\.$BMM)1@  664! !H              ( !+08! &5A,#(U-S@V
M-3 Q97@T+3%?;W)U:V$N:'1M4$L! A0#%     @ 08,V6_ZM:-@?#P  )S0
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7;%!+!08     "0 ) '4"  "TB $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>ea0257865-8k_oruka_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="orka-20250917.xsd" xlink:type="simple"/>
    <context id="AsOf2025-09-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2025-09-17</startDate>
            <endDate>2025-09-17</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-09-17" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-09-17" id="Fact000004">0000907654</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-09-17" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-09-17" id="Fact000010">2025-09-17</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-09-17" id="Fact000011">Oruka Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-09-17" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-09-17" id="Fact000013">000-22873</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-09-17" id="Fact000014">36-3855489</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-09-17" id="Fact000015">855 Oak Grove Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-09-17" id="Fact000016">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-09-17" id="Fact000017">Menlo Park</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-09-17" id="Fact000018">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-09-17" id="Fact000019">94025</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-09-17" id="Fact000020">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-09-17" id="Fact000021">606-7910</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-09-17" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-09-17" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-09-17" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-09-17" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-09-17" id="Fact000026">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-09-17" id="Fact000027">ORKA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-09-17" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-09-17" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
